An investigation of the role of glucose and fructose in non-alcoholic fatty liver disease using systems approaches. by Maldonado, Elaina Marie
An investigation of the role of glucose
and fructose in non-alcoholic fatty
liver disease using systems approaches
Elaina Marie Maldonado
Department of Nutritional Sciences
University of Surrey
This dissertation is submitted for the degree of
Doctor of Philosophy
September 2016
© 2016 Elaina Marie Maldonado

Declaration
This thesis and the work to which it refers are the results of my own efforts. Any
ideas, data, images or text resulting from the work of others (whether published
or unpublished) are fully identified as such within the work and attributed to their
originator in the text, bibliography or in footnotes. This thesis has not been submitted
in whole or in part for any other academic degree or professional qualification. I agree
that the University has the right to submit my work to the plagiarism detection service
TurnitinUK for originality checks. Whether or not drafts have been so-assessed, the
University reserves the right to require an electronic version of the final document (as
submitted) for assessment as above.
Elaina Marie Maldonado
September 2016

Acknowledgements
First and foremost, I would like to express my sincere gratitude to my supervisor,
Dr. J. Bernadette Moore, for giving me the opportunity to carry out this PhD. Your
excitement and passion for science is inspiring; and I thank you for all of your patience,
encouragement and guidance throughout the years. My sincere thanks also goes to my
other supervisors, Dr. Nick Plant, Dr. Marcus Tindall and Prof. Andrzej Kierzek for all
of your enthusiasm, intellectual discussions and support. I also gratefully acknowledge
the funding received towards my PhD from the BBSRC Doctoral Training Partnership
(DTP) with the University of Reading.
I would like to give a special thanks to Dr. Ciarán Fisher for being such a great
postdoc. I also acknowledge him for providing data with BSc student Ruth Passmore,
Fig. 3.3A and 3.3B; the fluorescent lipid image in Fig. 3.6A; and with BSc student
Laura Coster, Fig. 3.6B. I would also like to acknowledge Dr. Naila Rabbani and
Prof. Paul Thornalley from the University of Warwick for providing their expertise
and the measurement of methyglyoxal in my samples for Fig. 3.6C and 3.6D. I am also
very grateful to Dr. Barbara Fielding for your guidance and expertise in lipids and
GC-MS; and to Dr. Nicola Jackson, Dr. Fariba Shojaee-Moradie and Prof. Margot
Umpleby.
I would like to thank all the current and past members of the Department of Nutritional
Sciences, FHMS, and CVSSP for making this time such an enjoyable experience. I’d
also like to acknowledge the many BSc and MSc students, particularly Pippa Gunn
and Beth Purchase, who embraced the lab culture and became great additions to our
group. Also, many thanks to Amy Barber, Dr. Jo Sier and Dr. Ruan Elliot for their
support and discussions. I would also like to especially thank Philippa Gibson for
being the heart and soul of our group and being my #1 tea buddy with the rest of
the tea buddy gang, Eleanor Healing and Sarah Lang; I’ll miss our daily allotment,
puppies, chickens and horse chats.
Finally, I would like to give a special thanks to my mother dearest for being my biggest
fan and my family for sending their love from overseas. Last but certainly not least,
thank you Dr. Marco Volino for all your love, encouragement and support.

Abstract
Whether or not dietary fructose exacerbate hepatic lipogenesis and non-alcoholic fatty
liver disease (NAFLD) pathogenesis remains an unresolved question. Furthermore, few
studies have utilised systems approaches, notably at a genome-scale level, to investigate
specific monosaccharides on hepatic steatosis. Therefore, the aim of this work was
to develop a predictive, multi-scale computational model of hepatic monosaccharide
transport, signalling and metabolism; validated experimentally to an in vitro model of
steatosis.
Utilising quasi-steady state Petri nets (QSSPN), a dynamic network of hepatic glucose
and fructose transport was reconstructed and integrated with a human hepatocyte-
specific genome scale metabolic network constrained by in vitro flux data. Additionally,
a regulatory, kinetic model of hepatic insulin signalling was reconstructed and success-
fully integrated in QSSPN. Together with our novel simulation method, dynamic flux
variability analysis, simulations predicted minimum and maximum flux rates allowing
the calculation of extracellular glucose and fructose, and triacylglycerol production
over time, while also satisfying the demands of a ‘healthy hepatocyte’.
Immortalised hepatic cells, HepG2, treated with fatty acids were confirmed as an
in vitro model of NAFLD after the characterisation of both viability, as measured
by LDH and MTT assays, and intracellular lipid by Nile red staining. Differential
effects of glucose and fructose on lipid metabolism were also investigated in an in vitro
mixed-nutrient model of glucose, fructose and oleate. Intracellular lipid was assessed by
Nile red and the gold standard, gas chromatography mass spectrometry. While oleate
induced intracellular lipid (P < 0.05), no statistical differences were detected between
sugar treatments. Additionally, intracellular lipid by Nile red was measured in HepG2
cells treated with glucose or fructose ± insulin. Notably, while hepatic monosaccharide
uptake in vitro was reproduced by our in silico model, differential lipogenic effects of
fructose were not found experimentally, nor predicted by our in silico model.
In conclusion, in vitro hepatic monosaccharide uptake and intracellular lipid was
reproduced in our in silico model with no differential lipogenic effects of fructose
detected. This highlights existing concerns of current public health recommendations
targeting single nutrients, e.g. fructose, to combat lifestyle-related metabolic diseases
such as NAFLD. Future work should aim to predict the outcomes and investigate
underlying molecular and regulatory mechanisms of sugar and lipid metabolism in
response to mixed meals containing physiological levels of glucose and fructose without
confounding excess energy.
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Chapter 1
Introduction
1.1 Context and motivation
Systems biology has evolved as a complementary method of understanding a biological
organism. It is an approach that promotes the integration of different levels of
organisation varied from genes to cells to whole body, and combining multiple scientific
disciplines such as biology, mathematics and computer science [Döring and Ströhle,
2015]. It is a natural continuation within experimental biology that combines molecular
and computational approaches to understand highly complex interactions [Kitano,
2002a, Holzhütter et al., 2012]. The benefit of integrating different levels of organisation
and studying it as a whole, rather than just the sum of its parts, is that emergent
properties can be discovered, from systems cell biology [Mast et al., 2014] to population
health [Pearce and Merletti, 2006].
Computational approaches can gain a synergistic effect towards understanding how
organisms function and predict behaviour [Kitano, 2002a]. The best practice of this
approach is carried out in an iterative cycle of model development and prediction, wet-
lab experimental investigation and model refinement [Kitano, 2002b]. Historically, these
approaches have been used extensively in microbiology with much success [Price et al.,
2004]. It can quickly assess research questions by iteratively testing and generating
hypotheses, and guide research at a lower cost and at a faster pace than traditional
biological approaches. In more recent years, systems biology approaches have been
applied to much larger and more complex systems such as human metabolism [Duarte
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et al., 2007, Ma et al., 2007, Thiele et al., 2013]. Despite the availability of these
reconstructions for nearly a decade, the application of systems biology is still relatively
new in nutritional sciences [Moore and Weeks, 2011].
Nutritional sciences are ideal for the use of systems approaches given its complex nature
due to small but magnified, chronic, dynamic effects of the diet as it provides the
resources for development and growth, maintenance of health, or emergence of disease
[Kaput and Morine, 2012]. This is both a grand opportunity as well as a hurdle as
the main challenges are to capture small, accumulative factors that only manifest into
disease over a matter of years, and to distinguish differential effects of one nutritional
component from hundreds of others [de Graaf et al., 2009]. Even though current models
are incomplete, they can still serve as tools to manage large, complex datasets and
generate predictions of testable hypotheses [Holzhütter et al., 2012]. In fact, there are
vast amounts of nutritional data that can be of further use by systems approaches,
such as information provided by the emerging fields of nutrigenetics and nutrigenomics
[Norheim et al., 2012]. Furthermore, there are currently several computational models
that are already available for the use of nutritional research [McAuley et al., 2013],
as sourced from decades of modelling in nutritional sciences, e.g. compartmental
modelling. Hence, systems biology offers valuable interdisciplinary methods to gain a
better understanding of nutrition and its effects on human health and disease, and aid
in the development of personalised nutrition [Joost et al., 2007].
A public health disease that is highly influenced by genetics and environmental factors
in one of the most complex organs in the human body is non-alcoholic fatty liver
disease (NAFLD). Although NAFLD has increased in its prevalence by 20-fold over
three decades [Farrell et al., 2013], the underlying molecular mechanisms and regulatory
signalling pathways remain poorly understood due to the complex interactions of genetic
and environmental factors [Buzzetti et al., 2016]. Yet, diet is a major modifiable factor
that can help prevent NAFLD development and progression [Zivkovic et al., 2007].
This provides an opportunistic case of which systems biology could make great progress
in the understanding of its dynamic, complex behaviour [Fisher et al., 2014, Petta
et al., 2015].
To date, the UK population is consuming more than the recommended intake of salt,
saturated fat and free sugars [Bates et al., 2014]. The main form of free sugars is sucrose,
composed of both glucose and fructose in equal parts yet, fructose has been under
extensive review in recent years. This has mainly stemmed from the increasing intakes
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of high fructose corn syrup and sugar sweetened beverages, which has been associated
with an increase risk of metabolic diseases [Johnson et al., 2007]. Furthermore, fructose
has been proposed to contribute to the development of NAFLD [Gaby, 2005, Softic
et al., 2016]. However, the current findings are controversial as many in vivo studies
have used supraphysiological doses of fructose to induce NAFLD [Moore et al., 2014].
Additionally, human NAFLD studies are often confounded by excess energy [Chiu
et al., 2014, Chiavaroli et al., 2015b].
1.2 Problem statement and objectives
The scientific evidence of the effects of fructose, in comparison to glucose, on the
development of NAFLD are equivocal. Some evidence suggest a positive association
[Lê et al., 2009, Stanhope et al., 2011], while more recent work has found that studies
are often confounded by other nutrients, e.g. saturated fats, and/or excess energy
from fructose [Chiu et al., 2014, Chiavaroli et al., 2015b]. Additionally, there are
only a few studies that have applied systems approaches to investigate the differential
effects of monosaccharides on hepatic steatosis. Here, the aim was to dissect the
differential lipogenic effects of glucose and fructose on hepatic steatosis in silico and to
experimentally validate this in vitro.
The first objective was to systematically characterise in vitro models used for the
study of lipid loaded hepatocytes induced by fatty acids. As a case study, the in vitro
model was used to investigate the effects of fatty acid induced steatosis on glyoxalase 1
detoxification of a cytotoxic byproduct of glucose metabolism, methylglyoxal, by stable
isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS). The
in vitro model was further utilised to investigate potential synergistic effects of glucose
and fructose in a co-treatment with monosaturated fatty acid, oleate, on intracellular
lipid by gas chromatography mass spectrometry (GC-MS). The second objective was
to construct a novel, multi-scale, dynamic model composed of a human hepatocyte
genome scale metabolic network integrated with a reconstructed hepatic glucose and
fructose transport network and a quantitative, kinetic model of an insulin regulatory
signalling pathway. The last objective was to perform predictive simulations of TAG
production with either glucose or fructose feeding by quasi-steady state Petri nets
(QSSPN, [Fisher et al., 2011]), and validate this experimentally to an in vitro model of
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hepatic steatosis. This was to investigate if fructose, in comparison to glucose, had
any differential lipogenic effects in liver to provide further evidence to better inform
nutritional recommendations for the prevention of NAFLD.
1.3 Aim, hypothesis and objectives
The aim of this work was to utilise a novel computational model to investigate the
relative contributions of glucose and fructose to hepatic TAG production, and experi-
mentally validate this to an in vitro model of hepatic steatosis.
It was hypothesised that this novel in silico modelling approach would predict differen-
tial hepatic lipogenic effects of fructose in comparison to glucose.
The objectives of this project were to:
• Systematically characterise in vitro models used for the study of lipid loaded
hepatocytes.
• Reconstruct a multi-scale model composed of a human hepatocyte genome scale
metabolic network integrated with hepatic glucose and fructose transport and a
quantitative, kinetic model of an insulin regulatory signalling pathway.
• Perform predictive, dynamic simulations utilising QSSPN, and validate experi-
mentally to an in vitro model of hepatic steatosis.
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1.4 List of contributions
The contributions presented in this thesis are listed below.
Chapter 3
• Confirmed the response of intracellular lipid and cell viability to saturated and
mono-unsaturated fatty acids treatment in immortalised hepatocyte cell lines.
• Demonstrated an accumulation of methylglyoxal as a functional consequence of
reduced glyoxalase 1 levels in response to fatty acid induced lipid loading in vitro
by the gold standard, stable isotope dilution LC-MS/MS.
Chapter 4
• Demonstrated a comparative response of intracellular lipid to low and high
glucose acclimatisation in HepG2 cells.
• Investigated the response to a mixed-nutrient treatment composed of oleate and
glucose or added fructose with no synergistic lipogenic effect of added sugars
detected in HepG2 cells using the gold standard, GC-MS.
Chapter 5
• Demonstrated a novel integration method utilising QSSPN by integrating a
human hepatocyte genome scale metabolic network constrained by in vitro data
with a reconstructed network of hepatic glucose and fructose transport, and a
published kinetic model of hepatic insulin signalling.
• Performed predictive, dynamic simulations of minimum and maximum flux rates
by a novel simulation method, dynamic flux variability analysis (dFVA), with no
differential lipogenic effects detected between fructose and glucose.
• Validated in silico predictions experimentally to an in vitro model of hepatic
steatosis, confirming no differential lipogenic effects of fructose in comparison to
glucose.
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Chapter 2
Non-Alcoholic Fatty Liver Disease:
Modelling its Aetiology and
Pathogenesis
2.1 Introduction
Liver disease is the fifth most common cause of death in England after cancer, heart
disease, stroke and lung disease [Department of Health, 2014]. Yet, liver disease is the
only major cause of death in the UK that is increasing year on year [Williams et al.,
2014]. Along with alcoholic fatty liver disease, NAFLD explains a large proportion of
this rise [Claridge, 2011]. NAFLD is currently estimated to be affecting 20-30 % of the
general population of the western world [British Liver Trust, 2016b]. In fact, it is now
the most common cause of liver disease and accounts for a growing proportion of patients
undergoing liver transplantation [British Society of Gastroenterology, 2016]. NAFLD is
mainly linked with obesity, diabetes, and many other metabolic disorders, leading to its
naming as the hepatic manifestation of the metabolic syndrome [Marchesini et al., 2003].
However, the underlying molecular mechanisms and impact are poorly understood,
which can be further explored by the use of systems biology approaches.
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In the last decade, there has been an increased use of computer science to help
answer biological questions. Additionally, there have been publications of mathematical
networks of human metabolism, and methods for combining multiple sources of data
and predicting biological outcomes [Bordbar and Palsson, 2012]. These advancing
methods could then be used for a better understanding of NAFLD [Fisher et al.,
2014].
2.2 Non-alcoholic fatty liver disease
First recognised six decades ago [Zelman, 1952, Westwater and Fainer, 1958], NAFLD
is now known as a histological spectrum of liver diseases (Figure 2.1). It can disrupt
the normal physiology of the liver, which is responsible for over 500 different functions,
including: processing digested food and providing energy; managing levels of fat, amino
acids and glucose in the blood; storing iron, vitamins and other essential compounds;
detoxifying drugs and toxins; and producing bile [British Liver Trust, 2016a]. NAFLD
ranges from fat accumulation (steatosis) to inflammation (non-alcoholic steatohepatitis,
NASH) and can lead to fibrosis and cirrhosis. There are reversible and irreversible
stages of NAFLD, including steatosis and NASH that may fluctuate between the two
stages, and may even resolve itself [Sung et al., 2013]. However, fibrosis and cirrhosis
are irreversible stages that may develop from NASH and lead to further complications,
such as hepatocellular carcinoma, the need for transplant, or liver-related death.
Figure 2.1 Dynamic spectrum of non-alcoholic fatty liver disease (NAFLD).
NAFLD is characterised by the accumulation of fat (steatosis) and may develop inflammation
(non-alcoholic steatohepatitis), both of which are reversible stages of NAFLD. Irreversible
stages may develop from steatohepatitis to fibrosis or cirrhosis, and may later lead to cancer,
the need of liver transplant, or death (Modified from [Moore, 2010]).
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Other causes of liver disease must also be excluded for the diagnosis of NAFLD, such
as alcohol consumption of more than the recommended guideline amounts. The UK
has recently revised this guideline to be no more than 14 units/week1 for both men
and women. Although research exclusion criteria for excessive alcohol consumption
has varied, most research would have a limit of 20 g/day for women and 30 g/day for
men [Chalasani et al., 2012, Ratziu et al., 2010]. The exclusion criteria would also
capture those with other secondary causes of fatty liver disease such as viral infections,
drug-induced steatosis or hereditary disorders as classically defined by Ludwig et al. in
1980 [Ludwig et al., 1980].
2.2.1 Diagnosis
At the present time, liver biopsy is seen as the gold standard for diagnosis and staging as
it can distinguish simple steatosis from NASH and fibrosis. The histological diagnostic
threshold for hepatic steatosis is set at ≥ 5 % hepatocytes presenting steatosis, typically
seen as macrovesicular lipid droplets [Neuschwander Tetri and Caldwell, 2003, Kleiner
and Brunt, 2012]. The histological features of NASH, in addition to steatosis, are
distinctively characterised by hepatocellular injury that include hepatocyte ballooning
and lobular inflammation [Kleiner and Brunt, 2012]. Fibrosis is featured in advanced
NASH and may progress to cirrhosis [Hübscher, 2006, Brunt, 2012]. A biopsy specimen
adequate for diagnosis can vary from 1.5-3 cm in length and 1.4-2 mm in diameter, only
representing 1/50,000 of the total liver mass [Bravo et al., 2001]. The heterogeneity of
the liver may then lead to sampling errors [Merat et al., 2012]. Its invasiveness can
also cause morbidities and mortalities [Gilmore et al., 1995, Bravo et al., 2001].
Non-invasive methods for diagnosis have often been utilised as a first measure in clinical
practice but are also explored as a supplement or an alternative for liver biopsy in
clinical research. Serum liver enzymes, including aspartate aminotransferase, alanine
aminotransferase and γ-glutamyltransferase can be measured as they are normally
raised as a result of liver injury. However, normal levels of liver enzymes have been
found to be in approximately 80 % of NAFLD patients [Browning et al., 2004]. Raised
liver enzymes have also not been found to be specific to NAFLD and do not relate to the
staging of the disease [Mofrad et al., 2003, Charatcharoenwitthaya et al., 2012].
1The UK defines 1 alcohol unit as 10 mL or 8 grams (g) of pure alcohol. Therefore, 14 units/week
equates to 16 g/day.
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Non-invasive imaging diagnostic methods include ultrasound, computed tomography
(CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy
(H-MRS). The latest published guidelines on the assessment and monitoring of NAFLD
have advised ultrasound, when available, as the preferred first line of diagnosis [EASL
et al., 2016, NICE, 2016]. Although ultrasound is relatively inexpensive and widely
utilised, it has several limitations. Ultrasound is operator dependent, cannot re-
producibly quantify steatosis, and interpretations of scans are qualitative. It also
fails to accurately detect steatosis of ≤ 30 % and becomes less accurate in morbidly
obese patients (body mass index (BMI) ≥ 40) [Schwenzer et al., 2009, Machado and
Cortez-Pinto, 2013]. CT has similar accuracy as ultrasound but exposes patients to
radiation and so, not appropriate as a screening and staging tool. A quantitative
method for imaging steatosis is MRI which can detect as little as 3 % of steatosis,
measured as a signal fat/water fraction [Machado and Cortez-Pinto, 2013]. H-MRS
can also sensitively quantify steatosis at a higher resolution as it detects acyl groups in
hepatocyte triacylglycerol (TAG) stores [Machado and Cortez-Pinto, 2013]. However,
normal liver fat by H-MRS as defined by [Szczepaniak et al., 2005] is 5.56 %. This
level of fat has been found to correspond to a histological liver fat level of 15 %
[Petäjä and Yki-Järvinen, 2016], highlighting the variation in diagnostic cut-offs at
which NAFLD can be diagnosed. Although these quantitative methods are highly
valuable in research, they are costly, less widely available in clinical practice and as
such, quantifying steatosis is less of a priority in the clinical setting [Schwenzer et al.,
2009, EASL et al., 2016].
When imaging methods are not available, or feasible for large scale application, liver
enzymes, and prediction scores based on different anthropometric and metabolic
parameters could be used. The NAFLD liver fat score, fatty liver index, and the
commercially available SteatoTest are the best validated prediction scores which can
reliably predict the presence of steatosis with an area under an receiver operating
characteristic curve of 0.80, 0.83 and 0.80 in comparison to liver biopsy, respectively
[Poynard et al., 2012, Fedchuk et al., 2014].
To date, there is no alternative method to biopsy that can adequately diagnosis NASH.
Although there are biomarkers, such as plasma cytokeratin 18 fragments as markers of
hepatocyte apoptosis, and scores in development to improve sensitivity and specificity
of non-invasive methods to help diagnose NASH [Musso et al., 2011]. Non-invasive
methods have also been developed to assess fibrosis, including prediction scores and
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elastography that uses imaging to map elastic properties of soft tissue, which are
promising. Although, these methods cannot accurately stage fibrosis, they currently
can distinguish between non-advanced and advanced fibrosis or cirrhosis [Fedchuk
et al., 2014]. These methods can at least help exclude later stages of NAFLD for some
patients and serve to reduce the number of patient biopsies [Cobbold et al., 2012].
Currently, these methods are only recommended for triaging patients rather than for
screening tools in the general population [EASL et al., 2016, NICE, 2016]. Furthermore,
it remains a research priority to find patient-friendly diagnostic methods that are
cost-effective, and can accurately assess and monitor NAFLD without complications
[Papagianni et al., 2015]. The discovery of new diagnostic biomarkers or panels thereof
as a patient-friendly method could be further aided by systems biology approaches
[Petta et al., 2015].
2.2.2 Prevalence
Depending on the study population and method of diagnosis, the prevalence of NAFLD
varies from 4-46 % throughout the world, with 3-5 % estimated to have NASH [Sherif
et al., 2016]. Current estimates of the prevalence of NAFLD are believed to be grossly
underestimated due to the limitations of diagnostic methods as described above [Lazo
et al., 2013]. Amongst the general European population, the prevalence of NAFLD
was estimated to be 20-33 % [Blachier et al., 2013]. Within the UK, 33 % of the
population was estimated to have NAFLD, and 2-5 % with NASH [British Society of
Gastroenterology, 2016]. NAFLD has also been found to be prevalent amongst the
general paediatric European population with up to 12.5 % estimated to be affected
[Blachier et al., 2013].
NAFLD has been found to be more prevalent in obese and type II diabetic (T2D)
populations. This is particularly worrisome as the latest statistics from the Health
Survey for England are that 41 % of men and 31 % of women are overweight and an
additional 24 % of men and 27 % of women are obese amongst people aged 16 and over
[Health Survey for England, 2014]. A systematic review had also provided insight on
the prevalence of NAFLD in severely obese patients that were submitted to bariatric
surgery [Machado et al., 2006]. This review included 12 studies of biopsy-proven
NAFLD with a total of 1620 severely obese patients (BMI of >40 kg/m2 or >35
kg/m2 with co-morbidities). In total, there was an average of 91 % of obese patients
12 Non-Alcoholic Fatty Liver Disease: Modelling its Aetiology and Pathogenesis
presented with steatosis, of which 37 % had NASH and 1.7 % unexpected cirrhosis.
Additionally, even in heavy drinkers, obesity was also found to increase steatosis by
two-fold [Bellentani et al., 2000]. The prevalence of NAFLD also increased amongst
children who were obese, 36-44 % [Blachier et al., 2013].
In a European T2D population, NAFLD prevalence increased to 46-69.5 % [Blachier
et al., 2013]. Furthermore, insulin resistance (IR) was found to be common in NAFLD
patients, even without the diagnosis of T2D [Sanyal et al., 2001]. The diabetes
prevalence in England, as diagnosed in 2013, was 6 % of people aged 17 and over, with
no distinction between type 1 and type 2 [Public Health England, 2014]. However, it
was estimated that about a quarter of people with T2D were unaware of their condition,
rising the prevalence estimation to 7.4 %.
Cardiovascular disease (CVD) has also been strongly linked with NAFLD with a
larger intimal-media thickness and double the frequency of carotid plaque detected in
ultrasound-proven NAFLD patients compared to a control group [Brea et al., 2005].
Additionally, 69 biopsy-proven NASH patients were assessed from stage 0 without
fibrosis up to stage 3 with advanced fibrosis [Targher et al., 2006]. The stages of fibrosis
were shown to be associated with the degree of ultrasound-detected carotid intimal
median thickness after the adjustment of classic CVD risk factors, IR and metabolic
syndrome with approximately 0.1 mm increase in thickness per subsequent stage of
fibrosis [Targher et al., 2006].
NAFLD has often been termed as the hepatic manifestation of the metabolic syndrome.
As such, genetics play a significant role, consistent with a higher prevalence in certain
ethnic groups. The highest within a USA population was found amongst Hispanics
(45%), followed by Caucasians (33%) and African Americans (24%) as detected by
H-MRS [Browning et al., 2004]. More recently, another USA-based cohort found 151
out of 328 patients had confirmed NAFLD (46 %), of which 26 % had NASH [Williams
et al., 2011]. The highest prevalence was also found to be amongst Hispanics (58 %),
followed by Caucasians (44 %) and African Americans (35 %) suggesting underlying
differences in both lifestyle and genetic predisposition towards an increase risk of
NAFLD.
NAFLD has also been found in normal weight individuals. The prevalence of NAFLD
amongst lean individuals (BMI 18.5-25) has been estimated to be 7.4 %, of which 1.4
% had NASH, and rising to 27.8 % of overweight/obese with NAFLD of which 13.9
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% had NASH [Younossi et al., 2012]. However, this may be highlighting a particular
limitation of the BMI as a health indicator as it does not quantify how much nor where
body fat is being stored. In fact, increased visceral fat, which may be present within
the normal BMI range, has been more associated with metabolic disorders [Younossi
et al., 2012, Fedchuk et al., 2014]. This is particularly evident in populations with a
higher waist circumference (>88 cm for women and >102 cm for men) with a higher
prevalence of T2D [Public Health England, 2014].
It has also been highlighted recently by a review that there may be a distinguishable
difference between ‘acquired’ versus ‘genetic’ NAFLD [Petäjä and Yki-Järvinen, 2016].
The authors propose acquired NAFLD is mostly dependent on the occurrence of IR,
often stimulated by poor dietary and physical activity habits, and highly associated
with other metabolic disorders. Whereas, genetic susceptibility to NAFLD is linked to
mutations such as patatin-like phospholipase domain containing 3 (PNPLA3) genetic
variant I148M and transmembrane 6 superfamily member 2 genetic variant E167K
with increase risk of steatosis without IR. These genetic variants result in a high risk
of NAFLD progression without an increase risk of systemic metabolic disease [Petäjä
and Yki-Järvinen, 2016]. This may, in part, explain the occurrence of lean, non-T2D
patients with NAFLD due to genetic susceptibility that is specific to NAFLD. Yet,
these conditions are not exclusive as they may co-exist, featuring a higher genetic risk
for NAFLD and the metabolic syndrome [Luukkonen et al., 2016].
2.2.3 Natural history
Within the spectrum of NAFLD, simple steatosis is generally regarded as benign [Marra
et al., 2008]. However, steatosis with the presence of inflammation and ballooning is
regarded as a more progressive stage of disease, and may even include mild fibrosis
[Brunt, 2004]. Fibrosis may advance and lead to the development of cirrhosis and
end-stage liver disease [Brunt, 2004, Musso et al., 2011].
In an early clinical study with an average 13.7 year follow up, it was found that none
of the 58 biopsy confirmed steatotic patients with or without unspecific inflammation
progressed to chronic liver disease [Ekstedt et al., 2006]. Whereas in the same study, 7
out of 71 NASH patients developed end-stage liver disease during follow up. However,
current stratification of NAFLD combines individuals with simple steatosis with those
that have both steatosis and mild, non-specific inflammation as non-alcoholic fatty
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liver (NAFL). This is a particular issue as patients with steatosis alone have been
found to be least likely to progress (1/5 patients) [Pais et al., 2013]. In the same
study, a significantly large proportion of patients with some evidence of inflammation
progressed to NASH or fibrosis (13/16 patients) during a 3.3-5.7 year follow up.
Similarly, another study had shown that NAFL patients can progress to NASH
(12/27 patients, 1.7-22.6 years) and fibrosis (10/27 patients, 6.4-22.6 years), with
those featuring mild inflammation more likely to progress [McPherson et al., 2015].
Additionally, 3 out of 13 patients with simple steatosis were found to progress to full
NASH just after 3 years follow up [Wong et al., 2010].
The overall mortality rate was observed to be higher in NASH patients, par-
ticularly when advanced fibrosis was present with a hazard ratio of 3.3, 95 % CI
2.27-4.76 [Ekstedt et al., 2015]. NASH patients had a significantly lower survival
compared to a reference population, 70 % and 80 % respectively [Ekstedt et al., 2006]
and a standardised mortality ratio of 1.9, 95 % CI 1.19-2.76 compared to a general
Swedish population [Söderberg et al., 2010]. As may be expected, deaths amongst
NAFLD patients were more likely to be caused by liver related complications compared
to the reference population, 2.8 % and 0.2 % respectively [Ekstedt et al., 2006].
However, extra-hepatic causes of death, such as cancer and CVD fatal events, also have
a higher occurrence in NAFLD (CVD, 14/47; and extrahepatic malignancies, 13/47
deceased) compared to the general population (3/6 and 1/6 deceased, respectively)
[Söderberg et al., 2010]. Additionally, a meta-analysis found that NASH also increased
the risk of liver-related morality compared to steatosis (odds ratio 5.71, 95 % CI
2.31-14.13) [Musso et al., 2011]. However, the increase risk of CVD mortality was
similar in both steatosis and NASH patients (pooled odds ratio 0.91, 95 % CI
0.42-1.98), but higher than the general population (pooled odds ratio 2.16, 95 % CI
1.88-2.49).
As mentioned, with the limitations of the methods for diagnosis and staging
of the disease, it is difficult to monitor patients. With improved methods, the level
of urgency for treatment and the type of therapeutic approach can be assessed
appropriately. Although these methods are advancing, some of the limitations in
diagnostic methods can be resolved by gaining a better understanding in the underlying
molecular mechanisms of NAFLD pathogenesis and progression.
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2.2.4 Pathogenesis
The classical theory of the development and progression of NAFLD is the ‘two-hit
process’ [Day and James, 1998] with a first hit of lipid accumulation and the second
hit with inflammation. This was further developed in a hypothesis of ‘at least three
hits’ involving many more factors to include a combination of genetic susceptibility,
biological environment, and behaviour [Charlton, 2007]. Our understanding of
NAFLD pathogenesis has since grown in its complexity including genetic, metabolic,
environmental, and gut microbial factors [Byrne and Targher, 2015]. However,
mechanistically NAFLD can be simplified as the imbalance of import and export, and
the synthesis and utilisation of lipid in the liver as highlighted in Figure 2.2. These
processes include the import of dietary lipid and circulating free fatty acids (FFA) and
the export of lipid by very low density lipoprotein (VLDL), and dysregulation in the
flux through de novo lipogenesis (DNL) and fatty acid (FA) oxidation.
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Droplets 
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Figure 2.2 NAFLD pathogenesis. Nutrients from the diet and the adipose tissue con-
tribute to the available nutrients and metabolic factors influencing the physiology of lipid
metabolism in the liver (→) but may undergo pathological changes (99K). Together, they
may influence the various stages of NAFLD as described throughout the text. Abbreviations:
FA, fatty acids; FFA, free fatty acids, DNL, de novo lipogenesis; TAG, triacylglycerol; ROS,
reactive oxygen species; VLDL, very low density lipoprotein.
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2.2.4.1 Free fatty acid flux
The liver has multiple FA sources (Figure 2.2 (1)). However, human stable isotope
studies show that adipose tissue derived FFA is the largest source of lipid in the liver
and increases in the fasting state, and in those who have NAFLD, from 40 % up to 80
% [Donnelly et al., 2005, Barrows and Parks, 2006]. During feeding, insulin plays a
significant role in regulating the metabolic switch from fasting to the fed state. However,
systemic IR has been seen in NAFLD and shown to have a suppressed response to
insulin-mediated inhibition of adipose tissue lipolysis [Sanyal et al., 2001]. Therefore,
the adipose tissue is still undergoing lipolysis and releasing FFA after feeding. As such,
high circulating FFA has been shown to feature in NAFLD patients [Fabbrini et al.,
2008, Lambert et al., 2014].
In comparison, dietary FA from chylomicron (gut-sourced, ultra low-density lipopro-
teins) remnants contributed to 15 % of total liver fat and increases to 25 % in the
fed state [Donnelly et al., 2005, Barrows and Parks, 2006]. Also during the fed state,
‘spillover’ FA from peripheral tissue lipolysis of chylomicrons has also been found to
contribute up to 10-15 % [Donnelly et al., 2005, Barrows and Parks, 2006]. Together
with adipose tissue IR, NAFLD may result in higher, sustained circulating levels of
FFA. This would then equate to a larger flux of FFAs into the liver, as hepatic FFA
import is proportional to blood concentrations [Hagenfeldt et al., 1972, Iozzo et al.,
2004].
Once these FFA enter the hepatocyte, they are quickly formed into fatty acyl CoAs
which can then provide fatty acids for the production of triacylglycerol, via the
Kennedy pathway (Figure 2.3) [Coleman and Lee, 2004]. In fact, FA treatment has
become an established mechanism for developing in vitro models of hepatic steatosis
[Guguen-guillouzo and Guillouzo, 2010, Green et al., 2015b]. FA treatment on cultured
hepatocytes have frequently been used to confirm lipogenic effects [Gómez-Lechón
et al., 2007, Ricchi et al., 2009, Yao et al., 2011]. Additionally, these in vitro models
have been utilised for the investigation of progressive factors that may trigger simple
steatosis to develop NASH-like features [Malhi et al., 2006, Malhi et al., 2007, Garcia
et al., 2011, Chavez-Tapia et al., 2012]. Some examples of immortalised hepatocytes
treated with fatty acids to induce steatosis is summarised in Table 2.1. In addition,
disturbed cholesterol metabolism has also been linked with NAFLD [Arguello et al.,
2015]. An accumulation of free cholesterol in hepatocytes has been found to affect
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Figure 2.3 Triacylglycerol synthesis. Typical TAG synthesis in the liver from which
imported or newly synthesised fatty acids can be incorporated once converted into fatty
acyl CoAs (FA-CoA). Abbreviations: GPAT, glycerol 3-phosphate acyltransferase; AGPAT,
acylglycerophosphate acyltransferase; PAP, phosphatidic acid phosphohydrolase; DGAT,
diacylglycerol acyltransferase.
membrane fluidity and protein function as well as activate other hepatic resident cells
that would lead to progression in NAFLD as described in Section 2.2.4.5 [Ioannou,
2016].
Once transported into the liver, FFAs are converted into fatty acyl CoAs. These
derivatives may either undergo esterification into TAG (Figure 2.2 (3)) to be stored as
intrahepatic lipid or packaged for VLDL export (Figure 2.2 (5)), or enter the oxidation
pathway (Figure 2.2 (4)) [Hodson and Frayn, 2011, Mashek, 2013].
2.2.4.2 De novo lipogenesis
DNL has been found to contribute up to 25 % of liver fat in NAFLD patients [Donnelly
et al., 2005, Lambert et al., 2014]. In comparison, a DNL contribution of 10 % was
observed in overweight and obese patients [Marques-Lopes et al., 2001, Schwarz et al.,
2003, Lambert et al., 2014] and <5 % seen in healthy, lean populations [Marques-Lopes
et al., 2001, Parks, 2002, Schwarz et al., 2003]. These studies suggest an increase in
DNL flux plays a significant role in NAFLD.
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DNL is the production of FAs from non-lipid precursors (Figure 2.2 (2)). With available
acetyl CoA, acetyl CoA carboxylase (ACC) converts this to malonyl CoA and provides
the substrate for FA synthesis by fatty acid synthase (FAS). The end product of FAS is
palmitic acid (PA, 16:0) [Mashek, 2013]. Newly synthesised PA can undergo elongation
to produce stearic acid (SA, 18:0) and desaturation to form oleic acid (OA, 18:1n9); or
desaturation to produce palmitoleic acid (POA, 16:1n7) and elongation for vaccenic
acid (VA, 18:1n7) [Chong et al., 2007a, Wu et al., 2011] (Figure 2.4). Subsequently,
these FAs can be incorporated into TAG.
Figure 2.4 De novo fatty acid synthesis. De novo lipogenesis (DNL) is the endogenous
production of fatty acids from non-lipid precursors. The end product is palmitic acid (PA,
16:0) and can either be desaturated or elongated to produce palmitoleic acid (POA, 16:1n7)
and elongated to vaccenic acid (VA, 18:1n7), typically known as DNL fatty acids. PA could
also be elongated to produce stearic acid (SA, 18:0) and further desaturated into oleic acid
(OA, 18:1n9).
The primary substrate for the DNL pathway is carbohydrates, such as glucose and
fructose. Insulin plays an essential role in carbohydrate metabolism that promote the
storage of energy, such as glycogen and fat. Hepatic insulin acts by binding to its
receptor and activating insulin receptor substrate (IRS) 1 and IRS 2, which both can
initiate signalling cascades that regulate numerous pathways in liver metabolism [Ferré
and Foufelle, 2010]. Pathways stimulated by insulin are proposed to be dependent
on the downstream effects of IRS 1-specific and IRS 2-specific pathways [Ferré and
Foufelle, 2010].
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Figure 2.5 Insulin signalling. Insulin may bind to its receptor and activate insulin receptor
substrate (IRS) 1 and IRS 2. IRS 1 leads to a signalling cascade that activates lipogenesis.
IRS 2 also leads to a signalling cascade that inactivates gluconeogenesis, while promoting
glycogenesis. Abbreviations: protein kinase b, PKB; mechanistic target of rapamycin, mTOR;
forkhead box protein O1, FoxO1; glycogen synthase kinase 3 beta, GSK3β; sterol regulatory
element binding protein, SREBP; glycogen synthase, GS.
IRS-1 stimulates the mechanistic target of rapamycin (mTOR) signalling pathway,
which can then induce sterol regulated element binding protein (SREBP)-1c. This
allows SREBP-1c to act as a transcription factor to subsequently induce lipogenic
gene expression, e.g. ACC and FAS expression [Ferré and Foufelle, 2010]. Meanwhile,
IRS-2 inactivates forkhead box protein O1 (FoxO1) to then inhibit glucose 6 phos-
phatase (G6Pase), and subsequently inactivate gluconeogenesis [Ferré and Foufelle,
2010]. However, during metabolic disturbances, such as IR, there appears to be a
desynchronisation of the two signalling pathways where gluconeogenesis is no longer
inhibited, but lipogenesis is still active. Ongoing theories propose a phenomenon known
as selective IR [Brown and Goldstein, 2008]. This occurs when only IRS 2 is affected,
hence the retained stimuli for lipogenesis but lack of gluconeogenesis inhibition. This
features in certain models of IR [Shimomura et al., 2000, Brown and Goldstein, 2008]
and may well feature in NAFLD IR.
However, there are also insulin independent mechanisms that can potentially influence
hepatic lipogenesis that have been highlighted recently [Ferré and Foufelle, 2010].
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SREBP has also been found to be sensitive to nutrients, such as amino acids. This
provides an alternative theory to selective IR as an insulin independent pathway for
lipogenesis. ER stress (featured in NAFLD [Puri et al., 2008]) has also been shown
to induce SREBP [Ferré and Foufelle, 2010]. In addition, glucose and fructose also
induce a different lipogenic transcription factor, the carbohydrate response element
binding protein (ChREBP) [Sanders and Griffin, 2015]. ChREBP is located in the
cytoplasm when glucose concentrations are low, and enters the nucleus when glucose
concentration is high [Denechaud et al., 2008]. Active ChREBP induces genes involved
in glycolysis and lipogenesis, such as pyruvate kinase (PK), ACC and FAS [Denechaud
et al., 2008, Poupeau and Postic, 2011]. Together, SREBP-1c and ChREBP are key
players in the induction of lipogenesis.
As an insulin independent mechanism, glucose and fructose transport into liver are medi-
ated through insulin-independent bi-directional glucose transporter, GLUT2 [Mueckler
and Thorens, 2013]. GLUT2 is stimulated by glucose [Postic et al., 1993] and dependent
on its metabolism [Rencurel et al., 1996]. Furthermore, low concentrations of glucose
with increasing insulin levels were shown to inhibit hepatic GLUT2 expression in rats
but high glucose concentrations overrode the inhibitory effects of insulin [Postic et al.,
1993, Im et al., 2005]. Other transporters have been shown to potentially play a
significant role in glucose and fructose uptake in the liver, such as GLUT9 [Takanaga
et al., 2008] and GLUT8 [Debosch et al., 2014], respectively.
Insulin, via SREBP-1c, has also been found to be an important stimulator of glucokinase
(GCK) and GLUT2 transcription expression [Im et al., 2005]. Additionally, glucose
and fructose were found to stimulate GCK activity by inducing the translocation
from the nucleus to the cytosol. GCK in its inactive form is within the nucleus and
bound to glucokinase regulatory protein (GCKR) enforced by fructose 6-phosphate,
indicating sufficient glycolysis. However, GCK becomes active once unbound to GCKR,
as induced by fructose via fructose 1-phosphate (fructolysis) [Van Schaftingen et al.,
1994] and high glucose concentrations [De La Iglesia et al., 1999] to encourage glycolysis.
Although fructose was not found to increase the expression of GCK [Koo et al., 2008],
it was shown to stimulate the dissociation of GCK-GKRP and release GCK into the
cytosol for glucose metabolism independently of insulin [Doiron et al., 1994].
Simple sugars in particular have been targeted more recently as correlations to obesity
rates have been observed [Johnson et al., 2007] and sugar sweetened beverages have been
associated with an increase risk of metabolic diseases [Stanhope et al., 2009, Stanhope
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et al., 2015]. In particular, fructose has been targeted as it has been found to induce
hepatic steatosis and metabolic dysfunction [Johnson et al., 2013]. Fructose has been
shown to induce lipogenic expression and induce DNL [Parks et al., 2008, Janevski
et al., 2012]. The progression of NAFLD by fructose has been proposed by reducing
cellular energy and increasing a metabolic byproduct, uric acid [Abdelmalek et al.,
2010, Abdelmalek et al., 2012]. Fructose has also been found to strongly promote
hyperlipidemia [Chong et al., 2007b, Parks et al., 2008]. Additionally, some evidence
have also found fructose to promote a higher flux through DNL than glucose. Fructose
metabolism, unlike glucose, is unregulated due to it bypassing phosphofructokinase
(PFK)-1, a major regulatory step for glycolysis [Mayes, 1993]. Therefore, fructose
directly supplies trioses, glyceraldehyde and dihydroxyacetone phosphate, that may
enter the Krebs cycle, expend as carbon dioxide (CO2), convert as glucose or lactate,
or enter into glycogenesis or even lipogenesis. However, a review of isotopic metabolic
studies suggest a large proportion of fructose was converted into glucose (28.9-54 %),
lactate (ca. 28 %) and expended as CO2 (30.5-62 %), while the level of contributions into
other pathways were suggested to be small, but largely unknown [Sun and Empie, 2012].
Additionally, human studies have often used high doses of fructose and confounded by
excess energy [Chung et al., 2014, Chiu et al., 2014, Chiavaroli et al., 2015b].
Some animal studies have also shown the induction of fructose-driven DNL. High
fructose (60 %) in comparison to high (60 %) glucose diet fed rats have been shown to
have a wide range of induced lipogenic gene expression [Koo et al., 2008], including FAS.
This group later confirmed that fructose increased ChREBP activity and SREBP-1
protein levels within the nucleus of rat livers in comparison to glucose that could
then potentially stimulate lipogenic gene expression [Koo et al., 2009]. Fructose also
enhanced fructokinase expression and aldolase B expression [Koo et al., 2008], similarly
seen in an in vitro model [Hirahatake et al., 2011], adapting metabolism to become more
efficient for fructolysis. Genes involved in the glycolysis pathway were also enhanced,
including PFK and PK messenger (m)RNA in the fructose-fed group compared to the
glucose-fed group. Fructose was also found to enhance the conversion of glucose into
glycogen. Although this may only be an acute effect, as long-term effects of chronic
fructose feeding reduced glucose conversion into glycogen [Mayes, 1993]. Additionally,
gluconeogenic genes, fructose 1,6-bisphosphatase (FBPase) and G6Pase, were induced
in fructose-fed compared to the glucose-fed group [Koo et al., 2008]. This group later
found that nuclear FoxO1 was also elevated by 1.7-fold in the fructose group, but did
not reach significance [Koo et al., 2009].
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Figure 2.6 Glucose and fructose metabolism and regulation. The main hepatic glu-
cose and fructose transporter is GLUT2. Glycolysis is highly regulated by the cell energy
status and insulin. Meanwhile, fructolysis can produce trioses without inhibitory feedback.
Fructose also enhances its own metabolism by inducing ketohexokinase (KHK) expression.
Additionally, glucose and fructose promotes the availability of GLUT2 and glucokinase (GCK),
respectively. Insulin and glucose, via SREBP-1c and ChREBP respectively, promote the
lipogenic gene expression of acetyl CoA carboxylase (ACC), fatty acid synthase (FAS) and
stearoyl CoA desaturase (SCD) to encourage de novo lipogenesis (DNL). DNL intermediates,
such as malonyl CoA, inhibits β-oxidation (β-ox, in grey), further promoting DNL. Abbrevia-
tions: TAG, triacylglycerol; FA, fatty acid; glucose 6-phosphatase, G6Pase; glycogen synthase,
GS; fructose-1,6-bisphosphatase, FBPase; phosphofructokinase, PFK; pyruvate kinase, PK;
fructose 1-phosphate, F-1P; glucose 6-phosphate, G-6P; glucose 1-phosphate, G-1P; fructose
6-phosphate, F-6P; fructose 1,6-bisphosphate, F-1,6bP; glyceraldehyde, GA; dihydroxyacetone
phosphate, DHAP; glyceraldehyde 3-phosphate, GAP; glycerol 3-phosphate, G3P; carnitine
palmitoyltransferase, CPT, glucokinase regulatory protein, GCKR.
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Independently, while glucose lowered G6Pase expression, fructose and sucrose were
shown to induce G6Pase expression in mice [Stamatikos et al., 2016]. In order to
disregard the possibility of the conversion of fructose into glucose that may cause the
lipogenic effects, a FBPase inhibitor was used in an in vitro model cultured in low
and high glucose or fructose [Stamatikos et al., 2016]. It was found that only cells
fed supraphysiological levels of fructose induced lipogenic activity by ACC and FAS
mRNA induction. Fructose has also been found to feed into hepatic glycogen stores
[Petersen et al., 2001], in addition to inducing DNL and hepatic TAG production [Koo
et al., 2008].
Interestingly, hepatic TAG levels were only higher in the fructose fed group than in
the glucose fed group [Koo et al., 2008]. In contrast, both TAG and FFA levels were
significantly lower in the fasted fructose group than in the fasted glucose group [Koo
et al., 2008]. However, a similar animal experiment with the addition of high sucrose
(60 %) fed rats also showed an increase of lipogenic gene expression of ACC, FAS and
ChREBP, with no change in SREBP-1c mRNA [Janevski et al., 2012]. Additionally,
the protein expression of ChREBP and SREBP-1c were similar amongst all groups,
but were higher in the nuclear fractions of high-fructose and high-sucrose fed rats. This
indicates that although fructose may induce TAG, it appears to be similarly done by
sucrose. However, the body weight of animals from each group were the same. Plus,
the livers from the high-fructose and high-sucrose fed animals did not contain any more
fat than the control starch fed group [Janevski et al., 2012]. In both experiments, no
differences were noted in the genes involved in FA oxidation [Koo et al., 2008, Janevski
et al., 2012].
2.2.4.3 Fatty acid oxidation
Animal studies suggest that there may be defects in FA oxidation (Figure 2.2 (4))
in NAFLD [Anstee and Goldin, 2006]. On the contrary, an isotope study of 16 H-
MRS-proven NAFLD patients detected a positive correlation (r=0.71) between hepatic
fat content and Krebs cycle flux, suggesting increased oxidation [Sunny et al., 2011].
One major regulator of hepatic lipid metabolism that may have an influential role,
particularly in FA oxidation, is peroxisome proliferator-activated receptor (PPAR)α
[Rakhshandehroo et al., 2009]. PPARα is expressed at particularly high levels in the
liver, while the other isoforms of PPAR (PPARγ and PPARδ) are expressed at low
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levels [Poulsen et al., 2012]. PPARα is stimulated by FAs and active during fasting
when there is a high influx of FA into the liver, and induces gene expression involved
in FA catabolism and ketogenesis [Sanderson et al., 2010].
However, these mechanisms were mainly studied in mice while human protein expression
studies are still lacking [Afman and Müller, 2012]. Controversies of applying murine
studies to human were somewhat resolved by showing a comparable PPARα mRNA
expression levels in primary human and murine hepatocytes relative to universal 18S
expression [Rakhshandehroo et al., 2009]. Nevertheless, PPARα agonists, e.g. clofibrate
and fenofibrate, have different effects on rodents (carcinogen) and humans (dyslipidemia
treatment) [Klaunig et al., 2003]. Yet, there is promising progress with dual PPAR
α/δ and PPAR α/γ agonists in trails as treatment options [Wong et al., 2016]. For
this reason, future studies will be required to reveal the direct influence of PPARs in
human hepatic metabolism.
Dysregulation of the normal response to nutrition intake may also influence FA oxi-
dation. Malonyl CoA, the primary carbon source utilised for FAS, is produced as a
product of ACC from acetyl CoA, an end product of glycolysis as seen in the DNL
pathway. This affects mitochondrial β-oxidation as FA transport from the cytosol
to the mitochondria is inhibited by increasing levels of malonyl CoA via inhibiting
carnitine palmitoyl transferase-1 (Figure 2.6) [McGarry et al., 1977, Browning and
Horton, 2004]. Consequently, FA utilisation decreases as observed in normal physiology.
However, NAFLD patients present a constant high rate of DNL throughout the day
[Donnelly et al., 2005], inferring an abnormal alteration in FA metabolism which may
be an influential factor in NAFLD. This could also be explained by abnormal circadian
rhythmicity as cortisol metabolism which influences lipid metabolism has also been
found to be altered in NAFLD [Ahmed et al., 2012]. Therefore, an increase flux
through DNL may not be the main cause of excess lipid, but also inhibition of FA
utilisation that exacerbates lipid accumulation. In addition, this may lead to the build
up of lipid intermediates (e.g. FFA, diacylglycerol (DAG), ceramides) that may induce
detrimental effects, such as IR [Dowman et al., 2010, Luukkonen et al., 2016].
2.2.4.4 Lipid export
Another possible mechanism of lipid accumulation is a decrease in lipid export (Figure
2.2 (5)). Transcript levels of VLDL assembly proteins (apolipoprotein B and microsomal
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triglyceride transfer protein) and liver fatty acid binding protein from 22 biopsy-proven
NAFLD patients were shown to be significantly induced compared to healthy controls
[Higuchi et al., 2011]. Yet, the mRNA expression of microsomal triglyceride transfer
protein in patients with >30 % steatotic hepatocytes reduced significantly by more than
half compared to patients with lower steatosis levels. There was also a trend of lower
mRNA expression of apolipoprotein B by a quarter in patients with >30 % steatotic
hepatocytes than patients with <30 % . While an isotope study observed an increase
in VLDL secretion rate in patients with higher hepatic fat content [Fabbrini et al.,
2008], VLDL secretion rates plateaued in patients with 10 % or more intrahepatic fat.
This infers that genes related to lipid export are enhanced in mild levels of steatosis
but may be compromised at a higher degree of steatosis.
2.2.4.5 Progression of non-alcoholic fatty liver disease
The later stages of NAFLD features NASH and fibrosis. These stages involve an
interplay of multiple cell types residing in the liver and pathogenic cell-to-cell communi-
cation [Marra et al., 2008]. Briefly, NASH (Figure 2.2 (6)) develops from the interplay
of reactive oxygen species (ROS), cellular and DNA damage, cytokines, endotoxins,
genetic predisposition, and the recruitment and signalling of immune cells, including
Kupffer cells (KC) [Dowman et al., 2010]. One proposed mechanism is by an increase in
β-oxidation flux [Sunny et al., 2011], resulting in excess oxidative byproducts, such as
ROS. This could then create a pro-oxidative state with an overwhelmed or compromised
antioxidative metabolism. In addition, cytokines from adipose tissue (adipokines) as
well as hepatocyte-derived cytokines (hepatokines) are believed to be released and
further enhance a pro-inflammatory state [Marra et al., 2008, Lebensztejn et al., 2016].
This overall increase in pro-oxidative/pro-inflammatory state and increase in damage
activates repairing mechanisms that may become hyperactive, leading to fibrosis.
Hepatic fibrogenic factors are regulated by the activation of hepatic stellate cells (HSC)
creating fibroblasts. Fibrosis (Figure 2.2 (7)) progresses from the interplay of the
factors listed above and the signalling pathways of KC and HSC. These cells, once
activated, can lead to collagen production and even apoptosis that can further increase
the risk of cirrhosis development [Svegliati Baroni et al., 2008]. Cirrhosis develops as
scar tissue and replaces liver tissue to the point of significant loss of function without
any noticeable traces of NAFLD [Brunt, 2004]. NAFLD most likely attributes to what
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is known as crytogenic cirrhosis, and may even become malignant as cirrhosis increases
the risk of developing hepatocellular carcinoma via cellular degeneration and genetic
modification as described above [Neuschwander Tetri and Caldwell, 2003, Hübscher,
2006, Minicis et al., 2012].
Although later stages of NAFLD include the involvement of other cell types, the initia-
tion may begin from hepatocytes as they can secrete factors that induce inflammation
and apoptosis [Dowman et al., 2010]. The importance of cell-to-cell signalling within
the liver for the progression of NAFLD is highlighted in emerging in vitro methodologies
such as co-culturing hepatocytes and HSCs [Giraudi et al., 2015].
2.2.5 Therapeutic approaches
Currently, lifestyle changes are encouraged as a therapeutic approach to manage
NAFLD. This includes eating a healthy diet and increasing physical activity to prevent
and resolve NAFLD, regardless of BMI, as advised by both the European Association
for the Study of the Liver (EASL) and the National Institute for Health and Care
Excellence (NICE) [EASL et al., 2016, NICE, 2016]. Lifestyle changes by exercise
and dietary modifications that induces weight loss of ≥7 % have been shown to have
the most beneficial effects [Musso et al., 2012, Zelber-Sagi et al., 2016]. However,
long-term maintenance of weight loss is the largest and a significant limitation to this
recommendation [Wing and Phelan, 2005]. Even without significant weight loss, an
improvement of the nutritional quality of the diet and increasing physical activity has
shown to improve NAFLD [Musso et al., 2003, Keating et al., 2015]. Yet, the optimum
diet to treat NAFLD is not known as its likely influenced by the heterogeneity of
NAFLD and patient inter-variability [Dyson et al., 2014, Kaput and Morine, 2012].
General recommendations towards acquiring a more healthy dietary profile include a
significant reduction of dietary sources of saturated fats, while increasing unsaturated
fatty acids, particularly omega 3 polyunsaturated fatty acids (PUFA) [Musso et al.,
2003]. Simple sugars should also be reduced while increasing sources of fiber, and fruits
and vegetables [McCarthy and Rinella, 2012, Hossain et al., 2016]. Specific dietary
recommendations regarding fructose have been acknowledged but conclusions from
scientific evidence were mixed. EASL had specifically addressed fructose and advised
to reduce its consumption, while NICE did not have any specific recommendations
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due to the lack of relevant scientific evidence for the UK [EASL et al., 2016, NICE,
2016].
If lifestyle interventions are unsuccessful, other treatments are available [Dyson et al.,
2014]. Those with NASH, particularly with fibrosis, or with high risk of NAFLD
progression, pharmaceutical treatment may be recommended [EASL et al., 2016]. Due
to common morbidities found along with NAFLD, pharmacotherapeutic drugs that
are used to manage obesity, T2D and CVD may be recommended if at high risk of
progression and not responding to lifestyle changes [Hossain et al., 2016]. Bariatric
surgery may also be a potential treatment reserved for those who have a BMI of 40, or
between 35 and 40 with comorbidities, and not responsive to lifestyle or pharmaceutical
intervention [EASL et al., 2016].
In a meta-analysis, seven random control trials (RCT) with a total of 572 patients
with thiazolidinedione treatments, typically used for T2D and known as PPAR gamma
agonists, from 6 to 24 months were found to improve histological steatosis and inflam-
mation [Musso et al., 2010]. Whereas, metformin (insulin sensitiser) treatment for 6 to
12 months was found to have limiting and inconsistent improvements of histological
steatosis in five RCT with a total of 287 participants [Musso et al., 2010]. PUFA
studies that were included in the meta analysis had no histological evidence. However,
two RCT PUFA studies of a 6 month intervention with 40 and 144 patients found
ultrasound steatosis improvements in 50-53 % of patients and reversed in 20-33 %
of patients [Musso et al., 2010]. Other lipid lowering drugs, including fibrates and
statins, used in RCTs that were collected for the meta-analysis had no histological
evidence or no improvements [Musso et al., 2010]. Histological evidence that was
collected for antioxidant supplementation for NAFLD treatment were mainly vitamin
E interventions [Musso et al., 2010]. Four RCTs investigating vitamin E that were
collected found improved steatosis after a 6 to 24 month intervention. Particularly, a
high quality RCT with 247 patients found that 800 IU of vitamin E with lifestyle advice
improved steatosis and inflammation compared to placebo [Sanyal et al., 2010].
Amongst pharmacological agents, evidence suggested that vitamin E and pioglitazone
(a diabetic drug) are the most effective drugs in treating NASH, but also at the expense
of potential adverse effects. It has been suggested that pioglitazone, vitamin E, or
their combination could be used as treatment for NASH [EASL et al., 2016]. Yet, there
are still no specific treatments for NAFLD, despite it being one of the most prevalent
chronic liver diseases.
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2.3 Systems approaches in nutrition
Traditional biological approaches were predominantly based on reductionism stemmed
from René Descartes (1596–1650) [Trewavas, 2006, Döring et al., 2015]. Following this,
there were fundamental discoveries in mathematics and physics leading to mechanistic
synonyms to describe biology as purely clockwork that could be dissembled and
reassembled to describe its functional behaviour [Trewavas, 2006]. On the contrary,
the ideology behind systems biology has stemmed back to Aristotelian’s notion of
emergence from a system (384–322 B.C.), to the recapturing of holism in biology by
Jan Christiaan Smuts (1926), general systems theory by Paul A. Weiss and Ludwig von
Bertalanffy (1940-1950), and cybernetics by Norbert Wiener (1965) [Novotny et al.,
2003, Trewavas, 2006, Döring et al., 2015]. Additionally, there were many key players
promoting the use of mathematics for systems biology, including Robert Rosen, Mihaijlo
Mesarovic and Francis E. Yates [Novotny et al., 2003, Döring et al., 2015].
Mathematical modelling has been approached for the study of nutrient metabolism,
e.g. in isotope studies that use stable or radioactive isotopes (tracer) to study the
substance of interest (tracee). The first radioactive study was quoted to be for the
study of phosphorus metabolism in 1935 [Green and Green, 1990]. Isotope studies
have traditionally been qualitative, as they measure a tracer to track the tracee in the
metabolic system. These models had taken the shape of compartmental modelling,
so as to describe a system consisting of compartments with well defined rules for the
flow of target substance(s) between compartments [Jacquez, 1985]. A similar approach
has also been taken within pharmacology research, known as physiologically based
pharmacokinetic (PBPK) modelling [Gerlowski and Jain, 1983]. With compartmental
modelling, these measurements can be used to gain further insight about the tracee in
the metabolic system that cannot be directly observed or measured. This approach
appeared to be taken from two main angles: empirical modelling based on observations
to gain further insight, or ‘model-based’ modelling with the addition of integrating
prior knowledge to generate new hypotheses [Green and Green, 1990]. This has enabled
experimental data to be analysed more effectively and maximised the amount of
information from these expensive experiments [Baer et al., 1999]. However, with the
aid of quantitative mathematical modelling, these data with the incorporation of prior
knowledge can provide predictive information about the dynamic behaviour of the
system and generate hypotheses for further testing experimentally. Compartmental
30 Non-Alcoholic Fatty Liver Disease: Modelling its Aetiology and Pathogenesis
modelling has been utilised for the study of nutrient digestion and absorption, and
whole body metabolism. Some examples have been applied to study minerals and
vitamins [Foster et al., 1979, Green et al., 1985, Faulks et al., 1997], lipids [Green
et al., 1984, Beltz et al., 1985, Magot, 1988] and glucose [Cobelli et al., 1982, Ader
et al., 1985]. Computational modelling with nutritional relevance have continued to
be used to gain insight, e.g. whole-human energy [Duarte et al., 2007], glucose and
insulin [Dalla Man et al., 2007], folate [Nijhout et al., 2004], and whole-body cholesterol
metabolism [Mc Auley et al., 2012].
Meanwhile, there has been growing evidence of genetic influence on individual responses
to nutrition. As early as the 1950s, it has been observed that individuals responded
differently to nutrition [Williams et al., 1950] and nutrition can be involved in disease
prevention [Williams, 1971]. Genetically very similar, individuals have slight variations
of genes which can lead to different responses to nutrients. Conversely, nutrition can
alter the expression of genes [Afman and Müller, 2006, Williams et al., 2008], examples
being the MTHFR variant for higher folic acid requirements [Kang et al., 1988, Jacques
et al., 1996] and APOA1 variant in female PUFA intakes influencing high density
lipoprotein (HDL) levels [Ordovas et al., 2002]. The use of human clinical data to
integrate with computational models have also been used, e.g. to study glucose and
insulin regulations in healthy and T2D patients [Silber et al., 2007].
The Human Genome Project (2003) was a major milestone for molecular biology. It
promoted advances in technologies such as genome sequencing, subsequently lowering
the costs of these studies [Collins and Hamburg, 2013] and allowing these methods to
be applied to the wider scientific field. These methods have since been applied to gain
a better understanding of genotype-phenotype relationships. High-throughput tech-
nologies have evolved to include genomics, transcriptomics, proteomics, metabolomics,
and many more are emerging and being applied to nutritional sciences [Kussmann
et al., 2006, Micheel et al., 2012]. This has led to further discoveries of gene-nutrition
interactions. Some examples are the alpha-ketoglutarate dependent dioxygenase gene
(FTO) variant with obesity-related traits [Scuteri et al., 2007] and fatty acid desat-
urase (FADS ) gene cluster with the intake of different PUFAs influencing low density
lipoprotein (LDL) and HDL levels [Hellstrand et al., 2012, Liu et al., 2015]. With
such influential gene-nutrient associative studies, the idea arose for the study of nu-
trigenomics and personalised nutrition for preventative medicine [Afman and Müller,
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2006, Joost et al., 2007], but not without some potential drawbacks regarding ethics
and effectiveness [Chadwick, 2004].
There are several challenges for modelling in nutrition to be able to understand
and disentangle the complex relationship between nutrition and health for successful
personalised nutrition [van Ommen et al., 2008a]. One challenge is to integrate the
multi-scale responses to nutrients, ranging from whole body to subcellular levels, and
over time scales from minutes to years [de Graaf et al., 2009]. Additionally, a major
challenge is to find a comprehensive, uniform, effective storage of data of both the
outputs and inputs of nutritional studies [van Ommen et al., 2008b, van Ommen
et al., 2010]. One of the main goals of systems research remains as the prediction of
a systems’ behaviour with the current knowledge on its genetics and environmental
conditions to which it is responding. Ultimately, this could improve health care by
enabling personalised medicine, where disease prevention, diagnostics and therapy can
be tailored to each individual’s genetic background and lifestyle.
2.4 Computational approaches
With the development of high throughput, -omics methods, there has been the pro-
duction of a vast amount of data comprising of large, complex information. However,
the vastness of this data makes drawing meaningful conclusions more challenging. The
development of computer methods and software tools for understanding biological data
has enabled the discipline, bioinformatics, which has grown alongside high throughput
methods, hoping to enable large data management, analysis and interpretation [Ben-
ton, 1996]. Although bioinformatics can provide further insight from the analysis of
experimental data, it is limited in its ability to predict dynamic behaviour of complex
systems. Computational modelling with molecular biology is a fundamental part of
systems approaches, and provides a natural continuation within experimental biology
to infer how molecules synergistically capture behaviour by cooperation to understand
complex interactions that underpin emerging properties [Kitano, 2002a, Holzhütter
et al., 2012]. For application purposes, there are several complementary tools and
approaches that can be used, e.g. genome-scale metabolic networks (GSMN).
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2.4.1 Genome-scale metabolic networks
In more recent years, approaches have been applied to generate mathematically struc-
tured ‘knowledge bases’: GSMN. Contrary to a database, which typically is an organised
collection of data, a knowledge base is a dynamic resource that may in itself have a
capacity to learn and give answers. GSMNs require the integration of data by following
standardised ‘best practices’ on building models [Thiele and Palsson, 2010]. This is for
the best representation of a biological system that can perform more accurate predic-
tions of phenotypic responses to genetic and environmental perturbations. However,
one of the main issues is the lack of standardisation, which is essential to practice
across multiple disciplines [Williams et al., 2008]. It is particularly useful so both
the biologists and computer scientists across disciplines can communicate efficiently
and gain a better understanding of the different types of data and methods that can
be used for systems biology research [Brazma et al., 2006]. Representation formats,
such as systems biology markup language, have been developed to help address this
problem so models can be shared, evaluated and developed amongst others in the
systems biology community [Hucka et al., 2003]. Additionally, there are computational
model repositories such as BioModels [Juty et al., 2015] and BiGG models [King et al.,
2016] to help increase the integrity of these models by manual testing, standardising
and enabling sharing. Although pathway and metabolic networks are available from
databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) [Kanehisa
et al., 2012] and Reactome [Croft et al., 2011], they lack comprehensive information
such as biological constraints (e.g. thermodynamics), which limits their utility to study
dynamic behaviour [Bauer-Mehren et al., 2009]. GSMN enable researchers to conduct
system-level metabolic response analysis and flux simulation, which is not possible
using general metabolic pathway databases.
GSMNs are essentially an organised list of metabolic reactions derived from all available
data of an organism’s metabolism into a mathematically structured network and can be
used to target fluxes of specific phenotypic behaviour, e.g. growth or energy production.
GSMNs were initially used to represent single cell organisms and included only a few
metabolic reactions to ultimately increase biomass. However, metabolic reconstructions
have increased in availability and application [Oberhardt et al., 2009]. They have now
been applied to represent and study multicellular organisms with much larger genomes,
such as a global reconstruction of human metabolism [Duarte et al., 2007].
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Recon 1 was the first global human metabolic reconstruction, published in 2007, that in-
corporated numerous metabolic genes and enzymes that have been studied individually
for decades [Duarte et al., 2007]. It was created manually ‘component-by-component’
by the bottom-up approach of a reconstruction made up of genomic and bibliomic
data. Recon 1 had incorporated 3731 reactions containing 2233 metabolic and 1078
transport intrasystem reactions, 1469 compounds with compartment specific metabo-
lites (8 compartments), and 1496 genes. Although this was the first human metabolic
reconstruction seen in its entirety, it lacked annotated reactions, making it difficult to
match compounds to databases and literature, and lacked tissue specificity.
Another global human metabolic reconstruction was published within the same year,
the Edinburgh human metabolic network reconstruction (EHMN) [Ma et al., 2007].
This human GSMN had incorporated 2823 reactions, 2671 compounds and 2322 genes
from different databases. EHMN provided a better annotated metabolic reconstruction
with multiple synonyms, structure information and IDs from different databases for
easier compound matching. However, it lacked subcellular compartments and tissue-
specificity, but has increased in its quality since with the addition of sub-cellular
compartments [Hao et al., 2010].
HepatoNet1 [Gille et al., 2010] was published in 2010 as the first comprehensive human
hepatocyte GSMN. HepatoNet1 is liver-specific and based on transcriptomics as well
as protein expression data. The reconstruction included six intracellular and two
extracellular compartments with 777 metabolites, including several compounds in
different reaction states and metabolite pools. HepatoNet1 has a total of 480 individual
enzymes and complexes with 953 enzymatic reactions with all but 11 reactions identified
by Enzyme Commission numbers. There are also 1308 transport reactions in total
with only 86 identified by Transporter Classification Database numbers, covering 58%
of the transport reactions. Additionally, KEGG, Recon 1 and PubMed IDs are also
used to identify reactions for easier compound-matching.
Recon 2 [Thiele et al., 2013] has since been published as an expanded and improved
version of Recon 1 with the input of EHMN, HepatoNet1, an acylcarnitine and fatty-
acid oxidation module [Sahoo et al., 2012] and the human small intestinal enterocyte
reconstruction [Sahoo and Thiele, 2013]. The development of Recon 1 into Recon 2
significantly expanded the structure by including 2-fold more reactions and 1.7-fold more
unique metabolites. The information coverage, topological and functional properties of
Recon 2 were all improved compared to Recon 1. However, many blocked reactions
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and dead-end metabolites still existed. Recon 2 had also automatically generated 65
drafted cell type-specific metabolic models by using expression profiling data from
the Human Protein Atlas [Uhlen et al., 2010]. The Recon 2 liver cell type-specific
network was compared to HepatoNet1 and large discrepancies were found between the
two, most likely due to the gaps, dead-end metabolites and the resolution of the two
different reconstruction networks. Since, major updates in Recon 2 have taken place,
such as the update of gene-reaction associations in Recon 2.04. Most recently, Recon
2.2 has been published as the most complete annotated consensus human metabolic
reconstruction available [Swainston et al., 2016]. This GSMN has been improved by
fully mass and charge balancing all reactions, as well as updating specific pathways,
e.g. fatty acid metabolism.
During this time, many methods have been developed to advance GSMN and trialled
with biological research questions [Wang et al., 2012b, Mardinoglu et al., 2014, Schultz
and Qutub, 2016]. Shlomi and colleagues proposed Boolean gene-to-reaction mapping
to create various human tissue-specific metabolic networks from generic human models
by integrating tissue-specific gene and protein expression data, including a liver-specific
metabolic network [Shlomi et al., 2008]. However, this method only predicts one
metabolic state under which the expression of data is measured. Instead of predicting
only one metabolic state of a tissue, a refined method that targets a tissue-specific
metabolic model (liver) from a generic model (Recon 1) based on network integration
with various molecular data sources was developed [Jerby et al., 2010]. This was to
allow a variety of different tissue-specific molecular data sources to be used in the
reconstruction for functional metabolic network models of human tissues. However,
due to being an automated method, it is unlikely that all inaccuracies in the molecular
data were filtered out. This highlights the advantages of manual curation.
Although reconstructions are still in need of improvements, this is part of the systems
biology cycle of testing and refinement. The advances in GSMN represent a grand
opportunity to gain new insights into molecular processes, particularly with advancing
methods for analysis and predictive power.
2.4.2 Constraint-based methods
For many years, small-scale, kinetic models predominated molecular biology based on
the traditional ‘reductionist’ approach. With the growing use of systems biology, other
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methods have been developed to analyse models. Currently, there is still a significant
lack of data to build comprehensive, large-scale, quantitative models as some experi-
mental data are impossible to capture, particularly in vivo. Additionally, this approach
of data collection is labour intensive and computationally heavy. However, recent
developments of modelling tools allow predictive modelling without the requirement of
kinetic data by constraint-based methods (CBM) [Price et al., 2004]. GSMNs can then
be constrained by the natural constraints in nature rather than kinetics.
CBM are based on the assumption that metabolic fluxes are under a myriad of naturally
occurring constraints, e.g. thermodynamic constraints [Price et al., 2004, Haggart et al.,
2011]. These constraints are represented mathematically into balance and bounds.
Assuming the system is at steady-state, balance constraints are to conserve quantities.
Bounds constraints are the upper and lower limits of the metabolic reaction fluxes
that are set for each reaction based on individual variables and parameters. Both of
these constraints, incorporated together, create a biologically sound solution space that
holds true for any condition aimed for the particular organism. This equates to all
the possible phenotypes, or objectives, that will be found in the solution space [Orth
et al., 2010]. Within CBM, flux balance analysis (FBA) is a method that analyses a
stoichiometric matrix of the reactions based on balance and bounds constraints and aim
to target an optimal solution within the biological solution space. FBA is commonly
used as it systematically analyses all the metabolic reactions and targets the reactions
that allows the optimal solution to occur [Orth et al., 2010].
In single cell organisms, FBA was first used to target an objective function and detect
an optimal solution via linear programming to minimise or maximise a targeted
objective, such as biomass, in 1984 [Watson, 1984]. However, traditional FBA can not
be used for multicellular organisms that have multiple tissues with multiple cell types
each with different functions. In these instances, there are many objective functions
that may need to be targeted for a desirable phenotype. It will then be ideal to
carry out many objective functions simultaneously to monitor productions from the
reactions rather than only targeting one objective function that could lead to bias or
the loss of vital information. Even in relatively simple organisms, objective functions
are still a matter of debate as they may need to change accordingly, e.g. when
exposed to different environmental conditions or describe a metabolic switch [García
Sánchez and Torres Sáez, 2014]. Limitations of FBA are that it is deterministic, only
predicts metabolic fluxes at steady state and cannot predict metabolite concentrations
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[Raman and Chandra, 2009, Orth et al., 2010]. As FBA identifies the metabolic
flux distribution, there is no additional information on the metabolite concentrations
or on the dynamic characteristics of the metabolic fluxes [Mahadevan et al., 2002].
Therefore, it cannot simulate stochastic-like properties of biological systems and does
not consider minute fluxes within metabolism that are not at steady state such as
adaptations to environmental stimuli. FBA also does not consider regulatory effects.
The current field of signalling and gene regulated network reconstructions has
been behind in development compared to GSMN. This is likely due to the difficulty
of gathering a large amount of meaningful, detailed information on cross-talks and
regulatory feedbacks. Additionally, these networks become increasingly complex as the
network becomes bigger with a lack of sufficiently advanced tools to interpret them in
a meaningful way [Hyduke and Palsson, 2010]. However, there is increasing interest
towards signalling networks [Papin et al., 2005, Hyduke and Palsson, 2010].
Methods to enhance FBA have been developed to allow simulations of dy-
namic changes in external conditions (dynamic FBA, dFBA) [Varma and Palsson,
1994] and the integration of regulatory constraints (regulatory FBA, rFBA) by Boolean
logic operators [Covert et al., 2001]. This allows the prediction of regulatory and
metabolic steady states for every short, consecutive time interval during the simulation.
Yet, only one single metabolic state can be evaluated at each time interval and the
Boolean regulatory constraints still make this a deterministic analysis. Methods to
integrate regulatory, signalling and metabolic networks are proposed by the application
of integrated dynamic FBA (idFBA) [Lee et al., 2008]. Additionally, integrated
FBA (iFBA) is proposed to simultaneously model metabolic, regulatory and signal
transduction networks by integrating FBA with regulatory Boolean logic and ordinary
differential equations [Covert et al., 2008a]. Flux variability analysis (FVA) had
been developed to determine the upper and lower bounds of all steady state reaction
fluxes to predict a range of solutions and the robustness of the model in response to
various perturbations. A comparison of methods are shown in Table 2.2. Yet, future
challenges are to develop robust methods that can undergo analyse with multiple
objective optimisations, and to represent and predict biology-like stochastic, dynamic
behaviour [Raman and Chandra, 2009].
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2.4.3 Petri nets
A mathematical and graphical tool based on graph theory that has been applied to
modelling is the Petri net (PN). PN was developed by a German mathematician and
computer scientist, Carl Adam Petri, and written as part of his thesis, Communication
with Automata, in 1962 [Petri, 1966]. PN was originally used to represent technical
systems, e.g. manufacturing control systems and production lines [Murata, 1989,
Zurawski and MengChu Zhou, 1994]. PN is now also used to represent biological
networks and their behaviour in a concurrent, asynchronistic and non-deterministic
manner with the enabling of hierarchical structure to represent biological systems in
a relatively accurate fashion. The different levels of description, or abstraction, can
vary from single molecules to whole populations depending on the studied system. A
tool that is used as an editor and animator of PN is Snoopy [Rohr et al., 2010]. It
is an open source tool that can be particularly useful for non-mathematicians as it
allows the construction of sound PN models without any extensive knowledge of its
mathematical underlying structure.
PN consist of four basic components; places, transitions, edges and tokens as illustrated
in Figure 2.7. Places can represent biological components such as genes, proteins
or metabolites. Transitions can represent biological interactions such as membrane
transport, phosphorylation or gene transcription depending on the level of the model
description. Edges direct the flow of the network and connect places to transitions,
and vice versa. Tokens are indicated by black dots or integer numbers within places
that can be inferred as discrete levels of activity or molecular quantities.
Places are the only nodes that hold tokens while transitions fire tokens from pre-places
(places prior to the transition) to post-places (places following the transition). This
enabling of the transition to ‘fire’ is dependent on all of the conditions prior to the
transition having been met. The edges carry a weight that indicates the amount of
tokens required to enable a transition to fire and how many token(s) the transition
will pass from the pre-place to the post-place. If the conditions prior to the transition
do not meet the requirements to fire then the transition is disabled and will not fire.
Once the transition has fired, standard edges consume the token(s) from the pre-place
as it is carried to the post-place, just as a substrate is consumed to form a product
after a reaction.
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Figure 2.7 Petri net elements. Basic Petri nets are composed of places, transitions and
edges which are denoted as circles, squares and arrows, respectively. Tokens are noted by
black dots that are only held within places. Extended Petri nets include course and logic
nodes, and read and inhibitor edges.
Two additional edges are included in extended PN formalism: inhibitor and read edges,
indicated by an edge with an unfilled and a filled circle, respectively (Figure 2.7). The
weight of the inhibitor edge and read edge determines the amount of tokens needed
to disable or enable the transition to fire, respectively, assuming all pre-transition
conditions are met. However, when transitions are fired, the tokens do not change
within the pre-place. As indicated by the name, inhibitor edges behave similarly to
inhibitor compounds that will not allow the reaction to occur while read edges act
similarly to catalysts that are never consumed within an enzymatic reaction but enable
the reaction to occur. Figure 2.8 shows an example of a metabolic reaction before
firing (Figure 2.8A) and after firing (Figure 2.8B).
Additional nodes in extended PN formalism are course and logic nodes (Figure 2.7).
A course place and a course transition are denoted as a circle within a circle and a
square within a square, respectively. These nodes are used to visualise structural levels
to give the notion of hierarchical and different abstraction levels in the construction
of the network. Logic nodes are denoted as grey-filled places or transitions. These
are used to represent the same condition for the nodes under an identical label at the
same or different levels in the network. The connector-like logic nodes are enabled
or disabled for logic transitions or holds the same number of tokens in logic places,
simultaneously.
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A) B)
Figure 2.8 A metabolic reaction represented in a Petri net format. A metabolic
reaction is constructed in Petri nets. Places represent compounds (substrate A, substrate
B, catalyst and inhibitor) and the transition represents an interaction (reaction). Tokens
represent the amount of compounds present. As edges have a standard weighting of 1, the
presence of a substrate A, substrate B and a catalyst with the absence of an inhibitor (A)
allows the reaction to occur to produce a product (B). Substrates A and B are consumed,
while the catalyst is not consumed as edges and read edges are used to carry out these
metabolic processes, respectively. The movement of tokens from (A) to (B) is an example of
a token game.
PN have been applied to many different types of biological networks. Models of signal
transductions of apoptosis [Heiner et al., 2004] and iron metabolism [Sackmann et al.,
2006] have been modelled in PN formalism. Metabolic networks are also modelled
in PN formalism by representing compounds with places, directional reactions with
transitions and edges. The status of the tokens was then interpreted as stoichiometric
information for each reaction [Koch et al., 2005]. Gene regulation in PN formalism was
modelled by incorporating a Boolean logic binary system into the metabolic PN of the
biosynthesis of tryptophan in Escherichia coli [Simao et al., 2005]. PN have also been
applied to model a more complex network based on experimental data and the published
literature of the human gene regulation processes in Duchenne muscular dystrophy
[Grunwald et al., 2008]. It has also been applied for studying feeding entrainment
of circadian clocks in hepatocytes to investigate the effects of meal time patterns on
health [Tareen and Ahmad, 2015]. Additionally, PN have been used for investigating
the lifecycle of the insulin receptor, and specialised to each relevant human cell type
for further insight on IR [Scheidel et al., 2015].
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PN have been shown to be well established within the field of biological modelling. It
has been particularly useful by its adaptable formalism with various extensions that can
be applied to various research questions. With the availability of non-mathematician
friendly software, such as Snoopy, PN can be applied to those with limited mathematical
and computational ability to research complex, biological behaviour.
2.4.4 Quasi-steady state Petri nets
A novel method that integrates extended PN formalism with CBM in a non-deterministic
fashion has been introduced, termed Quasi-Steady State Petri Nets (QSSPN) [Fisher
et al., 2013]. QSSPN enables simulations that result in predictions of the stochastic,
dynamic behaviour of a multi-formalism network without the requirement of kinetic
data.
QSSPN is based on the Gillespie algorithm [Gillesple, 1977] and the hybrid maximal
timestep method [Puchałka and Kierzek, 2004]. It links two types of interactions:
quasi-steady state fluxes (QSSF) and dynamic transitions (DT) [Fisher et al., 2013].
QSSF represents the metabolic reactions in a metabolic reconstruction network and
analysed by FBA. DT represents other types of interactions such as the signalling
pathways and gene regulation that are modelled in the extended PN formalism. The
connection between DT and QSSF is manually linked by setting two types of PN
places; constraint and objective places. The constraint places are used to set the flux
bounds in QSSF that undergoes FBA. The objective places represent the metabolic
outputs of QSSF that reset the token status in DT. Iterative cycles of simulating FBA
and updating token status occurs between QSSF and DT during a QSSPN simulation
resulting in dFBA, hence the term quasi-steady state. The QSSPN algorithm used
stochastic transition propensity during simulations [Fisher et al., 2013]. This type
of transition varies the probability of transitions to fire, allowing the expression of
dynamic behaviour in the network without the requirement of kinetic parameters.
After running multiple QSSPN simulations, resulting in diverse behaviour patterns,
Monte Carlo sampling can be applied to detect the probability of expressed targeted
behaviours within a sample of trajectories.
The PN gene regulation and signalling networks are constructed and edited in Snoopy
[Rohr et al., 2010]. Substrates, activators and inhibitors are represented by pre-
places that are connected to transitions, while transitions are connected to post-places
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representing products. The PN gene regulation template is in systems biology graphical
notation, a visual language to represent networks of biochemical interactions in a
standard, unambiguous way [Novère et al., 2009]. The connection between substrates
and products are made by standard edges, while activators and inhibitors are connected
by read and inhibitor edges, respectively. Black edges indicate biological interactions,
while light grey edges denote computational rules, not relevant to biology. Tokens in the
constraint places are inferred as discrete levels of activity ranging from downregulated
(0 tokens), basal (1 token) to upregulated activity (2 tokens). Whereas, a maximal
set of tokens can be assigned in the objective places and are inferred as discrete
levels of availability. Once all pre-conditions are met, transitions are enabled to fire
based on their propensity function accordingly. When a transition fires, substrate
pre-place tokens are consumed and fired into a product post-place, whereas activator
and inhibitor place tokens are not consumed.
The QSSPN method has been applied to study a human-specific bile acid gene regulated
signalling network integrated with HepatoNet1. This model was shown to produce valid
biological behaviour patterns from the network comparable to published experimental
results [Fisher et al., 2013]. Additionally, this model generated novel hypotheses from
gene knockout simulations that revealed potential genotype-phenotype relationships.
QSSPN has since evolved with the most recently published extension, agent based-
QSSPN [Ptak et al., 2016]. This has been used to simulate populations of living cells
and their interactions. Each cell is modelled by QSSPN that integrates the dynamic,
regulatory network represented in a PN and GSMN, and linear programming is used to
explore the steady-state metabolic flux distributions in the whole cell model [Ptak et al.,
2016]. This was used to provide a mechanistic link between genotype and behaviour of
a multicellular system.
The major advantages of this method is the ability to integrate models from different
formalisms to build multi-scale, dynamic models to simulate stochastic, asynchronous,
biology-like behaviour as described above. Additionally, this method can allow both
qualitative and quantitative data integration within the same model. This can be
done by replacing the stochastic transitions with continuous transitions in the PN
model as more quantitative data becomes available with the increase sensitivity and
selectivity of high-throughput technologies. The latest software available to implement
QSSPN is the Multi-Formalism Interaction Network Simulator (MUFINS) [Wu et al.,
2016, MUFINS, 2016], which has been extended originally from SurreyFBA [Gevorgyan
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et al., 2011]. This software allows the development and simulation of multi-formalism
models within a user-friendly interface.
2.5 Concluding remarks
The use of modelling is not a new concept in nutritional sciences. In fact, modelling
has been utilised in this field for many decades [Green and Green, 1990]. This
has enabled experimental data to be analysed more effectively and maximised the
amount of information from these expensive experiments [Baer et al., 1999], as well as
provide a basis for predictive modelling [van Ommen et al., 2008a]. Similarly with the
current advances in computational modelling, systems biology could be utilised to gain
better understanding of NAFLD than traditional biological approaches [Fisher et al.,
2014, Petta et al., 2015].
NAFLD is a complex, heterogeneous multi-factorial disease, as with most non-
communicable diseases present today. This histological spectrum of liver diseases
arises from the interplay of genetics, environmental and metabolic factors that con-
tribute to its development and progression. Ultimately, hepatic steatosis results in
an imbalance of lipid import, synthesis, oxidation and export. Yet, even within this
simplistic definition, it is clear that there are multiple, interactive pathways that are
likely to contribute.
It is evident from the literature that the underlying regulatory and molecular mecha-
nisms are still poorly understood in NAFLD. As the diet is one of the main modifiable
factors that could prevent and even resolve NAFLD, modelling approaches could be
applied to study its effects on hepatic lipid metabolism. In particular, fructose has
been under extensive review regarding its potential effects on NAFLD [Chung et al.,
2014, Chiu et al., 2014]. Yet, studies that have investigated fructose have often been
confounded by excess energy, as well as other confounding factors, e.g. saturated fats
and physical activity [Chiavaroli et al., 2015b]. With the aid of systems approaches,
there is the potential to integrate multiple levels of organisation from genome scale
metabolism with signalling and regulation that encompasses NAFLD. This is so to
capture more knowledge of the disease, control for confounders, and generate predic-
tions in hope to elucidate differential effects of nutritional factors, such as fructose in
comparison to other dietary factors, associated with NAFLD.

Chapter 3
Characterisation of Fatty Acid-
Induced Hepatic Steatosis In Vitro
3.1 Introduction
NAFLD is on the rise with currently 20-30 % of the general population in the western
world diagnosed with NAFLD [British Liver Trust, 2016b]. It is mainly linked with
obesity, diabetes, and many other features of the metabolic syndrome. However, the
underlying molecular mechanisms and impact are poorly understood. Elucidation of
affected molecular mechanisms and pathways requires robust and well defined in vitro
models.
More recently, in vitro models have been utilised for the study of the development and
progression of NAFLD [Kanuri and Bergheim, 2013, Green et al., 2015b]. Notably, in
vitro models are now routinely used to mimic IR with raised circulating FFA, as seen
in some NAFLD patients [Sanyal et al., 2001, Seppälä-Lindroos et al., 2002, Bugianesi
et al., 2005, Ortiz-Lopez et al., 2012], in order to study the impact of raised FFA has at
the cellular level. As the predominant cell type in the liver representing approximately
80 % of the cell population [Braun and Sandgren, 2000, Severgnini et al., 2012],
hepatocytes treated with FAs in vitro have become an established model for the study
of NAFLD [Gómez-Lechón et al., 2007, Ricchi et al., 2009, Chavez-Tapia et al., 2012].
However, the cell lines, culture media, treatment conditions and monitored endpoints
vary greatly in the published literature as outline in Table 2.1.
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Some variation in the response to FAs has been found due to the type of cell line used.
Two of the most common hepatocyte derived cell lines are HepG2 and HuH7 cells.
HepG2 cells are a hepatoblastoma derived cell line established in 1979 that originated
from a 15 year old Caucasian American male [López-Terrada et al., 2009]. HuH7
cells are derived from a hepatocellular carcinoma of a 57 year old Japanese male in
1982 [Nakabayashi et al., 1982]. Most cell lines have been found to have an increase
in intracellular lipid in a dose dependent manner to increasing FA concentrations
[Gómez-Lechón et al., 2007, Yao et al., 2011, Chavez-Tapia et al., 2012]. However,
the magnitude of intracellular lipid that was accumulated was found to differ between
cell lines with HuH7 cells producing 3 fold more TAG than HepG2 cells after a 24 h
incubation [Ricchi et al., 2009].
The amount of glucose in treatment media also widely varies among in vitro studies
of hepatocyte FA loading. Most investigations have reported the use of high glucose
containing media (25 mM) [Malhi et al., 2007, Giraudi et al., 2015, Green et al., 2015a]
while others have used low glucose levels (5 mM) [Dashti and Wolfbauer, 1987, Levy
et al., 1991, Green et al., 2015a], or intermediate concentrations of glucose (10-11
mM) [Gibbons et al., 1994, Skoog et al., 2010]. These glucose concentrations reflect
fasting levels (ca. 5 mM) and increasing increments of portal glucose concentrations
after feeding (ca. 10 - 20 mM) [Anderson, 1974, Satake et al., 2002, Sugimoto et al.,
2010, Patel et al., 2015]. In some instances, glucose concentrations in the medium were
not reported [Dixon et al., 1991, Gómez-Lechón et al., 2007, Meex et al., 2011, Qi et al.,
2012]. The amount of glucose used to culture cells is most likely to influence metabolism,
such as found by [Iyer et al., 2010] and may even influence TAG metabolism such as
has been seen [Green et al., 2015a]. Therefore, excess glucose is likely a confounding
factor in FA treatments, and may influence the degree of lipid accumulation.
Systematic characterisation is essential for the understanding of the models that are
utilised. This will enable researchers to use the most appropriate model for their
research, such as discovering therapeutic targets or biomarkers for disease development
or progression. To date, biomarkers for early diagnosis and accurate disease staging
of NAFLD remain scarce. A potential candidate is methylglyxoal (MG), a natural
intermediate in glucose metabolism and is broken down by glyoxalase (GLO)1 into the
less toxic end-product, D-lactate [Rabbani and Thornalley, 2011]. GLO1 is part of the
glyoxalase system present in all mammalian cells. Elevated levels of MG, also a highly
reactive glycating agent forming advanced glycation endproducts (AGEs), have been
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associated with diabetes [Thornalley et al., 1989], obesity [Wilson et al., 1991] and
vascular disease [McLellan et al., 1994]. However, its role in the hepatic manifestation
of the metabolic syndrome, NAFLD, is still under investigation.
Previously, using proteomics, hepatic GLO1 expression was identified to be down-
regulated by high-performance liquid chromatography mass spectrometry (LC-MS)
proteomic analysis in an apolipoprotein (apo)E knockout NAFLD mouse model [Spanos
et al., 2016]. It was also confirmed in liver biopsies from paediatric NAFLD patients as
seen by immunohistochemistry staining [Spanos et al., 2016]. Yet, the causal relation-
ship between hepatic steatosis and the reduction of GLO1 is still not confirmed. Within
this chapter, two immortalised hepatic cell lines, HepG2 and HuH7, were systematically
characterised as in vitro models of hepatic steatosis. Intracellular lipid and cell viability
were assessed to determine the dose response of saturated and mono-unsaturated
FAs and to establish the cellular response from cells that have been acclimatised to
physiological and supraphysiological concentrations of glucose. The objectives were
to characterise and utilise a suitable in vitro model of hepatic steatosis to assess the
direct effect of lipid loading on GLO1 expression and its functional consequence on
MG levels.
3.2 Methods
3.2.1 Cell culture
HepG2 (ATCC, Middlesex, UK) and HuH7 (JCRB, Japan) cells were subcultured in 1
g/L (5.55 mM) or 4.5 g/L (25 mM) glucose containing Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % foetal bovine serum (FBS), 1 % non-
essential amino acids (NEAA), 2 mM L-glutamine, and 100 U/mL penicillin and 100
U/mL streptomycin (Lonza, Basel, Switzerland). After supplementation, final glucose
concentrations of the 1 g/L and 4.5 g/L glucose containing DMEM were estimated as
0.87 g/L (4.8 mM, low glucose) and 3.92 g/L (21.7 mM; high glucose), respectively.
Cells were maintained at 37 ◦C in a 5 % CO2 air environment. Cultures were monitored
for the absence of contamination, including mycoplasma1.
1Mycoplasma-free cultures were verified by a qPCR-based service for detection of mycoplasma in
cell cultures (MYCOPLASMACHECK, GATC BioTech, UK).
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To ensure cell proliferation between the cell lines were similar with the same culture
conditions before experimentation, HepG2 and HuH7 cell seeding densities were com-
pared. A growth curve for HepG2 cells was generated (Figure 3.1A). The seeding
density of HuH7 cells was based on obtaining a similar mitochondrial dehydrogenase
activity as HepG2 cells seeded at 30,000 cells/cm2 (Figure 3.1B). Therefore, HepG2
and HuH7 cells were seeded at 30,000 and 25,000 cells/cm2 on day 0, respectively.
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Figure 3.1 Cell growth curve and seeding density comparison. Cell growth and
seeding density comparison in cells cultured in low glucose DMEM and monitored by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A) HepG2 cell growth
curve over 96 h. B) HuH7 cell seeding densities were compared to HepG2 cells seeded at
30,000 cells/cm2 after 72 h of growth. Data of three technical replicates (n=1) are shown as
mean ± standard deviation (SD).
3.2.2 Fatty acid treatment
Mono-unsaturated OA and saturated PA were utilised as lipid loading treatments.
Briefly, 25 mM of OA or PA in dimethyl sulfoxide (DMSO) were complexed with
5.56 % fatty acid free (FAF) bovine serum albumin (BSA) in double distilled water
(ddH2O) (fatty acid:FAF-BSA, 1:9, v/v) at a molar ratio of 3.3:1 for 1 hour (h) at
37 ◦C (all reagents, Sigma-Aldrich, Poole, UK). This method was developed in-house,
although the use of DMSO as a FFA vehicle has been performed previously [Madec
et al., 2011, Chavez-Tapia et al., 2012]. While complexing, the stock solutions were
vortex mixed every 10 minutes (min) and filtered sterile prior to final mixture with
sterile serum-free culture media. Cells were washed with phosphate buffer saline (PBS)
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Figure 3.2 Schematic cell experimental setup. A schematic diagram of the typical cell
experiment protocol used throughout this thesis, displaying typical HepG2 phenotype (×100
magnification) as cultured in low glucose, serum containing DMEM at each stage of the
protocol.
twice and treated with a range of concentrations from 100 to 500 µM of either OA or PA
in serum-free DMEM with a final concentration of 2 % DMSO. Glucose concentrations
in the treatment medium were subsequently diluted to 4.31 mM and 19.38 mM glucose
in low and high glucose containing DMEM, respectively. Treatment was applied on
day 3 and incubated for 24 h before collection for experimental endpoint measurements
(Figure 3.2).
3.2.3 Intracellular lipid
Nile red fluorescent lipophilic dye (Sigma-Aldrich, Poole, UK) was used to detect
intracellular lipid and modified from what has been previously performed [McMillian
et al., 2001]. Briefly, an automated cell counter (T20; Biorad, UK) was used to count
and collect 500,000 cells after trypsin treatment to detach cells. Cells were centrifuged
for 10 min at 800 × g at room temperature and the supernatant was removed. Cells
were treated with 500 µL of 1 µM Nile red in PBS pre-warmed to 37 ◦C, re-suspended
in solution, and incubated for 10 min in darkness at 37 ◦C. Cells were centrifuged again
(800 × g for 10 min at room temperature) and the supernatant removed before adding
500 µL of pre-warmed PBS to re-suspend the cells into single-cell suspension by the
use of a 19 gauge needle and syringe. Three technical replicates of 100 µL of Nile red
stained cells suspended in PBS per well in 96-well half-area black plates were incubated
for 2 min and shook for 30 seconds (s) at 37 ◦C before reading at fluorescence excitation
485-12 nm and filter emission 520 nm with the gain set at 1575. Fluorescence expressed
as relative fluorescence unit (RFU) was measured by an automated microplate reader
(BMG LABTECH FLUOstar Omega, Ortenber, Germany).
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3.2.4 Cell viability
Cell viability was determined by two colorimetric assays, Vybrant® MTT Cell Prolif-
eration Assay Kit (Fisher Scientific, Loughborough, UK) and lactate dehydrogenase
(LDH) Cytotoxicity Detection Kit (TaKaRa Bio Europe/Clontech, Saint-Germain-en-
Laye, France). Briefly, a sample of treatment media was diluted with fresh serum
free media (1:1, v/v) before adding 100 µL of the diluted treatment media with 100
µL of LDH assay reaction mixture. After a 30 min incubation in darkness at room
temperature, the absorbance was read at 490 nm. The remaining treatment media
on cells was replaced with 100 µL of fresh serum free media. Cells were then treated
with 10 µL of 12 mM MTT dissolved in sterile PBS with a final concentration of 1.09
mM of MTT. After a 4 h incubation at 37 ◦C in darkness, the media was removed
and 100 µL of DMSO was added to lyse the cells and dissolve the formazan crystals.
Cells were then incubated for 10 min in darkness at 37 ◦C and a 10 s shake before
the absorbance was measured at 540 nm. Absorbance as optical density (OD) was
measured by an automated microplate reader (BMG LABTECH FLUOstar Omega,
Ortenber, Germany).
3.2.5 GLO1 protein expression
Immunoblotting was used to detect relative GLO1 protein expression. Briefly, HepG2
cells were lysed in radioimmunoprecipitation buffer (RIPA; Sigma, UK) with a pro-
tease inhibitor cocktail (Roche, UK). Protein lysates were resolved by sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) transferred to polyvinylidene
difluoride membranes (PVDF; Millipore, UK). Membranes were blocked in 5 % (w/v)
milk in tris-buffer saline and Tween 20 (TBS-T) for 1 h followed by 12-16 h incuba-
tion with primary antibody in TBS-T. HepG2 extracts were probed with anti-GLO1
(SAB4200193; Sigma UK) at 1:4000 and anti-TUBA1A (ab7291; Abcam, UK) was
used at 1:10,000. After washing, secondary antibody incubations were done for 30 min
for fluorescently tagged antibodies (LICOR Biosciences, UK). Proteins were visualized
by fluorescence imaging using a LI-COR Odyssey. Densitometry was done using Image
Studio (LI-COR Biosciences, UK) software.
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3.2.6 Intra- and extra- cellular methyglyoxal
To detect the functional consequence of altered GLO1 expression, its substrate MG was
assessed. Briefly, HepG2 cells were cultured and treated with vehicle, 400 µM PA and
500 µM OA for 24 h as described above. Prior to cell collection, media samples were
collected, kept on ice, and stored at -80 ◦C. Cells were trypsin treated, resuspended
into medium and counted. Cells were then collected after centrifugation at 500 × g for
5 min, and stored at -80 ◦C. MG content of cells and in culture medium was measured
by stable isotopic dilution with [13C3]MG. MG is first treated with a derivatising
agent (1,2-diaminobenzene) and a deproteinising agent (trichloroacetic acid) to produce
an authetic MG adduct (2-methylquinoxaline, 2MQ) that was detected using liquid
chromatography-tandem mass spectrometry (LC-MS/MS) [Rabbani and Thornalley,
2014a].
3.2.7 Data analysis
Biological replicates were defined as subcultured cells after trypsin treatment (Lonza
Sales Ltd, Switzerland) and cultured to no higher than passage 30 to maintain pheno-
typic consistency. Each biological replicate had three technical replicates that were
averaged to obtain the treated/vehicle value to determine each value as shown in
equations below.
Results are expressed as mean ± standard error of the mean (SEM), unless oth-
erwise specified. Individual values for each assay were calculated by the following
equations:
Nile red =
TreatedRFU
V ehicleRFU
(3.1)
MTT % =
TreatedOD
V ehicleOD
× 100 (3.2)
LDH % = 100− TreatedOD − V ehicleOD
Positive ControlOD − V ehicleOD × 100 (3.3)
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Two-way ANOVA was performed to analyse the cell viability and intracellular lipid
data. Both ANOVA analyses underwent Dunnett’s multiple comparison tests, as data
cannot be accurately checked for normality due to low sample numbers in each group.
Unpaired t-test was performed to analyse MTT cell viability between serum free- and
DMSO- treated cells. The significance was determined by a P value of ≤ 0.05. Graph
generation and statistical analyses were performed by GraphPad Prism (6.0h for Mac
OS X; La Jolla, California, USA).
3.3 Results
3.3.1 Intracellular lipid
Both HepG2 and HuH7 cells increase intracellular lipid in a dose dependent manner to
increasing FA concentrations as seen in Figure 3.3. HepG2 cells cultured in low and
high glucose media produced significantly greater intracellular lipid relative to vehicle
(2 % DMSO) with a 3 fold increase induced by 300 µM OA (P< 0.01) and nearly a 4
fold increase induced by 500 µM OA (P< 0.0001). PA induced a lower, but significant
fold increase with a 2.5-3 fold increase induced by 400 µM (P< 0.05) and 500 µM
PA (P< 0.01) in both low and high glucose culture cells. HuH7 cells cultured in low
glucose produced nearly 2 fold higher levels of intracellular lipid at the lowest dose
of OA treatment, 100 µM (P< 0.01), and appeared to be saturated at 400 µM (P<
0.0001). A higher concentration of PA, 200 µM, was needed to have a significant x1.5
increase of intracellular lipid in HuH7 cells cultured in low glucose media relative to
vehicle (P< 0.05). HuH7 cells in high glucose media also needed higher concentrations
of FA to induce significantly greater intracellular lipid with the lowest dose of OA and
PA, 300 µM, inducing 2-2.5 fold increase in lipid (P< 0.01). Both HepG2 and HuH7
cells cultured in high glucose tended to need higher doses of FA to induce a significant
increase of intracellular lipid relative to vehicle.
In both cell lines, OA-treated cells cultured in both low and high glucose media have a
0.5-1 fold higher magnitude of intracellular lipid relative to vehicle than PA-treated
cells at equimolar concentrations. This is consistent with the literature that show OA
induces more intracellular lipid retention than PA [Gómez-Lechón et al., 2007, Ricchi
et al., 2009]. However, there were no notable differences between cells that were culture
in low and high glucose containing media.
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Figure 3.3 Fatty acid induced intracellular lipid. Intracellular lipid was detected by
Nile red staining of HepG2 (A and B) and HuH7 (C and D) cells cultured in low (blue) and
high (gold) glucose DMEM after a 24 h OA () or PA () treatment. Data are relative to
vehicle (V, 2% DMSO) and shown as mean ± SEM; HepG2 (n=3), OA-treated HuH7 (n=5),
and PA-treated HuH7 (n=6). Two-way ANOVA with Dunnett’s test post hoc was performed
to detect statistical significant differences between FA dose and vehicle denoted as * P < 0.05,
** P < 0.01, *** P < 0.001 and **** P < 0.0001.
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3.3.2 Cell viability
The cell viability of both HepG2 and HuH7 cells showed a negative response to
increasing concentrations of PA, but were largely unaffected by OA and low and high
glucose concentrations (Figure 3.4). However, this response was influenced by the cell
line and method of detection.
A) B)
C) D)
Figure 3.4 HepG2 and HuH7 cell viability. Cell viability was detected by LDH (A and
C) and MTT (B and D) assays of HepG2 (A and B) and HuH7 (C and D) cells cultured in
low (blue) and high (gold) glucose DMEM after a 24 h OA (•) or PA (◦) treatment. Data are
relative to vehicle (V, 2 % DMSO, set as 100 %) and shown as mean ± SEM; HepG2 (n=5)
and HuH7 (n=4). Two-way ANOVA with Tukey’s test post hoc was use to detect significant
differences between FA dose and vehicle denoted as * P < 0.05 and **** P < 0.0001 and
differences between OA- and PA-treated cells are denoted as † P < 0.05, †† P < 0.01 and ††††
P < 0.0001 in low (blue), high (gold) or both (black) glucose cultured cells.
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HepG2 cell viability detected by MTT assay (Figure 3.4B) was greatly compromised
by PA treatment. The lowest dose of PA, 100 µM, caused a significant 38 % and 30 %
reduction in viability relative to 2 % DMSO vehicle (P<0.0001) in low and high glucose
cultured cells, respectively. The most detrimental effect in viability was detected after
a 24 h treatment of 500 µM PA with a 64 % reduction in viability of both low and high
glucose cultured HepG2 cells. However, 500 µM OA treatment in high glucose cultured
HepG2 cells caused a statistical increase in viability relative to vehicle (P=0.02).
HepG2 cell viability detected by LDH assay (Figure 3.4A) followed the same pattern
as the MTT assay but less sensitive to dose. Cells cultured in low glucose was only
significantly affected by PA of at least 400 µM in concentration (P<0.0001), whereas a
significant reduction in viability of cells cultured in high glucose was only detected after
a 500 µM PA treatment (P<0.0001). Contrary to the MTT assay, the LDH assay did
not detect altered viability by OA treatment in comparison to vehicle in HepG2 cells.
Differences in viability detected between assays are likely explained by the differences
in measured endpoints; MTT as cellular metabolic activity and LDH as cytolysis.
FA-treated HuH7 cells had no significant differences to vehicle as measured by the
MTT assay (Figure 3.4D). However, PA-treated HuH7 cell viability was significantly
reduced in comparison to OA-treated cells cultured in high glucose at 400 µM and 500
µM treatments. HuH7 cell viability detected by the LDH assay (Figure 3.4C) had no
significant changes in response to FA treatment or between cells cultured in low and
high glucose media. Differences in viability between cell lines could be due to their p53
status as HepG2 have wildtype, while HuH7 have mutated p53 [Bressac et al., 1990], a
tumour suppressor that induces apoptosis, cell-cycle arrest and senescence in response
to stress [Bieging and Attardi, 2012].
3.3.3 Assessment of vehicle quality
After closer inspection, there were differences in the response to vehicle, 2 % DMSO
in serum-free media, detected between HepG2 and HuH7 cells (Figure 3.5). These
differences became evident when all controls (serum, serum-free and vehicle) of the FA
treatments were assessed.
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Figure 3.5 Quality of fatty acid treatment controls. Cell viability was detected by
LDH (A and C) and MTT (B and D) assays in both HepG2 (A and B) and HuH7 cells
(C and D) cultured in low (blue) or high (gold) glucose DMEM after 24 h in serum-free or
added 2 % DMSO (vehicle in Figure 3.4). HepG2 by LDH (n=2) and MTT (n=8); HuH7
by LDH in low (n=3) and high (n=4) glucose; HuH7 by MTT in low (n=4) and high (n=5)
glucose. Data are relative to serum cultured cells set at 100 % (dotted line) and shown as
mean ± SEM. Two-way ANOVA with Bonferroni’s test post hoc was use to detect differences
between serum-free and added 2% DMSO treated cells with statistical significance indicated
by * P < 0.05 and **** P < 0.0001.
The use of DMSO as vehicle on the low and high glucose cultured HuH7 cells
caused a dramatic 44 % and 46 % reduction in cell viability, respectively, compared to
serum-free media treated cells over a 24 hour period (P < 0.0001) as measured by the
MTT assay. The LDH assay also detected changes in HuH7 cell viability by the use
of serum-free media in comparison to the serum cultured cells (set as 100 % in Fig.
3.5), and a slight recovery in viability by the use of DMSO in high glucose cultured
cells.
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However, the use of DMSO as a vehicle on HepG2 cells did not affect viability in
comparison to the cells treated with only serum-free media over a 24 hour period,
except for a slight decrease in viability detected by the MTT assay in high glucose
culture cells. This compromise in HuH7 cell viability due to the use of 2 % DMSO
in serum-free media as a control for the treatment vehicle led to the decision to use
HepG2 cells in future experiments so to avoid confounding factors that may mask the
effects of FA treatment.
3.3.4 Altered GLO1 expression and its functional conse-
quence
Hepatic GLO1 levels have been shown to be reduced in paediatric NAFLD patients and
in a murine model of NAFLD [Spanos et al., 2016]. As an in vitro model of NAFLD,
HepG2 cells treated with FAs were used to induce hepatic steatosis. GLO1 protein
levels and its substrate, MG, were assessed.
HepG2 cells were treated with either vehicle, 400 µM PA or 500 µM OA for 24 h (Figure
3.6). Relative to vehicle, OA stimulated a significant 4-fold increase in intracellular lipid
(Figure 3.6A), while a slightly lower concentration of PA induced lipid accumulation
but to a lesser extent (P=0.0738). Inversely, GLO1 protein expression was reduced by
FA treatment as detected by western blot analysis with a significant 40 % reduction
induced by OA relative to vehicle (Figure 3.6B). PA also reduced GLO1 levels to a
lesser extent, suggesting the altered expression of GLO1 is related to the amount of
lipid accumulated in the cells.
The direct consequence of lower GLO1 protein levels as a loss of function was detected
by an increased accumulation of its substrate, MG. As measured by the gold standard,
stable isotope dilution LC-MS/MS, there was a significant 44 % increase in the
accumulation of intracellular MG induced by OA, while PA caused a 35 % rise in
intracellular MG levels in comparison to vehicle (P=0.101) (Figure 3.6C). MG was also
measured in the media as it may leak out of the cell, and has been found to glycate both
cellular and extracellular proteins [Rabbani and Thornalley, 2014b]. MG accumulation
was found in the media with a similar 45 % and 46 % increase in medium concentrations
induced by OA and PA relative to vehicle, respectively (Figure 3.6D).
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Figure 3.6 GLO1 expression and the functional consequence. HepG2 cells cultured
in low glucose DMEM were treated with either vehicle (V), 400 µM PA, or 500 µM OA
for 24 h. Intracellular lipid was detected by Nile red and images are magnified ×200 (A).
GLO1 protein expression was measured by immunoblotting with TUBA1A as loading control
(B). Cellular (C) and medium (D) concentrations of MG were quantified by LC-MS/MS.
Intracellular lipid (n=3) and GLO1 expression (n=7) is expressed as relative to V, while
MG (n=3) is expressed as absolute values and shown as mean ± SEM. One-way ANOVA
with Dunnett’s test post hoc was used to detect significant differences between vehicle and
treatment denoted by * P < 0.05 and **** P < 0.0001.
3.4 Discussion
In vitro models of hepatic steatosis were evaluated to determine the phenotypic response
of intracellular lipid and cell viability to FA treatment and to assess the appropriateness
of each model for the study of hepatic lipid loading. Cell lines, culture conditions and
methods of detection are discussed in detail. An investigation was also carried out
to demonstrate the usefulness of an appropriate in vitro model to evaluate the direct
affect of lipid loading in hepatocytes has on the expression of GLO1 as it has been
previously seen to be reduced in human and mouse NAFLD.
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3.4.1 Characterisation of in vitro models
HepG2 and HuH7 cells cultured in low and high glucose containing media with
physiological levels of FFA produced a dose-dependent response of intracellular lipid
to increasing FFA concentrations. Increasing concentrations of OA had no effect on
cell viability, while PA was found to significantly affect cell viability. However, the
responses varied depending on the cell line and cell viability assay used.
Physiological fasting plasma FFA concentrations vary greatly. Healthy individuals
aged 30–50 years were observed to have FFA levels from 95 to 2,080 µM (median 470),
sourced from the Oxford Biobank (Oxfordshire, U.K.) [Karpe et al., 2011]. Similarly, a
Canadian population in Toronto of healthy, young individuals aged 20-29 years had
levels ranging from 9 to 1,757 µM (median 416) [Abdelmagid et al., 2015]. Typical
FFA concentrations are estimated to be from 300 to 600 µM after an overnight fasting
and up to 1,300 µM after a 72 h fast [Frayn et al., 1996], but levels are normally
significantly suppressed after feeding. However, individuals with IR have elevated
FFA concentrations [Frayn et al., 1996], a strongly associated morbidity of NAFLD.
Accordingly, higher levels of circulating FFA have been seen in NAFLD patients
compared to lean [de Almeida et al., 2002, Diraison et al., 2003, Gambino et al., 2016]
and BMI-matched controls [Seppälä-Lindroos et al., 2002, Fabbrini et al., 2008]. The
range of FA concentrations that were used in the experiments within this chapter
reflects the physiological levels of FA found in healthy and NAFLD patient serum levels,
rather than excessively high concentrations of FFA such as 3 mM being used in some in
vitro studies [Gómez-Lechón et al., 2007, Yao et al., 2011]. However, NAFLD patients
do not always present with significantly higher circulating FFA than non-NAFLD
controls [Ortiz-Lopez et al., 2012]. Therefore, individual FAs were investigated as there
have been evidence of differential effects between specific FAs.
Saturated PA (16:0) and monounsaturated OA (18:1) were used as treatments as they
are the most abundant circulating saturated and monounsaturated FFA in humans. PA
and OA are estimated to contribute as much as 28.3 and 32.7 mol % (mol/ 100 mol total
FAs) of plasma FFA, respectively [Hodson et al., 2008]. PA and OA concentrations have
been seen to be significantly increased in patients with NASH than controls in plasma
(154.8 vs 97.2 µM PA and 148.0 vs 85.3 µM OA, respectively), although composition
did not vary as much (27.5 vs 27.7 % PA and 26.3 vs 24.4 % OA, respectively)
[de Almeida et al., 2002]. Elevated hepatic PA (30.3 % vs 27.7 %) and OA (18.1 %
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vs 12.1 %) with lower levels of total PUFA (5.5 % vs 9.8 %) were also detected in
NASH compared to non-NAFLD patients, respectively [Allard et al., 2008]. A previous
study has demonstrated saturated FAs interrupting TAG or lipid accumulation in liver
cells by the induction of ER stress and mitochondrial-mediated apoptosis resulting
in lower intracellular lipid content [Mantzaris et al., 2011]. However, the capacity
of cells to accumulate lipid was recovered with the addition of OA [Gómez-Lechón
et al., 2007, Mantzaris et al., 2011]. Accordingly, experiments within this chapter
have demonstrated differential effects between OA and PA, as OA stimulated greater
intracellular lipid, while PA was more toxic at equimolar concentrations. It has been
previously found that PA is more lipotoxic, while OA could rescue PA-induced apoptosis
in non-adipose tissue derived cells by promoting neutral lipid storage [Listenberger
et al., 2003]. This is also in agreement with the published literature using similar
hepatocyte in vitro models used in this chapter [Gómez-Lechón et al., 2007, Ricchi
et al., 2009, Oh et al., 2012].
HepG2 cells were found to be more responsive to FA treatment in comparison to HuH7
cells by having an larger magnitude of intracellular lipid (Figure 3.3) and lower viability
in response to PA (Figure 3.3.2). HepG2 cells were also found to be more sensitive
than HuH7 cells as measured by percent of apoptosis to PA treatment [Ricchi et al.,
2009]. However, the lack of sensitivity by HuH7 cells may have been due to the use of
DMSO as the vehicle of treatment (Figure 3.5), which may also be responsible for the
slight lower magnitude of lipid accumulation in comparison to HepG2 cells (Figure 3.3).
HepG2 cells responded with a dramatic detrimental effect at the lowest dose of PA in
both low and high glucose culture cells detected by the MTT assay but only showed
a detrimental effect with at least 400 µM PA by the LDH assay (Figure 3.4). OA
increased viability in high glucose cultured HepG2 cells, inferring a slight proliferation
effect by the MTT assay, but this was not detected by the LDH assay.
The differences found between the viability assays can be explained by the type of
end point measurements that were detected as both assays measure the conversion
of tetrazolium to formazan, but detect different cellular endpoints that catalyses this
reaction. MTT assay measures the activity of mitochondrial dehydrogenase conversion
of MTT into formazan relating to the cellular metabolic activity [Mosmann, 1983].
LDH assay measures the amount of lactate dehydrogenase that has leaked out of the cell
into the media relating to the cell membrane integrity [Korzeniewski and Callewaert,
1983]. Therefore, the use of different types of viability assays also warrants careful
3.4 Discussion 61
consideration as the assays will differ in results depending on the type of damage the cell
undergoes after treatment [Weyermann et al., 2005, Fotakis and Timbrell, 2006, Bopp
and Lettieri, 2008]. Thus, this study suggests HepG2 metabolic activity is dramatically
more vulnerable to PA treatment than its cell membrane integrity. As such, PA
treatment of at least 400 µM was found to significant affect HepG2 membrane integrity,
most likely due to cell death and rupture rather than just a reduction in metabolic
capacity. Although OA has also been found to sensitise hepatocytes to inflammation
by inducing lower viability [Malhi et al., 2006, Malhi et al., 2007, Mantzaris et al.,
2011], this was not suggested within the results of this chapter.
An increase of intracellular lipid in HepG2 and HuH7 cells was observed in this study,
but the dynamics of lipid mobilisation were not directly measured. HepG2 cells have
the capacity to synthesise TAG in the absence of hormones or lipogenic precursors.
However, this rate is significantly increased when exposed to extracellular OA, and
to a lesser extent from DNL [Gibbons et al., 1994]. This may be partially due to a
decreased rate of degradation of apoB [Dixon et al., 1991]. However, the secretion of
TAG is poor as HepG2 have a slower rate of secretion in comparison to primary rat
hepatocytes and produces low density lipoprotein (LDL)-like lipids [Gibbons et al.,
1994]. Lipid secretion has been shown to increase with the treatment of OA; with cells
producing more TAG-loaded lipoprotein, indicating a shift from LDL to VLDL-like
lipid [Dashti and Wolfbauer, 1987, Meex et al., 2011]. HuH7 cells were also shown not
to be a better cell model of secreting TAG-rich lipoprotein lipids due to producing
lower amounts of apoB100 compared to HepG2 cells in density gradient centrifugation
derived-VLDL in BSA-control, and significantly less in 0.6 mM OA treated cells [Meex
et al., 2011].
The pathophysiological characteristics of lipid mobilisation in HepG2 and HuH7 cells
may have been derived as they were from tumours, inherited from their donors, or
even undergone genetic drift while in culture. Immortalised cell lines are commonly
known to lose at least some physiological expression and function in comparison to
primary human hepatocytes [Guo et al., 2011]. Additionally when primary cells are
isolated for culture, liver-like expression dramatically changes over a matter of days
[Shulman and Nahmias, 2013]. To test genetic susceptibility to steatosis, HepG2 and
HuH7 cells were genotyped within our lab group (unpublished, P.Gibson, 2014). They
were found to have PNPLA3 I148M (C to G) mutation (data not shown) and detected
by another research group in HepG2 cells [Green et al., 2015a]. This mutation in
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PNPLA3, encodes for a protein called adiponutrin which has TAG catalytic activity,
suggests a greater potential to retain intracellular lipid and develop steatosis [Romeo
et al., 2008]. In fact, HepG2 cells have been found to be more steatotic than human
liver [Dixon and Ginsberg, 1993].
With a greater genetic susceptibility for steatosis and possibly more initial intracellular
lipid, this may in part explain the lack of difference in lipid levels between low and high
glucose cultured cells seen in Figure 3.3. However, statistical analysis of lipid levels
were not possible between cell lines, or between low and high glucose concentration
groups due to measurements being semi-quantitative. Although the intracellular lipid
detection assay used in this chapter was adjusted to cell count, all interpretations
were made after the adjustment to be relative to each vehicle and therefore, cannot
distinguish initial or absolute total lipid concentrations. Nevertheless, HuH7 cells
cultured in low and high glucose were observed to have responded with slightly lower
magnitude of lipid after OA and PA treatment than HepG2 cells. HepG2 and HuH7
cells accumulating the same magnitude of intracellular lipid by Nile red was also shown
in a previous study [Ricchi et al., 2009], and a similar fold change relative to vehicle
[Chavez-Tapia et al., 2012]. However, the type of lipid that was accumulated was found
to be different between HepG2 and HuH7 cells. In particular, TAG levels increased
at a higher magnitude in HuH7 cells than in HepG2 cells [Ricchi et al., 2009]. As
only Nile red was used in the experiments within this chapter (Figure 3.3), these
results only show the total lipid accumulation rather than the accumulation of specific
lipid species. In the next chapter, a method of lipid quantification is developed by
the use of an olive oil standard curve and Nile red staining so to distinguish initial
differences of intracellular lipid between the concentrations of glucose used to culture
cells. In addition, lipid quantification was also measured by the gold standard, gas
chromatography mass spectrometry (GC-MS), to investigate the differential effects
sugars may have on intracellular lipid. These models of hepatocyte lipid loading will be
used to facilitate an iterative systems biology approach of in silico model reconstruction,
hypothesis generation and experimentation.
Most commonly used methods for lipid detection include Nile red and oil red O
(ORO) staining, enzymatic TAG assay and the gold standard, mass spectrometry.
Understanding the methodology used is essential, as these assays detect different
lipid species. Nile red at excitation wavelength between 450-500 nm resolves highly
hydrophobic environments such as lipid droplets, much more so than less hydrophobic
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environments such as cell membranes if detected at an excitation wavelength between
515-560 nm, and emissions of >528 and >590 nm, respectively [Greenspan et al., 1985].
The former (450-500 nm) spectra was used in the experiments within this chapter,
thus targeting lipid droplet detection. Although Nile red and ORO lipid dyes are
thought to be comparable, Nile red was found to detect more lipid droplets than ORO,
indicating that Nile red is a more general lipid stain than ORO [Fowler and Greenspan,
1985]. In fact, ORO has been found to specifically stain only TAG and cholesteryl
ester, cholesteryl oleate [Ramírez-Zacarías et al., 1992]. Therefore, Nile red may lead
to an overestimation, while ORO could underestimate the extent of steatosis. The
TAG enzymatic assay commonly used to detect intracellular lipid quantifies glycerol
that was enzymatically dissolved from TAG. However, this assay could then become
even less specific than Nile red due to the possible detection of non-TAG glycerol
released from other compounds including monoacylglycerol (MAG) and DAG, as well
as detecting free glycerol [Al-Anzi and Zinn, 2010].
A strong correlation between ORO and Nile red was detected (Pearson’s correlation
coefficient r=0.6795) during an extensive comparison between ORO, Nile red and
enzymatic TAG assay in our lab. Yet, the greatest reproducibility was achieved by
relative-to-vehicle, Nile red quantification after cell count adjustment (data not shown
here). Therefore, Nile red was the preferred method of lipid detection with the use
of the correct wavelengths for lipid droplet detection to gather the full extent of
steatosis, rather than possible underestimation by ORO staining, or overestimation by
the enzymatic TAG assay.
Subsequent in vitro studies are continued with HepG2 cells due to the greater re-
sponsiveness to FA treatment and to avoid confounding factors (i.e. DMSO affecting
viability) that may taint future experiments.
3.4.2 GLO1 in hepatic steatosis in vitro
The lipid loading hepatocyte model was used to investigate a dysregulation of the gly-
oxalase system, a novel proposition in NAFLD. This dysregulation has been previously
shown in a murine model of NAFLD and paediatric liver biopsies as an association
with fatty liver and reduction in GLO1 expression [Spanos et al., 2016]. Here, the
effects on GLO1 expression in response to lipid loaded HepG2 cells and its functional
consequence were mechanistically tested.
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GLO1 is the first enzyme of the glyoxalase system present in the cytosol of all mam-
malian cells [Thornalley, 2003]. The glyoxalase system, made up of GLO1 and GLO2,
is responsible for the degradation of glycating agents, such as MG, that form AGEs.
MG is broken down by GLO1 and GLO2 via the intermediate S-D-lactoylglutathione
into the less toxic end-product, D-lactate, with the aid of reduced glutathione [Rabbani
and Thornalley, 2011].
MG is a naturally occurring intermediate of the degradation of triose phosphates via
the glycolysis pathway. It is a highly reactive, glycating agent forming AGEs of protein,
nucleotides and basic phospholipids [Rabbani and Thornalley, 2015]. Normally, MG is
efficiently metabolised with concentrations found to be no more than 1 µM and 10 µM
in the extracellular and cellular space, respectively [Rabbani and Thornalley, 2014a].
However, if there is an imbalance in this anti-glycation system, there is an increase
risk of excess AGEs and the dysfunction of vital metabolic processes.
The glyoxalase system has already been extensively studied in diabetes and obesity in
a recent review [Rabbani and Thornalley, 2014a], two highly associated morbidities
of NAFLD. One of the first associations with diabetes was observed as an increase
of MG levels in the red blood cells of diabetics in comparison to healthy individuals
[Thornalley et al., 1989]. It is now known to be strongly associated with hyperglycemia
and an increased flux of glycolysis, resulting in excess formations of AGE. This leads to
an increased susceptibility to damage of the small vascular systems as seen in long-term
complications of diabetes such as retinopathy, nephropathy and neuropathy. The
insulin response element has also been located on the GLO1 gene promoter, further
confirming the association between GLO1 and insulin sensitivity, and the development
of IR could lead to a dysregulation in GLO1 activity [Ranganathan et al., 1999].
Studies that have investigated GLO1 and the consequence of its altered activity in the
liver have been performed but remain relatively unexplored in the study of NAFLD.
One study has shown a fructose-fed induced rat model of NAFLD had lower hepatic
GLO1 activity [Mohamed Salih et al., 2009] and hepatic S-lactoylglutathione was
significantly reduced as detected by a metabolomic study in a LDL receptor knockout
NASH mouse model. Increased levels of MG were also detected in an in vitro model of
fructose-induced NAFLD in primary rat hepatocytes [Wei et al., 2013]. However, its
investigation in steatotic hepatocytes and the translation to human NAFLD have yet
to be studied extensively, as has been done more recently [Spanos et al., 2016].
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In this in vitro model of NAFLD, physiological levels of glucose were used to culture
cells due to hyperglycemia-linked association with excess MG levels. Steatosis was
also confirmed by Nile red staining and resulted in a lower expression of GLO1.
The reduction of GLO1 protein expression was found to be a biologically significant
alteration due to the subsequent accumulation of its highly reactive glycating substrate,
MG, in both the intra- and extra- cellular space of a human immortalised cell model
of NAFLD [Maldonado et al., 2015]. Further investigation is warranted to confirm
the role of GLO1 in the molecular pathogenesis of NAFLD, i.e. by measuring GLO1
activity and MG levels in primary hepatocytes sourced from NAFLD patients.
3.5 Conclusion
As NAFLD has become one of the most common liver diseases in the western world, in
vitro studies of hepatic lipid loading are crucial to elucidate the underlying molecular
mechanisms and impact on regulatory signalling pathways that are poorly understood
to date. Here, in vitro models were characterised and used to determine the molecular
changes to GLO1 that occur in response to lipid loaded hepatocytes. The magnitude
of intracellular lipid accumulation was found to differ between the cell lines in response
to FA treatment. In contrast, no differences in the response to FA treatment were
found between the cells cultured in different glucose concentrations. However, the
FA effect on cell viability was dramatically different between cell lines as well as the
method of measuring viability. Due to these differences, the importance of establishing
a well characterised in vitro model is highlighted in order to produce robust data for
better understanding of NAFLD and aid in the discovery of potential diagnostic and
therapeutic targets. As such, GLO1 was found to be downregulated in response to
hepatic lipid accumulation in vitro. Subsequently, an accumulation of MG, as measured
by LC-MS/MS, in FA-treated cells and their associated medium were found. This
suggests lipid accumulation increases MG formation and/or decreases MG metabolism.
Further assessment of the consequence of lower levels of GLO1 in NAFLD patients
will need to be established.

Chapter 4
A Mixed-Nutrient Hepatocyte Model:
Interaction of sugar and fat?
4.1 Introduction
NAFLD is a multi-factorial disease that is influenced by both genetic susceptibility and
lifestyle habits, including diet and physical activity. Diet is a major modifiable factor
that can help prevent its development and progression. To date, the UK population is
consuming more than the recommended intake of salt, saturated fat and added free
sugars [Bates et al., 2014]. Recently, the Scientific Advisory Committee on Nutrition
had revised the recommended intake of free sugars from 10 % to 5 % of total energy
intake [SACN, 2015]. However, the population level of intake range from 11.2 ± 5.6 to
15.4 ± 6.4 % of total energy across all ages, with 11-18 year old adolescents being the
highest consumers. Correlations of increased sugar intake and obesity rates have been
highlighted [Johnson et al., 2007]. Particularly in the USA as consumers have high
intakes of free sugar, this trend was found; but was not evident in the UK or Australia
with largely constant intakes over time, but an increasing obesity population [Barclay
and Brand-Miller, 2011].
Sugar, and in particular fructose, has been under extensive investigation for its effects
on metabolic health [Elliott et al., 2002, Livesey and Taylor, 2008, Johnson et al.,
2013, Stanhope et al., 2015, Chiavaroli et al., 2015a]. It has also been studied more
specifically as a cause of NAFLD development and an accelerator towards its progression
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[Lê et al., 2009, Abdelmalek et al., 2010, Chung et al., 2014, Chiu et al., 2014]. Fructose
has been suggested as one of the main dietary mediators of NAFLD. It induces a
lower insulin response in comparison to glucose [Elliott et al., 2002, Chong et al.,
2007b, Koo et al., 2008]. Therefore, fructose may be preventing the insulin-mediated
activation of adipose tissue lipoprotein lipase, which would then lead to impaired
TAG clearance. This could lead to hyperlipidemia [Chong et al., 2007b] and possibly
increased lipid import into the liver to promote steatosis. Hepatic fructose metabolism
also bypasses the metabolic regulatory point that controls glucose metabolism, i.e.
phosphofructokinase (see Figure 2.6). It can then provide additional substrates for
DNL to synthesise fatty acids (see Figure 2.4) and TAG synthesis via the Kennedy
pathway (see Figure 2.3) [Nagle et al., 2009]. It may also metabolise into other
intermediates, such as uric acid that have been associated with gout [Stanhope and
Havel, 2008, Lanaspa et al., 2012].
Fructose has also been found to increase lipogenic gene expression to promote DNL
[Koo et al., 2009, Janevski et al., 2012] and induce the production of intermediates of
DNL that are inhibitory factors of β-oxidation [Nagle et al., 2009]. Therefore, fructose
may be inducing lipogenesis but also negatively influencing the oxidation of lipid. With
an increase of DNL, but a decrease in oxidation, intermediates of lipogenesis could be
accumulating, such as phosphatidic acid, ceramide, and diacylglycerol (DAG) [Saltiel
and Kahn, 2001, Wei et al., 2007, Wei et al., 2013]. DAG has been found to play a
role in insulin signalling disruption [Nagle et al., 2009, Lee et al., 2010, Ishii et al.,
2015], and may contribute to hepatic IR that is commonly seen in NAFLD [Sanyal
et al., 2001, Bugianesi et al., 2005, Ortiz-Lopez et al., 2012]. Therefore, fructose may
be altering the lipid profile that is encouraging hepatic metabolic disruption.
To date, several systematic reviews and meta-analyses of human studies have been
performed to assess the effects of fructose on various health outcomes in relation to
NAFLD factors, such as liver enzymes and measurements of liver fat (ultrasound,
biopsy or MRI) [Chiu et al., 2014, Chung et al., 2014]. In addition, some data suggests
when individuals are already overweight/obese or T2D, they may be more susceptible
to the deleterious effects of fructose [Sievenpiper et al., 2009, Stanhope et al., 2009].
However, these human studies that have investigated the differential effects of glucose
and fructose have commonly utilised high doses and/or were confounded by excess
energy intakes [Livesey and Taylor, 2008, Chung et al., 2014, Chiavaroli et al., 2015a].
The use of high doses may reveal mechanistic differences between monosaccharides but
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do not directly relate to public health. This is particularly relevant as the uppermost
UK population intake of fructose is estimated to be 60 g/day, while human studies
have used doses from 100-200 g/day [Chiu et al., 2014, Chung et al., 2014].
In vitro studies have also been used to explore the differences between the type and dose
of monosaccharides in relation to lipogenic potential and other metabolic differences in
the liver. HepG2 cells have been previously shown to accumulate excess intracellular
lipid when cultured in high concentrations of glucose (e.g. 25 mM), in comparison
to lower concentrations of glucose (e.g. 5 mM) [Lanaspa et al., 2013, Green et al.,
2015a], on contrary to the results found in Chapter 3. The varying levels of glucose in
treatment media could then be influencing lipid results of published studies as described
in Chapter 3.
Furthermore, HepG2 cells have commonly been used to investigate differential effects
between glucose and fructose. In some cases, a positive lipogenic effect of fructose
was shown by increased levels of intracellular lipid [Huang et al., 2011, Lanaspa et al.,
2012]. HuH7 cells have also been treated with fructose and showed an increase in
intracellular lipid with only a very small amount of total monosaccharide (0.72 mM)
with increasing fructose:glucose molar ratios [Windemuller et al., 2016]. Most recently,
HepG2 cells were utilised to study the interaction of FAs and monosaccharides. Over
several combinations of doses and nutrients, HepG2 cells showed an additive effect of
a combination of glucose and fructose beyond FA-induced lipid accumulation [Zhao
et al., 2016]. In contrast, other studies have found lipogenic gene expression levels of
FAS and ACC were not changed by fructose (5.5 mM G + 5 mM F) in comparison to
glucose-only fed HepG2 cells [Hirahatake et al., 2011, Stamatikos et al., 2016]. However,
after the exposure to a high dose of fructose (5.5 mM G + 25 mM F), FAS and ACC
expression were found to be enhanced [Stamatikos et al., 2016]. Yet, total intracellular
lipid were not measured in these studies.
In the previous chapter, intracellular lipid was determined between low and high
glucose acclimatised cells using relative quantification. In order to more accurately
quantify any lipid changes, lipid quantification was performed by Nile red staining
with the use of an olive oil standard curve for comparison. In addition, we aimed to
investigate the effects of added fructose in comparison to equimolar concentrations of
glucose on intracellular lipid in mixed-nutrient conditions in vitro. In these experiments,
the early stages of lipid accumulation were monitored over a 6 h period by Nile red
staining and the gold standard, GC-MS. Thin-layer chromatography was used prior
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to GC-MS analysis to detect individual FAs and lipid species, in addition to total
intracellular lipid. Total lipid in HepG2 cells treated over a 24 h period was also
measured by Nile red staining. The objective of these experiments was to elucidate if
the type of monosaccharide influences the rate of intracellular lipid accumulation prior
to saturation, and if there were differences in the production of DNL FAs or alterations
in the lipid species profile.
4.2 Methods
4.2.1 Cell culture and treatment
HepG2 cells were subcultured as described in Section 3.2.1 prior to treatment. Cells
were seeded on day 0 at 30,000 cells/cm2 with serum containing DMEM. On day 3,
cells were washed with PBS twice before applying serum free treatment DMEM (Gibco,
Fisher Scientific, Loughborough, UK). Treatment media contained either 5 mM glucose
(5G) + vehicle (2 % DMSO), 5 mM glucose (5G) + 400 µM OA, 25 mM glucose (25G)
+ 400 µM OA, or a sugar mixture of 5 mM glucose + 20 mM fructose (5G+20F) +
400 µM OA (Sigma-Aldrich, Poole, UK) supplemented with 1 mM sodium pyruvate
(Gibco, Fisher Scientific, Loughborough, UK), 1 % NEAA, 2 mM L-glutamine and 100
U/mL penicillin and 100 U/mL streptomycin (Lonza, Fisher Scientific, Loughborough,
UK). OA and vehicle treatment were prepared as described in section 3.2.2.
4.2.2 Nile red staining
Low and high glucose acclimatised cells
Nile red staining was performed as described in Section 3.2.3 with slight modifications.
Briefly, one million live cells were harvested after trypsin treatment as determined by
trypan blue exclusion, centrifuged at 500 x g for 5 min, and the supernatant removed.
500 µL of 7.7 µM Nile red in PBS pre-warmed to 37 ◦C was added, cells were re-
suspended, and incubated for 10 min in darkness at 37 ◦C. Cells were centrifuged again
(500 x g for 5 min) and the supernatant removed before adding 500 µL of pre-warmed
PBS to re-suspend the cells into single-cell suspension. Three technical replicates of 100
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µL of Nile red stained or non-stained cells were added per well into a black, half-area
96-well plate.
Meanwhile, an olive oil standard curve was prepared as inspired by [Malapascua et al.,
2012]. The olive oil standards were based on the working stock of 200 mg/mL of
glyceryl trioleate (≥ 99 % triolein, Sigma) in isopropanol:chloroform (19:1, v/v) and
stored in a glass vial in darkness at 4 ◦C. Standard curves were prepared by a serial
2-fold dilution in glass vials ranging in concentrations from 0 to 100 mg/mL. The
average adjusted R2 value for the olive oil standard curves was 0.98 ± 0.02 standard
deviation. Intra-variability was determined from the calculated concentrations of
samples in triplicate ranging from cells that were untreated and treated with 400 µM
OA to cover the concentration range of the standard curve. The average coefficient of
variation (CV) value was 7.9 % (median 5.7 %), however the values ranged from 0.2 -
23.7 % across samples that were run in triplicate. Inter-variability was not determined
due to the instability of live cell samples after processing.
Briefly, working stocks and standards were vigorously vortexed for 70 s immediately
before added into the next lower concentration standard. 50 µL of each olive oil
standard were further diluted in 5 mL of ddH2O after vigorous mixing. Nile red was
added at a final concentration of 7.7 µM immediately after mixing vigorously for 70
s and incubated for 5 min in darkness at 37 ◦C. Standards were vigorously vortexed
again for 70 s immediately before adding 100 µL per standard in triplicate into black
half area 96-well plate prior to incubation for 2 min and shook for 30 s at 37 ◦C.
Samples were read at fluorescence excitation 485-12 nm and filter emission 520 nm
with the gain set at 1575 by a BMG LABTECH FLUOstar® Omega microplate reader
(software v3.00 R2, firmware v1.41; Ortenber, Germany). The data was obtained from
the MARS data analysis software (program v2.40, build 13). Samples were interpolated
from the linear standard curve that was reduced to 0 - 6.25 mg/mL of olive oil so to
reduce processing time, but still spans the full range of sample concentrations. An
example can be seen in Appendix A. For relative expression, raw fluorescence unit data
was translated into relative quantification by calculating the relative fluorescence to
vehicle after adjusting for background fluorescence of non-Nile red stained cells.
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Mixed-nutrient treated cells
Nile red quantification was performed as outlined in section 3.2.3 with slight modifica-
tions. Briefly, 500,000 live cells were harvested after trypsin treatment as determined
by trypan blue exclusion, centrifuged at 500 x g for 5 min, and the supernatant
removed. 500 µL of 1 µM Nile red in PBS pre-warmed to 37 ◦C was added, cells were
re-suspended, and incubated for 10 min in darkness at 37 ◦C. Cells were centrifuged
again (500 x g for 5 min) and the supernatant removed before adding 500 µL of
pre-warmed PBS to re-suspend the cells into single-cell suspension. Three technical
replicates of 100 µL of Nile red stained or non-stained cells were added per well into a
black, half-area 96-well plate prior to incubation for 2 min and shook for 30 s at 37 ◦C
before reading fluorescence excitation 485-12 nm and filter emission 520 nm with the
gain set at 1575 by a microplate reader (BMG LABTECH FLUOstar® Omega).
4.2.3 Intracellular lipid extraction
Intracellular lipid was also assessed by GC-MS. Cells were counted on an automated
cell counter and 3 million cells were collected, centrifuged at 500 x g for 5 min, PBS
washed, and centrifuged again. Cells were re-suspended in 1 mL of ddH2O and 5 mL
of chloroform:methanol (2:1, v/v), supplemented with 10 % butylated hydroxytoluene,
was added. Each sample and ddH2O blank were spiked with 25 µg per internal standard;
including triheptadecanoin, diheptadecanoin, monoheptadecanoin and heptadecanoic
acid (Larodan, LGC, Teddington, UK). Lipid extraction was performed following
Folch’s method [Folch et al., 1957]; cells were vortexed vigorously for 2 min and then
mixed on a rotation mixer for 15 min. 1 mL of 1 M sodium chloride in ddH2O was
added to each sample, mixed briefly and centrifuged at 2000 x g for 10 min at 14 ± 4
◦C. The lower phase, containing purified lipid, was transferred into clean vials before
evaporation to dryness under nitrogen.
4.2.4 Thin layer chromatography
Intracellular lipid species were separated by thin layer chromatography (TLC) [Fielding
et al., 1993]. Purified lipid extracts were reconstituted in 50 µL chloroform and
spotted onto silica gel 60Å aluminium TLC plates (Macherey-Nagel, Fisher Scientific,
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Loughborough, UK) by a Hamilton syringe. The plates were first developed twice with
diethyl ether until the solvent front reached 3 cm from origin with 5 min air-drying
after each development to separate MAG from phospholipid (PL). The plates were then
developed with hexane:diethyl ether:acetic acid (70:30:1.8, v/v/v) until the solvent
front reached 1 cm from the top to separate MAG, DAG, TAG and FFA. Plates
were air-dried and lightly sprayed with 0.1 % 8-anilino-1-naphthalenesulfonic acid in
ddH2O. Lipid bands were visualised (Appendix B) and marked under a UV viewing
cabinet (Spectroline CM-26, Sigma-Aldrich, Poole, UK). Lipid samples were collected
by scraping silica containing the individual lipid species into clean vials.
4.2.5 Fatty acid derivatisation
Intracellular lipid species were broken down into individual FAs and methylated prior
to detection by GC-MS. Briefly, 400 µL of toluene was added to the silica scrapings
and pulse vortexed. 800 µL of 6 % sulphuric acid in methanol was added, vortexed
and incubated for 2 h at 80 ◦C. Samples were allowed to cool prior to adding 2 mL of
neutralising solution (0.5 M potassium bicarbonate and 0.5 M potassium carbonate in
ddH2O) and 2 mL of hexane. Samples were then mixed for 15 min and centrifuged for 10
min at 2000 xg at 14 ± 4 ◦C. The upper solvent phase containing purified, methylated
FAs were transferred into clean vials and evaporated to dryness under nitrogen. Prior
to GC-MS detection, samples were reconstituted in 200 µL of hexane.
4.2.6 Gas chromatography mass spectrometry
FA methyl esters (FAME) were separated using Agilent 6890 (model number 122-7032,
version N.04.08) gas chromatography with a DB-WAX, 30.0 m x 250 µm x 0.25 µm
capillary column coupled with 5975MSD or 5973N. Inlet temperature was set at 250
◦C. Initial flow was 1 mL/min and held constant throughout, and acquisition mode
was set as scan. Hexane washes were included before and after each sampling. The gas
carrier was helium and run under the initial temperature of 100 ◦C for 3 min, with
ramping of 25 ◦C for 12.5 min until the temperature reached 220 ◦C and ramping of
25 ◦C for 19.7 min. The interface G1701DA MSD ChemStation, Build D.00.00.38 was
used for data extraction.
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A certified reference material of authentic standards (F.A.M.E. Mix RM-6; Sigma-
Aldrich, Poole, UK) containing methyl- oleate, palmitate, stearate, linoleate, palmi-
toleate, linolenate and myristate were used to identify FAME at their respective
retention times. The composition of RM-6 after each GC-MS run was compared to
the composition from the manufacturer (Appendix Table C.1) shown to have a good
agreement throughout the experimental duration. Identification of each FAME was
also confirmed by molecular ion (mass-to-charge ratio) via mass spectra scanning.
Examples of the mass spectra of methyl- palmitoleate, palmitate and oleate are shown
in Appendix Figure C.1-C.3. To test the inherited variability of GC-MS quantification,
intra-variability was calculated by taking the peak area of each FAME and dividing this
to the total area of detected peaks. RM-6 FAMEs were run in duplicates within the
same run. The average intra-variability CV was 2.29 % (median 1.95 %), ranging from
0.09 - 5.60 % across all duplicates. Inter-variability had an average CV value of 2.15 %
(median 1.70 %), ranging from 0.65 - 4.44 % across all RM-6 FAMEs. Quantification
of biological sample FAs (µg) were calculated by dividing the peak area of the internal
standard, 17:0 heptadecanoic acid, by the peak area of the target FA and multiplying
by the amount of internal standard spiked prior to sample processing (25 µg).
4.2.7 Sugar consumption in vitro
Sugar consumption was monitored by sampling culture media over time and quantified
by using glucose and fructose assay kits (ab65333 and ab83380, respectively; Abcam,
Cambridge, UK). Briefly, medium or diluted medium (medium:assay buffer, 1:4, v/v)
was diluted with assay buffer (1:24, v/v). The prepared medium was then incubated with
glucose reaction mix (assay buffer:probe:enzyme mix, 23:1:1, v/v/v) or fructose reaction
mix (assay buffer:probe:enzyme mix:fructose converting enzyme, 18:1:1:5, v/v/v/v)
at a 1:1 (v/v) ratio mixture for 30 min or 1 h, respectively, in darkness at 37 ◦C. To
detect background glucose in fructose containing media, samples were incubated with
fructose reaction mix without fructose converting enzyme (assay buffer:probe:enzyme
mix, 23:1:1, v/v/v). Both assay measurements were read at the absorbance of 570
nm by a microplate reader (BMG LABTECH FLUOstar® Omega). Both glucose
and fructose are stable in medium over the experimental period, and no extracellular
degradation is expected. The disappearance of monosaccharide from medium is highly
suggestive and was regarded as cellular uptake and consumption. Monosaccharide
consumption was inferred from the difference of medium concentrations.
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4.2.8 Data analysis
Biological replicates were defined as independent experiments done on subcultured
cells after trypsin treatment. Cells were subcultured to no higher than passage 30.
Results are expressed as mean ± SEM, unless otherwise specified. Graph generation
and statistical analyses were performed by GraphPad Prism (6.0h for Mac OS X; La
Jolla, California, USA) and significance was determined by a P value of ≤ 0.05.
4.3 Results
An olive oil standard curve was developed to compare absolute and relative quan-
tification of intracellular lipid in low and high glucose cultured cells as detected by
Nile red staining. GC-MS as the gold standard was also utilised to assess total lipid,
lipid species and FA composition to investigate the early differential effects on lipid
metabolism of cells exposed to a ‘mixed-nutrient’ treatment of OA supplemented
with low or high glucose, or fructose containing media. This detailed assessment was
performed in order to distinguish the total amount and rate of lipid accumulation
between treatments to investigate if glucose and fructose have differential effects in
mixed-nutrient conditions.
4.3.1 Low versus high glucose acclimatised cells
An olive oil standard curve was developed to quantify the absolute amount of intracel-
lular lipid in cells that were conditioned in either low or high glucose containing media
(Figure 4.1A). High glucose cultured cells in serum and serum-free media appeared to
have more lipid than cells cultured in low glucose, however this was not statistically
significant. Cells were also treated with 400 µM OA as a positive control for the
induction of intracellular lipid. OA induced a significant 4-fold increase of intracellular
lipid in comparison to vehicle in both low and high glucose cultured cells (P < 0.001,
Figure 4.1A). There were no differences detected between low and high glucose cultured
cells in either vehicle or OA-treated cells. Data were also represented as relative
quantification (as in Chapter 3) to display the similarities in lipid pattern between
absolute and relative measurement (Figure 4.1B). Due to the similarities between data
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representations and better reproducibility from relative quantification, intracellular
lipid continued to be represented as relative Nile red quantification.
A) B)
Figure 4.1 Absolute versus relative Nile red lipid quantification. HepG2 cells were
subcultured in low (blue) or high (gold) glucose and serum containing DMEM. Cells (n=4-7)
were given fresh serum media or treated with serum-free, vehicle (2 % DMSO) or 400 µM
OA containing media for 24 h in respective glucose concentrations prior to Nile red staining.
Intracellular lipid was quantified from an olive oil standard curve (A) or data was calculated
as relative to low glucose serum-free treated cells (B). Data are shown as mean ± SEM and
analysed by two-way ANOVA with Tukey’s test post hoc. Statistical differences between
vehicle and OA-treated cells were denoted as *** P < 0.001 and **** P < 0.0001.
4.3.2 Glucose versus fructose treated cells
Previous data in the lab had shown that 500 µM of OA treatment to HepG2 cells
cultured in 5 mM glucose containing DMEM induced a 2.5-3 fold increase in lipid
compared to vehicle at 6 h. This level of intracellular lipid was sustained up to 24 h, as
measured every 2 h up to 12 h and again at 24 h. Therefore, in this study, cells were
treated with vehicle or 400 µM OA with various concentrations of sugar and monitored
over 6 h prior to lipid saturation. Lipid was quantified at 0, 2, 4 and 6 h by the gold
standard, GC-MS; and at 0, 2, 4, 6 and 24 h by Nile red.
Nile red staining
Cells were subcultured in low glucose DMEM before treatment of either vehicle in 5
mM glucose containing media or 400 µM OA in either 5 mM glucose, 25 mM glucose,
or 5 mM glucose + 20 mM fructose containing media for 24 h. Intracellular lipid was
monitored during the early stages of lipogenesis to determine th differential effects of
monosaccharide on the rate of lipid accumulation. All treatment groups of cells that
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were treated with OA produced a significant 3-3.6 fold increase in intracellular lipid
after 24 h (P < 0.001) as shown in Fig. 4.2. Treatment with different concentrations of
monosaccharides on cells had no statistical difference in levels of lipid at any time point.
However, cells that were treated with 25 mM glucose produced a significant 2.3-fold
increase of lipid relative to vehicle at 4 h (P = 0.02). Whereas cells treated with 5 mM
glucose or the addition of 20 mM fructose produced a significant 2.5-fold and 2.7-fold
increase of lipid relative to vehicle (P = 0.008 and P = 0.003), respectively, only at
a later time point, 6 h. Therefore, the data suggests that high glucose culture cells
treated with OA induces a faster rate of lipid accumulation in comparison to the other
sugar treatments.
Figure 4.2 Nile red intracellular lipid time course. HepG2 cells (n=4) were subcultured
in low glucose, serum containing DMEM. Cells were treated with serum-free vehicle (2 %
DMSO) in 5 mM glucose containing media (dashed, set at 1) or 400 µM OA in either 5 mM
glucose (blue), 25 mM glucose (gold), or 5 mM glucose + 20 mM fructose (red) containing
media for 24 h. Intracellular lipid was measured at 0, 2, 4, 6 and 24 h by Nile red. Cells
treated with OA were made relative to serum-free vehicle. Data are shown as mean ± SEM
and analysed by two-way ANOVA with Tukey’s test post hoc to test factors of treatment and
time. Statistical significance is denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and ****
P < 0.0001 between 0 h and subsequent time points.
GC-MS quantification
Intracellular lipid by GC-MS was monitored during the first 6 h of treatment for
the early stages of lipogenesis to determine differential effects of monosaccharide on
the rate of lipid accumulation. Individual FAs from separated lipid fractions were
quantified. Data was also pooled together for total DAG and TAG levels, and total
lipid that was induced from each treatment during the time course.
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A) B)
C) D)
Figure 4.3 GC-MS oleate and palmitate in lipid fractions time course. HepG2 cells
were subcultured in low glucose DMEM and treated with vehicle in 5 mM glucose containing
media (blue; dashed, open circles) or 400 µM OA in either 5 mM glucose (blue; solid, filled
circles), 25 mM glucose (gold; solid, filled circles), or 5 mM glucose + 20 mM fructose (red;
solid, filled circles) containing media for 6 h. Three million cells were taken at 0, 2, 4 and 6 h.
TLC separated DAG (A and C) and TAG (B and D) fractions. GC-MS quantified 18:1n9 OA
(A and B) and 16:0 PA (C and D) from internal standard. Data are µg/3 million cells and
shown as mean ± SEM; HepG2 (n=3-4). Two-way ANOVA with Tukey’s test post hoc was
performed to detect statistical significant differences between vehicle and treatment denoted
as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001.
DAG composition remained largely unchanged after treatments (Figure 4.3C,
4.4A, and 4.4C), except for the increased levels of OA in the DAG fraction. OA
significantly induced its incorporation into DAG after 6 h in 5 mM glucose and with
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the addition of 20 mM fructose (P < 0.05), and 25 mM glucose containing media
(P < 0.01, Figure 4.3A). In fact, PA, POA and VA levels within the DAG fraction
were undetectable over the time course in each treatment (Figure 4.4A and 4.4C).
A) B)
C) D)
Figure 4.4 GC-MS palmitoleate and vaccenate in lipid fractions time course. Cells
were subcultured in low glucose DMEM and treated with vehicle in 5 mM glucose containing
media (blue, dashed, open circles) or 400 µM OA in either 5 mM glucose (blue; solid, filled
circles), 25 mM glucose (gold; solid, filled circles), or 5 mM glucose + 20 mM fructose (red;
solid, filled circles) containing media for 6 h. Three million cells were taken at 0, 2, 4 and 6 h.
TLC separated DAG (A and C) and TAG (B and D) fractions. GC-MS quantified 16:1n7
POA (A and B) and 18:1n7 VA (C and D) from internal standard. Data are µg/3 million
cells and shown as mean ± SEM; HepG2 (n=3-4). Two-way ANOVA with Tukey’s test post
hoc was performed to detect statistical significant differences between vehicle and treatment
denoted as * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001.
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Meanwhile, OA incorporation into the TAG fraction substantially increased over
time at 4 h (V+5G 2.1 ± 0.70 µg, OA+5G 36.3 ± 3.9 µg, OA+25G 43.3 ± 8.0 µg,
OA+5G+20F 37.6 ± 2.3 µg; P < 0.0001) and at 6 h rising to a total of 73.9 ± 9.9 µg,
85.3 ± 17.0 µg, and 68.6 ± 16.0 µg of OA (Figure 4.3B). This induction is equivalent
to a 33-, 39- and 31-fold increase in OA+5G, OA+25G, and OA+5G+20F treated
cells relative to vehicle (2.2 ± 0.5 µg), respectively (P < 0.0001). In addition, other
FA levels within the TAG fraction also increased over time. OA treatment induced
PA levels within the TAG fraction by 2.5-, 3.0- and 2.3-fold relative to vehicle at 6 h
(P < 0.01, Figure 4.3D). POA and VA also significantly increased in the TAG fraction
as induced by OA treatment (P < 0.05, Figure 4.4B and 4.4D). POA increased by
4.7-, 5.6- and 4.0-fold, while VA increased by 3.4-, 4.0- and 3.2-fold relative to vehicle
at 6 h. However, no significant differences were seen between sugar treatments at
any time point. All significant differences were found to be caused by OA treatment.
Interestingly, the mean levels of FAs within the cells cultured in 25 mM glucose
containing medium were consistently greater than the other sugar treatments. This
substantiates the result of Nile red assay (Figure 4.2), yet with more variation present
and not statistically different.
A) B)
Figure 4.5 Pooled lipid fractions for total intracellular lipid. Cells were subcultured
in low glucose DMEM and treated with vehicle in 5 mM glucose containing media (blue,
dotted) or 400 µM in either 5 mM glucose (blue, solid), 25 mM glucose (gold, solid), or 5
mM glucose + 20 mM fructose (red, solid) containing media for 6 h. Total FAs within DAG
and TAG fractions were shown separately (A) and pooled together as total lipid (B). Data
are µg FAs/3 million cells and shown as mean ± SEM; HepG2 (n=3-4). One-way ANOVA
with Tukey’s test post hoc was performed to detect statistical significant differences between
vehicle and treatment denoted as * P < 0.05 and ** P < 0.01.
4.3 Results 81
Within the pooled levels of lipid, TAG was significantly greater than DAG as expected,
as TAG is the main form of lipid storage. TAG was significantly increased after OA
treatment in each co-sugar treatment with a 11.2-fold increase in OA+5G relative
to vehicle+5G treated cells (Figure 4.5A). However, no significant changes to DAG
were observed, and no differences were detected between the sugar treatments. Total
lipid changed similarly as seen in TAG levels with a 9.1-fold increase in OA+5G
treated cells relative to vehicle, and no statistical differences detected between sugar
treatments (Figure 4.5B). In comparison to the Nile red assay, there was a 3-fold
increase between vehicle and OA-treated cells in 5 mM glucose containing media.
This suggests that Nile red is able to sufficiently detect intracellular lipid, but with a
suppressed signal in comparison to GC-MS. However, GC-MS comes at a cost of being
relatively labour intensive.
4.3.3 Sugar consumption in vitro
To confirm glucose and fructose within the medium were consumed, media concentra-
tions were monitored under the duration of intracellular lipid assessment. Glucose in
all treatments were found to be consumed over the duration of lipid sampling (Figure
4.6A). The rates of glucose consumption were very similar between groups; V+5G
-0.41 ± 0.02, OA+5G -0.43 ± 0.01, OA+25G -0.43 ± 0.10, and OA+5G+20F -0.35 ±
0.01 mM per hour (Figure 4.6). However, it appears that fructose was not consumed
(Figure 4.6B). In fact, results suggest that fructose concentrations in the medium were
increasing over time at a rate of 0.3416 ± 0.1180 mM per hour.
Moreover, there were differences detected in the amount of glucose in medium and the
estimated amount of glucose detected by the assay with an average of -27.5 ± 4 %
difference between the amount in medium (5 or 25 mM glucose) and the amount that
was quantified by the assays (approximately 3.5 mM and 19.2 mM). Measurements of
monosaccharide by the fructose assay also differed from the amount meant to be in
medium and the assay estimation, with an average of +55 ± 6.6 % glucose estimation
(5 mM vs 7.8 mM) and -22 ± 4 % fructose estimation (20 mM vs 15.5 mM). There
were differences also detected between the glucose and fructose assay estimation of
glucose. The fructose assay detected a rate of consumption of -0.87 ± 0.03 mM per
hour, in comparison to -0.35 ± 0.01 mM per hour as detected by the glucose assay.
Independent sugar uptake experiments were then carried out to monitor consumption
82 A Mixed-Nutrient Hepatocyte Model: Interaction of sugar and fat?
A) B)
C) D)
Figure 4.6 Sugar uptake time course over 6 h. HepG2 cells (n=3-4) were subcultured
in low glucose DMEM and treated with vehicle in 5 mM glucose containing media (blue,
dotted) or 400 µM OA in either 5 mM glucose (blue, solid), 25 mM glucose (gold, solid),
or 5 mM glucose + 20 mM fructose (red, solid) containing media for 6 h. Media samples
were taken at 0, 2, 4 and 6 h. Glucose medium concentration in all samples were measured
by a glucose specific assay and shown as glucosemedium over time (A) and the difference in
concentration as ∆glucosemedium after 6 h (C). Fructose in the 5 mM glucose + 20 mM
fructose samples were also measured by a fructose specific assay that quantified the amount of
glucose before and after the addition of fructose converting enzyme, resulting in background
glucose concentrations and the delta value interpreted as fructose. These results are shown
as monosaccharidemedium over time (B) and ∆monosaccharidemedium after 6 h (D). Linear
regression analysis was used to identify statistically significant non-zero slopes, and indicated
by ** P = 0.01, (gold) *** P = 0.001 for OA+25G and (black) **** P < 0.0001 for all others
within graph.
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over a 24 h time period to detect if fructose would eventually be consumed. Results
suggest that only once glucose is depleted, fructose can then be used as a substrate
(Figure 4.7).
A) B)
Figure 4.7 Independent sugar uptake time course over 24 h. Cells were independently
treated with 5 mM glucose (blue) + 20 mM fructose (red) containing media for 24 h.
Monosaccharide concentrations in medium were measured at 0, 6 and 24 h to detect uptake of
glucose and fructose over time (A), and shown as ∆monosaccharidemedium after a 24 h period
(B). Data are shown as mean ± SEM; HepG2 (n=3). Data were analysed by two-way ANOVA
repeated measures by both factors with Dunnett’s test post hoc. Statistical significance was
indicated by ** P < 0.01 between 0 and 24 h.
4.4 Discussion
As part of the typical UK diet, sucrose is the main form of free sugars as glucose is
rarely ever consumed alone. Sucrose is a disaccharide that consists of both glucose
and fructose linked by a glycosidic bond, 1:1. Yet, fructose has been under extensive
review in recent years as intakes of fructose-based sweeteners have become commonly
in use, in particular, in sugar sweetened beverages which has been associated with
an increase risk of metabolic diseases [Stanhope et al., 2009, Stanhope et al., 2015].
As the liver is the primary site of fructose metabolism, its effects in liver have been
examined, particularly in relation to NAFLD development and progression.
Focusing on in vitro studies, the addition of fructose in culture media has been
previously found to induce lipogenesis. More specifically, HepG2 cells were grown in
either low (5.5 mM) or a higher (11.1 mM) concentration of glucose with and without
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the addition of 0.55 mM fructose [Huang et al., 2011]. Over a 72 h period, a slightly
higher amount of intracellular lipid by ORO staining was detected in comparison to non-
fructose supplemented cells. HepG2 cells were also treated with higher concentrations
of fructose (5.5 mM) with glucose (5.5 mM). Although total intracellular lipid was not
measured after this treatment, extracellular PA and OA were detected with a 2- and
4-fold increase in FA levels, respectively [Huang et al., 2011]. Similarly, HepG2 cells
exposed to fructose over a 72 h period was also shown to increase TAG levels. TAG
levels were induced in a dose-dependent manner from 5 to 20 mM fructose exposure
as detected by an auto-analyser inferred from glycerol concentrations [Lanaspa et al.,
2012].
Within this work, HepG2 cells were used to investigate if low and high glucose condi-
tioned cells would result in a differential level of intracellular lipid. Additionally, we
investigated the effects of added fructose in comparison to equimolar concentrations of
glucose on intracellular lipid in mixed-nutrient conditions in vitro. The magnitude of
increased intracellular lipid by Nile red was found to be no different between HepG2
cells that were maintained in low and high glucose containing media as shown in
Chapter 3. However, previous results were represented as relative values, and not by
absolute quantification, meaning initial levels of lipid were not assessable. Therefore, an
olive oil standard curve was developed to compare absolute and relative quantification
with Nile red of intracellular lipid in low and high glucose cultured cells to overcome
this limitation. The data suggest that there may be a slight, but not statistically
significant increase in intracellular lipid in cells that were subcultured in high glucose
as measured by Nile red. Previous studies have found differences between low and
high glucose cultured HepG2 cells [Lanaspa et al., 2013, Green et al., 2015a], and the
importance of these differences when quantifying intracellular lipid have been discussed
previously (Chapter 3). To avoid the possible confounding factor of excess glucose,
cells were maintained in low glucose containing media prior to treatment.
A proposed mechanism of fructose inducing hepatic steatosis is via a metabolic byprod-
uct, uric acid [Johnson et al., 2013]. Fructose has been found to increase levels of
uric acid in vitro [Lanaspa et al., 2012] and in vivo [Lê et al., 2009, Abdelmalek
et al., 2010]. However, high doses of fructose and hypercalorific diets supplemented
with fructose were most likely the cause of hyperuricemia in human studies, and were
not found when fructose was isocalorically exchanged with other carbohydrate [Wang
et al., 2012a]. Fructose was also found to induce lipogenic gene expression [Janevski
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et al., 2012, Stamatikos et al., 2016], but reduced PPARα expression which may then
reduce β-oxidation [Nagai et al., 2002, Rebollo et al., 2014]. As such, a proposed
mechanism is that it may lead to increasing lipid intermediates that would accumulate
to cytotoxic levels and induce metabolic disruption, such as IR [Stanhope and Havel,
2008]. Intermediates of lipid metabolism have been suggested as mediators of hepatic
injury, such as DAG [Nagle et al., 2009]. As PA has been shown to induce DAG [Lee
et al., 2010, Ishii et al., 2015], we had co-treated HepG2 cells with monosaccharides
and OA to determine if fructose has a similar mechanism as PA by inducing DAG
levels.
Not all in vitro studies have observed a positive induction of lipogenesis by fructose.
One study [Hirahatake et al., 2011] in HepG2 cells carried out glucose-fed only (5.5 mM)
or with the addition of fructose (+5 mM) in media over a 72 h period with re-feeding
every 24 h. They found no differences in mRNA or protein expression of lipogenic
genes, FAS and ACC, between treatments. They also confirmed glucose and fructose
uptake within cells and found that glucose is consumed more quickly than fructose.
However, GLUT2, GLUT5, and ketohexokinase (KHK) gene expression increased over
the three days of fructose exposure. Accordingly, fructose consumption was increased
on the second and third day of exposure. Yet, intracellular lipid was not measured
in this study. This group further extended their research to investigate the effects of
fructose on global metabolism of HepG2 cells [Meissen et al., 2015]. They confirmed
that fructose was consumed, partially converted into sorbitol and phosphorylated into
fructose 1 phosphate. The outcomes were that fructose may be altering amino acid
metabolism, but no differences in TAG content were detected. Lower concentrations
of fructose (5 mM) was also independently found to induce no changes in lipogenic
expression (ACC and FAS), but were increased when HepG2 cells were cultured in
large amounts of fructose (25 mM) [Stamatikos et al., 2016]. However, fructose uptake
and intracellular lipid in HepG2 cells were not measured within this study.
Most recently, the response of HepG2 cells to a mixed-nutrient treatment of various
concentrations of glucose and fructose in mixture or in isolation with and without 1
mM OA or OA:PA (2:1) over a 24 h period has been examined [Zhao et al., 2016]. No
significant differences in TAG levels were detected between the different combinations
of sugar treatments. However, in cells that were treated with 1 mM OA or OA:PA
mixture, all cells increased TAG levels compared to non-FA treated controls. Cells
that were co-treated with 1 mM of FA and fructose, in comparison to co-treatment
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with glucose, fructose had lower TAG levels. Additionally, no differences were detected
between 5 mM glucose + 20 mM fructose treated cells and other treatments. The
only detected differences in TAG levels were induced by co-treatments of 1 mM of
FAs with 10 mM glucose + 15 mM fructose in comparison to the FA equivalent with
25 mM glucose. Although, the TAG level of induction appeared to be a very small
difference [Zhao et al., 2016]. Notably, fructose was not measured in this study to
ensure uptake in cells. Although fructose was most likely consumed over this 24 h
period, it is not clear of what proportions, particularly in the glucose and fructose
mixed treatments. Yet, similarly seen within our experiments, we also detected no
differences in intracellular lipid between 25 mM glucose and 5 mM glucose + 20 mM
fructose OA-treated cells after a 24 h treatment.
Notably, there are conflicting results in the literature regarding in vitro studies of
fructose-induced hepatic steatosis. However, it is clear these studies described above
have varying culture and treatment conditions as well as different methodologies to
quantify lipid. Our in vitro study had practiced standard culturing conditions prior to
treatment, and investigated the early responses of lipid metabolism to fructose and
glucose treatment by the use of the gold standard, GC-MS. Within this study, only
a subset of lipids were targeted with only the treatment fatty acid, OA, and DNL
associated fatty acids, PA, POA and VA, were quantified. Additionally, only the lipid
fractions TAG and DAG were monitored as TAG is the main form of lipid storage,
while DAG is an intermediate that has been associated with hepatic injury [Nagle
et al., 2009].
It was observed in this study that fructose was not taken up by the cells during the first
6 h of incubation. In fact, it was suggested that glucose was prioritised and consumed
before any uptake of fructose was taken place (Figure 4.7). During this time, it was
noted that fructose may have been produced and released into the medium at significant
levels. This unexpected result may suggest that the glycolysis flux was saturated and
glucose may have then been converted into fructose via the polyol pathway. The polyol
pathway is induced when glucose is in excess and is a known complication of diabetes
[Brownlee, 2005, Lanaspa et al., 2013]. This pathway has two enzymatic reactions
involving aldose reductase reducing glucose into sorbitol, and sorbitol dehydrogenase
oxidising sorbitol into fructose. However, the direct metabolism of fructose was not
measured in this study. Furthermore, the increase levels of fructose in the medium
suggests that fructose was not metabolised, but released into the medium. As fructose
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appeared not to be consumed in the first 6 h, we are unable to conclude distinct
differences between glucose and fructose on intracellular lipid accumulation as detected
by GC-MS. However, data from Nile red staining suggest there are no differences after
a 24 h exposure to glucose and fructose on total intracellular lipid, at which point
fructose would have been consumed. Additionally, confidence in the relative Nile red
quantification was increased as absolute quantification of lipid by the olive oil standard
curve showed a near identical pattern of lipid induction.
The inconsistent outcomes by fructose treatment highlights specific issues that may
have been overlooked during previous in vitro studies of fructose-induced NAFLD as
some have not confirmed the uptake of fructose. One particular issue, even if fructose
is consumed, is the assumption that glucose and fructose are consumed simultaneously,
assuming fructose is an additive or synergistic stimulus. However, it may be the case
that in vitro studies are performed in glucose-depleted conditions, at which point
fructose is consumed and acting in isolation. Although HepG2 cells are imperfect
models of in vivo hepatic metabolism, previous studies have shown positive lipogenic
effects by fructose. Therefore, our next objective is to investigate the effects of glucose
and fructose in isolation, but equimolar concentrations in HepG2 cells. We complement
this in vitro study with dynamic, multi-scale computational modelling to determine the
differential effects of specific monosaccharides on human hepatic lipid metabolism.
4.5 Conclusion
Some evidence suggests differential effects of fructose in comparison to glucose. However,
human studies have often shown that high doses of fructose, beyond population level
of intakes, are required to induce effects and/or excess energy is often a confounding
factor. In vitro studies have also been utilised to model fructose-induce NAFLD and
to investigate underlying molecular mechanisms. Here, we aimed to investigate if we
could reproduce fructose-induce hepatic steatosis in HepG2 cells. Our results suggest
that excess sugar, and therefore extra carbon substrate, may lead to higher TAG
levels, rather than specifically fructose. However, our in vitro model has shown that
glucose is the preferential sugar substrate for HepG2 cells. Notably, during the early
measurements, fructose was shown to be produced, rather than consumed. After a 24
88 A Mixed-Nutrient Hepatocyte Model: Interaction of sugar and fat?
h incubation, fructose was consumed, but no statistical differences in intracellular lipid
were detected.
It is clear from the literature that there are mixed conclusions on whether fructose
induces higher levels of hepatic intracellular lipid both in vivo and in vitro. This is
most likely due the widely used culturing conditions and the various techniques that are
used to quantify lipid. As discussed in the previous chapter, these factors can influence
experimental outcomes and it is clear that further studies are warranted. Therefore,
in the next chapter we aim to take advantage of recent advances in systems biology
by utilising a novel computational approach. With the aid of a dynamic, multi-scale
computational model, we aim to independently investigate if there are differential
effects between specific monosaccharides on hepatic steatosis and compare our in silico
predictions to our experimental data.
Chapter 5
Hepatic Glucose and Fructose
Metabolism In Silico
5.1 Introduction
NAFLD is a dynamic spectrum of liver diseases that develops from an interplay of
genetics and environmental factors that may take decades to manifest [Byrne and
Targher, 2015]. Computational modelling is a key component of systems biology
providing a complementary method of study with the potential to capture and dissect
genetic and environmental factors that may lead to disease development and progression.
It can quickly assess research questions by iteratively testing and generating hypotheses
and guide research at a lower cost and at a faster pace than traditional biological
approaches. NAFLD pathogenesis could be further investigated by the novel in silico
approaches that can model metabolism, gene expression, regulation and signalling
at a qualitative level, but are capable of integrating kinetic parameters as available
[Fisher et al., 2014]. However, in the context of NAFLD research, studies are still
predominantly in vivo and may not be taking full advantage of recent advances in
technology [Fisher et al., 2014].
As reviewed in detail by [Bordbar et al., 2014], there are several mathematical and
computational modelling techniques available. Each have their own sets of advantages
and disadvantages with various applicability, ranging from small kinetic to large,
semi-quantitative genome scale models. Relevant kinetic metabolic models include
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those based purely on ordinary differential equations (ODE)s and those that apply
an integration approach to represent signalling and gene regulation, e.g. by Boolean
logic operators. An example is a model of hepatic glucose metabolism that has specific
kinetic data based on fed and fasting physiological states to include hormonal regulation
[König et al., 2012]. There is also a kinetic hepatic metabolic model that has been
integrated with a Boolean logic network of hormonal signalling and gene regulation
[Ryll et al., 2014]. Other relevant kinetic models include a minimal model of glucose
metabolism [Dalla Man et al., 2007], compartmental kinetic models that have examined
TAG metabolism [Pratt et al., 2015] and glucose and lipid metabolism and transport
across human tissues [Pearson et al., 2014]. Pearson et al. have since expanded
this network to include kinetic data from experimental models of IR in individual
tissues, as well as simulations of ‘whole-body’ resistance, concluding IR causes a fatty
liver, and IR of tissues other than the liver can cause fat to accumulate in the liver
[Pearson et al., 2016]. However, there is still a lack of kinetic parameters to be able
to simulate models at a genome-scale level. To overcome this limitation, [Naik et al.,
2014] have proposed an alternative computational approach to study NAFLD. Naik et
al. identified crucial pathway branches (transport of glucose, lipids and ketone bodies)
where changes in flux distribution drove the healthy liver towards hepatic steatosis [Naik
et al., 2014]. Additionally, cholesterol metabolism and its transcription regulators were
highlighted as novel steatosis factors. This method simplified mathematical modelling
of metabolism with the inclusion of signalling and gene regulation without the need to
fully parametrise the model. However, this comes at the cost of assuming steady state
within the network, and therefore does not capture dynamic processes.
Meanwhile, there has been a vast improvement in the development of high quality
genome scale metabolic networks (GSMNs) with recent advances in genome sequencing
and improved genome annotation. This has led to improvements in the connections
between genotype-phenotype relationships [Thiele and Palsson, 2010, Pfau et al., 2015].
With the use of constraint based methods (CBM), GSMNs have been predominately
used to understand mechanistic, genotype to phenotype relationships and to carry out
predictive modelling. Many projects have been dedicated to produce whole-human and
cell-specific GSMNs that are still in development and continuously improving [Thiele
et al., 2013, Mardinoglu et al., 2014]. The development and application of different
CBM techniques have also been evolving as summarised in Table 2.2. The analysis
methods commonly used are FBA and FVA. Both methods use linear programming
to explore the solution space around an optimised user-defined objective. While FBA
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provides an example solution, FVA determines the minimum and maximum flux bounds
that are feasible within the network. This aids investigators to evaluate reactions
with large and small flux ranges, pinpointing reactions that are under more flexible or
tighter control, respectively. In the traditional use of FBA and FVA, these analyses
must occur under steady state.
More recently, CBMs of GSMNs have been combined with other computational tech-
niques to describe dynamic behaviour, and integrate signalling and regulation with
metabolism. With the increase of advancing high throughput, high dimensional "multi-
omics" techniques with enhanced sensitivity and selectivity available at a lower cost,
a new approach is the integration of whole human GSMN with -omics data. This
approach has been recently applied computationally to study NAFLD in an attempt
to contextualise a human GSMN to patient specific data [Hyötyläinen et al., 2016].
Hyotylainen et al. model predictions concluded that failure to meet excessive metabolic
challenges induced by fatty liver coupled with reduced metabolic adaptability may lead
to a vicious cycle leading to the co-morbidities of NAFLD.
Other integration approaches include the combination of a human-specific hepatocyte
GSMN to a PBPK model to describe the absorption, distribution, metabolism and
excretion of compounds [Krauss et al., 2012]. Additionally, a PN network has also
been integrated with a human specific hepatocyte GSMN that introduced a novel
computational method, QSSPN [Fisher et al., 2013]. This approach dynamically models
metabolism with gene and signalling regulation, including transcriptional, translational
and post-translational regulatory processes. This was performed by representing the
dynamic, gene and signalling regulation component of the model within the PN, while
the GSMN represented the quasi-steady state flux network. Within the PN, there are
two main connectors that are used to couple the dynamic PN with the GSMN, that
is the constraint and objective nodes. The constraint node sets bounds of the rate
limiting reactions within the GSMN. The objective node requests evaluation of the
maximal flux towards a target reaction by FBA. Within a single QSSPN run, there
are four steps: i) the firing of the PN leads to a change in status of the constraint
nodes; ii) the metabolic flux bounds are updated accordingly to the conditions of the
constraint node; iii) FBA is executed and updates the status of the objective node; iv)
the algorithm continues to the next iteration. Each iteration of steps (i-iv) reflects a
time step during at which FBA is carried out, defining dFBA.
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Utilising QSSPN, the aim of this work was to build a multi-scale model composed
of: (i) gene regulation and signalling relevant to lipid and sugar metabolism; (ii) a
kinetic model of insulin signalling created by the integration of a published ODE model;
and (iii) the HepatoNet1 liver-specific genome-scale metabolic network constrained
by in vitro flux measurements. In these simulations, a novel computational analysis
approach is proposed within the QSSPN framework, which we term dynamic FVA
(dFVA). Here, the exchange flux of interest was set as the objective function and used
the minimal and maximal objective function values to calculate upper and lower bound
time courses of metabolite concentration in the medium or extracellular space. These
bounds were consistent with stoichiometric and thermodynamic constraints of the
model, whilst also satisfying the demands of a ‘healthy hepatocyte’ biomass function.
The monosaccharide transport network and kinetic signalling model was constructed
in PN coupled with a hepatocyte-specific GSMN (HepatoNet1, [Gille et al., 2010])
that is arguably the most comprehensive reconstruction of the human hepatocyte. We
modified HepatoNet1 to represent in vitro conditions by adding culture medium as an
external nutrient dataset and constrain the model using cell consumption and secretion
rates.
As discussed in Chapter 4, there is conflicting evidence of the influence of fructose, in
comparison to glucose, on NAFLD development and progression. QSSPN was utilised to
investigate the influence of dietary components on the development of hepatic steatosis,
namely glucose and fructose metabolism as illustrated in Figure 2.6. This approach
captures the dynamic behaviour of monosaccharide transport and metabolism, and
predicts the subsequent production of TAG on a genome scale level. dFVA simulations
were performed to dissect what differential effects glucose and fructose may have on
hepatic metabolism at equimolar concentrations on a genome scale, without other
confounding factors, such as lipid, that may mask results. In addition, a kinetic insulin
signalling model was integrated into the model by QSSPN so to investigate the effects
it may have on glucose and fructose metabolism as it plays a vital regulatory role in
carbohydrate metabolism. Alongside this, an immortalised hepatocyte cell line, HepG2,
was used to provide in vitro data to experimentally validate in silico predictions.
Insulin sensitivity by western blot analysis as well as intracellular lipid and sugar
uptake with and without insulin stimulation were measured. This provides a first basis
of investigating the influence of the type of monosaccharide has on hepatocyte TAG
production with the aid of a novel dynamic multi-scale, computational model.
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5.2 Methods
5.2.1 Cell culture and treatment
HepG2 cells were subcultured as described in Section 3.2.1. The seeding and treatment
timeline was as described in Figure 3.2 and treatment included either 25 mM of glucose
or fructose containing media with or without insulin (Sigma, UK). Harvesting of
samples were performed as indicated below.
5.2.2 Monosaccharide consumption
Cells were treated with 3 mL of either glucose or fructose containing media with or
without 100 nM insulin. Media sampling occurred immediately prior to treatment
and after 24 and 48 h of incubation. Glucose and fructose in treatment media were
measured as described in Section 4.2.7.
5.2.3 Intracellular lipid staining
Cells were treated with either glucose or fructose containing media with or without
100 nM of insulin. Treatment incubation was carried out for 72 h in total. At 0 h and
every 24 h after, cells were collected to measure intracellular lipid. Nile red staining
was performed as in Section 4.2.2 with the exception that a different microplate reader
(BMG LABTECH CLARIOstar Omega, Ortenber, Germany) was used to quantify the
amount of intracellular lipid.
5.2.4 pAKT protein expression
HepG2 cells were subcultured in low glucose DMEM and treated with either 0, 1 or 100
nM of insulin for 15 mins. Treatment medium was aspirated and rinsed with ice cold
PBS. Cells were lysed with RIPA buffer containing x1 Halt™protease and phosphatase
inhibitor cocktail. Protein concentrations were determined by bicinchoninic acid
(BCA) assay (Fisher Scientific, Loughborough, UK) accordingly to Pierce BCA protein
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assay kit protocol for microplate procedure (sample:BCA working reagent, 1:20 (v/v)).
Samples were stored in -80 ◦C.
Loading buffer (x5; LI-COR Biosciences, Cambridge, UK) was added to protein samples
for a ×1 dilution of loading buffer and heat treated for 10 min at 60 ◦C. As a positive
and negative control for phosphorylated (p)AKT detection, AKT control cell extracts
(New England Biolabs Ltd, Hitchin, UK) were also included and prepared as instructed
by the manual. Proteins were separated by molecular weight via SDS-PAGE. Gels
containing 6 % acrylamide/bis [37.5:1] for stacking and 12 % for resolving were loaded
with 20 µg of protein per lane and resolved for 1 h at 180 V. Proteins were wet-
transferred onto PVDF membranes for 2 h at 300 mA. Membranes were blocked
with 0.1 % BSA in TBS for 1 h at room temperature. Blots were then probed with
primary rabbit anti-pAKT (Ser473, D9E) and mouse anti-AKT (pan, 40D4), both
at 1:2000 (New England Biolabs, Hitchin, UK) in TBS-0.2 % T overnight at 4 ◦C.
After washing for 5 min thrice (washing buffer: TBS-0.1 % T), blots were probed with
donkey anti-mouse IRDye 680RD and donkey anti-rabbit IRDye 800CW at 1:10000
(LI-COR Biosciences, Cambridge, UK) in TBS-0.2 % T-0.01 % SDS for 1 h at room
temperature in darkness. Membranes were washed again with washing buffer for 5
min thrice in darkness, rinsed twice with TBS and air-dried in darkness prior to blot
visualisation on LI-COR ODYSSEY CLx (Cambridge, UK) and quantified by Image
Studio v3.1, software v1.0.11.
5.2.5 Model construction
Metabolic network
The most comprehensive GSMN representing human hepatocyte whole-cell metabolism,
HepatoNet1 [Gille et al., 2010]) was downloaded from BioModels, a repository of
computational models of biological processes (ID: MODEL1009150000) [Juty et al.,
2015]. All fluxes were checked to ensure the direction of reactions, as written in the
HepatoNet1 comment list, were the same as the reaction direction of the stoichiometric
matrix. All fluxes were adjusted to a minimum flux of -1 and a maximum flux of 1 if
reversible, while irreversible reaction fluxes were adjusted as 0 to 1 or -1 to 0 depending
on directionality as indicated by the comment list. In addition, the TAG production
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reaction (r1223) was reversed so to represent this reaction with a positive flux purely
for computational purposes as QSSPN can only maximise a positive flux.
Specific adjustments were made to HepatoNet1 to represent the biology more accurately,
e.g. corrected fructose metabolism as shown in Table 5.1. The polyol pathway was
also included as this has been found to be a potential influence to the development
of hepatic steatosis [Lanaspa et al., 2013] and is part of fructose metabolism [Mayes,
1993]. Namely, HepatoNet1 reaction IDs: r0206 (KHK, EC 2.7.1.3), r0252 (TRIOK,
EC 2.7.1.28), and r0554 (ALDOB, EC 4.1.2.13) were adjusted to incorporate these
corrections (Table 5.1). In addition, a metabolite, sorbitol, plus sorbitol dehydrogenase
(SORD) and aldo-keto reductase family 1, member B1 (AKR1B1) reactions were added
to represent the polyol pathway. The hepatic protein [protein score] and RNA [FPKM]
expression of SORD and AKR1B1 in human liver were confirmed by expression data
from Human Protein Atlas [Uhlen et al., 2015], and also confirmed to be expressed in
HepG2 cells. A reaction was also added to include hepatic fructose sodium co-transport
reaction [Tazawa et al., 2005]. Thus, the total number of metabolites within the
modified GSMN is 778 and the total number of reactions is 2542.
Additionally, a biomass function was introduced as a constraint to ensure the presence of
essential building blocks for biomass were available at all times for a ‘healthy hepatocyte’.
This function was simplified based on a published whole human metabolism GSMN,
Recon 2, biomass [Thiele et al., 2013] and includes amino acids, nucleoside triphosphates
and deoxynucleotide triphosphates. First, FBA simulations to optimise biomass were
performed to establish the initial state of the model before any changes were made
to HepatoNet1; BIOMASS optimal maximisation flux: FBA = 0.03152. Simple FBA
simulations showed that after the modifications listed in Table 5.1 and with the same
external metabolite constraints (Table 5.2), optimised biomass was still maintained;
BIOMASS optimal maximisation flux: FBA = 0.03152. This FBA result confirms the
robustness of HepatoNet1 and verifies that the changes made, to ensure this model has
every possibility to produce TAG from fructose, did not change the ‘healthy hepatocyte’
status. Biomass doubling time estimations for HepG2 cells range from approximately
20 to 60 h [Nyberg et al., 1994, Kicic et al., 2002, Hermes et al., 2005, Norouzzadeh
et al., 2016]. A doubling time of 60 h for the biomass constraint was used in this
instance as an absolute minimum rate. The biomass lower and upper flux bounds were
set at 0.01666667 and 1000.0, respectively.
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Additional constraints were included to represent a more physiological relevant kinetic
activity of the first steps of glucose and fructose metabolism to best fit the model
with current biological knowledge. Flux constraints were set as a ratio of fluxes.
As a conservative measure, flux ratio assumptions were set based on a hexokinase
Michaelis-Menten constant (KM ) for glucose and fructose phosphorylation at carbon-6,
as hexokinase II is the most likely expressed hexokinase in HepG2 cells [Hirahatake
et al., 2011]. The hexokinase KM for glucose and fructose phosphorylation were set as
0.047 mM and 11.5 mM, respectively [Stocchi et al., 1982]. Thus, hexokinase II flux
ratio is set for the phosphorylation of glucose specific reactions (r0353-5) as 1, and
reactions specific to fructose phosphorylation (r0356-8) was set as 0.005. The polyol
pathway flux was also adjusted. The KM for glucose phosphorylation by hexokinase
was set at 0.047 mM, while the KM of the first reaction in the polyol pathway by aldose
reductase enzyme was set at 65.8 mM [Tanimoto et al., 1991, Sato et al., 1995, Brown
et al., 2005]. Thus, hexokinase phosphorylation of glucose is set as 1 again and the flux
of the reaction specific to AKR1 was set as 7.14 x 10−4. Additionally, TAG production
reaction (r1223) lower and upper bound values were set as 0 and 10, respectively, so as
not to mask the optimisation flux if above 1.
To represent the nutrient composition of culture medium, a list of transport reactions
were included in the GSMN as an external exchange set, which does not require
to be balanced within the GSMN as it is ‘external’. Originally, the HepatoNet1
physiological import and physiological export set was used as the external exchange set.
However, this external exchange set was modified as shown in Table 5.2 to represent
the nutrient composition of cell culture medium of serum-free DMEM supplemented
with glutamine and NEAA (Appendix D). Lower and upper bounds of the external
metabolite fluxes were constrained accordingly from an in vitro dataset sourced from
LC-MS/MS measurements. Measurements were taken from culture media of NCI-
60 cell lines consumption and release of metabolites dataset (CORE) [Jain et al.,
2012] where maximum consumption and release were set as lower and upper bounds,
respectively.
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Table 5.2 External metabolite exchange set
Reaction ID Reaction Lower Bound Upper Bound Description
EX_H2O HC00011_s = HC00011_s_xt -1.0 1.0 H2O exchange
EX_O2 HC00017_s = HC00017_s_xt -1.0 0.0 O2 import
EX_Pi HC00019_s = HC00019_s_xt -1.0 1.0 Pi exchange
EX_CO2 HC00021_s = HC00021_s_xt 0.0 1.0 CO2 export
EX_NH3 HC00024_s = HC00024_s_xt -1.0 0.0 NH3 import
EX_Alanine HC00048_s = HC00048_s_xt -0.005500 0.130813 Alanine exchange
EX_Arginine HC00065_s = HC00065_s_xt -0.070285 0.005786 Arginine exchange
EX_Asparagine HC00148_s = HC00148_s_xt -0.037002 0.005679 Asparagine exchange
EX_Aspartate HC00055_s = HC00055_s_xt -0.017289 0.016442 Aspartate exchange
EX_Cystine1 HC00389_s = HC00389_s_xt -0.608543 0.193094 Cystine exchange
EX_Glutamate HC00034_s = HC00034_s_xt -0.007645 0.193094 Glutamate exchange
EX_Glutamine HC00067_s = HC00067_s_xt -0.608543 -0.027744 Glutamine import
EX_Glycine HC00045_s = HC00045_s_xt -0.011301 0.023408 Glycine exchange
EX_Histidine1 HC00133_s = HC00133_s_xt -0.608543 0.193094 Histidine exchange
EX_Isoleucine HC00334_s = HC00334_s_xt -0.043197 -0.002126 Isoleucine import
EX_Leucine HC00121_s = HC00121_s_xt -0.052230 -0.003955 Leucine import
EX_Lysine HC00053_s = HC00053_s_xt -0.038469 -0.005086 Lysine import
EX_Methionine HC00075_s = HC00075_s_xt -0.014031 -0.001399 Methionine import
EX_Phenylalanine HC00081_s = HC00081_s_xt -0.014610 -0.001669 Phenylalanine import
EX_Proline HC00145_s = HC00145_s_xt -0.002389 0.011564 Proline exchange
EX_Serine HC00068_s = HC00068_s_xt -0.067881 -0.004097 Serine import
EX_Threonine HC00179_s = HC00179_s_xt -0.024476 -0.002757 Threonine import
EX_Tryptophan HC00080_s = HC00080_s_xt -0.006982 -0.000055 Tryptophan import
EX_Tyrosine HC00085_s = HC00085_s_xt -0.021401 -0.002104 Tyrosine import
EX_Valine HC00174_s = HC00174_s_xt -0.031520 -0.003558 Valine import
EX_Choline HC00112_s = HC00112_s_xt -0.004596 0.000521 Choline exchange
EX_Folate HC00396_s = HC00396_s_xt -0.000046 0.000198 Folate exchange
EX_Nicotinamide HC00149_s = HC00149_s_xt -0.001838 0.000057 Nicotinamide exchange
EX_Pantothenate HC00568_s = HC00568_s_xt -0.000075 0.000005 Pantothenate exchange
EX_Thiamin HC00316_s = HC00316_s_xt -0.000662 0.000497 Thiamin exchange
EX_Urate HC00310_s = HC00310_s_xt -0.000306 0.000212 Urate export
EX_Glucose HC00040_s = HC00040_s_xt -1.0 1.0 Glucose exchange
EX_Fructose HC00097_s = HC00097_s_xt -1.0 1.0 Fructose exchange
EX_L-Lactate HC00177_s = HC00177_s_xt -1.0 1.0 L-Lactate exchange
EX_Fe2+ HC01846_s = HC01846_s_xt -1.0 1.0 Fe2+ exchange
EX_Inositol HC00135_s = HC00135_s_xt -1.0 1.0 Inositol exchange
EX_Pyridoxine HC00268_s = HC00268_s_xt -1.0 1.0 Pyridoxine exchange
EX_Riboflavin HC00232_s = HC00232_s_xt -1.0 1.0 Riboflavin exchange
EX_Cholesterol HC00178_b = HC00178_b_xt 0.0 1.0 Cholesterol export
EX_H2S HC00250_s = HC00250_s_xt 0.0 1.0 H2S export
EX_Sulfate HC00062_s = HC00062_s_xt -1.0 1.0 Sulfate exchange
EX_Urea HC00089_s = HC00089_s_xt 0.0 1.0 Urea export
Originally sourced from HepatoNet1 PIPES external metabolite exchange set. Modifications were made to
represent serum-free, supplemented DMEM nutrient composition. Constraints were set on the metabolites that
were measured by [Jain et al., 2012]. A negative flux represents import while a positive flux represents export,
and set as the lower and upper bounds, respectively. Metabolite fluxes that were not measured by [Jain et al.,
2012] were set accordingly as described by HepatoNet1 PIPES. 1Metabolites were not measured in [Jain et al.,
2012] and fluxes were set as the lowest minimum and highest maximum flux values from the amino acid flux
values from the CORE dataset. The external metabolites are labelled as _xt, the sinusoidal space is _s, and the
bile space is _b.
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Signalling network
A PN formalism was used to represent the regulatory and signalling network composed
of monosaccharide transport, insulin signalling and to monitor the production of TAG.
PN construction was performed using the PN editor software Snoopy 2 and run on
Mac OS X; v1.13, build Apr 1, 2014 [Heiner et al., 2012]. Utilising the extended PN
class, compounds were represented by places (circles), while transitions (squares)
represent interactions in the model (Figure 5.1).
Figure 5.1 Glucose and fructose transport Petri net model. PN places (circles)
represent compounds, transitions (squares) as interactions, standard edges (point-ended
arrows) as consumption reactions, and read edges (circle-ended arrows) as catalysed reactions.
HepatoNet1 was constrained by the constraint places (Biomass and Glucose or Fructose, as
appropriate). Within this figure, constraints were set as 25 mM of glucose and a minimum
doubling time of 60 h. An objective function was set (e.g. glucose transport, EX_Glucose; or
the production of TAG, r1223) and fluxes were extracted via FLUX transitions (red rectangles)
and monitored via tracking post-places. This was performed to simulate a time course of
maximum and minimal optimisation of the objective function for dynamic flux variability
analysis (dFVA).
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In this network, two types of places were used in order to connect QSSF and
DT. Standard constraint places set the flux bounds in the metabolic network, QSSF.
An activity list can be used to set an activity in an arbitrary way with multiple
thresholds, or to link qualitative and quantitative models (e.g. EX_Glucose, Figure
5.1). Objective places that set the objective function represent the metabolic output of
the QSSF network. Transitions can be tagged and used to set rate values by labelling
them as "RATE". A specialised, FLUX transitions (red rectangles) were used to
extract real flux values from the simulated solution. The FLUX transitions can have
only one pre-place that must be an objective place and one post-place. Standard
(point-ended arrows) and read (circle-ended arrows) edges were used to simulate
consumption or catalysation of the interactions, respectively. Edges can be tagged to
specify the activity of the pre-place, e.g. ‘ACTIVITY 0’ followed by ‘END’ denotes
mass action activity. This enables dynamic simulations and improves integration of
quantitative models.
To represent in vivo-like transportation of glucose and fructose, Michaelis–Menten
kinetics (Equation 5.1) was utilised for calculation of the activity list within the
monosaccharide constraint places, such that
v =
Vmax [S]
KM + [S]
(5.1)
where v is the rate of the reaction, Vmax is the maximum rate possible for
the reaction, [S] is the substrate concentration and KM is the Michaelis–Menten
constant which is unique to each substrate.
The Vmax was set at 5 mmol/g dry weight (DW)/h for both glucose and fructose based
on an estimate from isolated hepatocytes [Baur and Heldt, 1977, Lemonnier et al.,
1981, Elliott and Craik, 1982, Mardones et al., 2011], favouring whole cell uptake,
rather than individually expressed transporters in oocytes. HepG2 cells are known
to express more than one glucose transporter, e.g. GLUT1, GLUT2, GLUT3 and
GLUT9, at least at the transcription level [Bell et al., 1993, Takanaga et al., 2008, Guo
et al., 2011, Hirahatake et al., 2011], but not the main fructose transporter, GLUT5
[Levi et al., 2007, Takanaga et al., 2008]. Glucose transport is symmetrical [Elliott and
Craik, 1982]. Therefore, the activity list for glucose and fructose transport constraint
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places are symmetrical in regards to the maximal import and export rates represented
as lower and upper bounds, respectively.
Table 5.3 Hepatocyte key assumptions
Description Estimations
Dimension 15 µm3
Volume 3.375 × 10−9 mL
Density 1.03 g/mL
Total Cell Weight 3.476 ng
Dry Weight 1.1588 ng(1/3 cell wt)
Wet Weight 2.25 pL(2/3 cell wt)
Estimations based on [Lodish et al., 2000] and Table 5.4.
Original parameters were converted to mmol/g DW/h based on assumptions
as outline in Table 5.3 and Table 5.4. The Michaelis–Menten constant were set at
17 mM for glucose and 66 mM for fructose based on GLUT2 transport properties
as it is the predominate glucose and fructose transporter in hepatocytes [Bell et al.,
1993, Mueckler and Thorens, 2013, Augustin and Mayoux, 2014]. Extrapolating
from a Michaelis–Menten curve based upon these kinetic values, 30 activity step
thresholds were generated (Appendix F). This ensures good resolution over a substrate
concentration range of 0 to 25 mM for each monosaccharide, which corresponds to the
concentrations used during in vitro experimentation.
Table 5.4 HepG2 macromolecular composition
Macromolecules % of dry weight
DNA 3.9
RNA 2.4
Carbohydrates 3.4
Lipids 18.0
Proteins 61.4
Rest 10.9
Composition was sourced from [Niklas et al., 2009].
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This unregulated model was expanded to include a regulatory signalling pathway
through the integration of an ODE model of insulin signalling [Kubota et al., 2012].
This model (ID: MODEL1204060000) was downloaded from BioModels [Li et al.,
2010]. The first step was to test this model in a well-established software application
for simulation and analysis of biochemical networks, COmplex PAthway SImulator
(COPASI) [Hoops et al., 2006]. The published kinetic insulin model was simulated
in COPASI on a Mac OS X; v4.15, Build 95 to ensure the model could successfully
replicate the behaviours reported in the original paper. Briefly, simulations were
carried out as a deterministic (LSODA) time course over a 480 min duration. COPASI
time course simulations resulted in similar behaviour as seen in the original publication
(Appendix E.1 and E.2). The insulin model was then converted into a PN formalism
using Snoopy (Figure 5.2). Large places denoted signalling molecules, medium
sized places represents reaction rates and the smallest places represent degradation.
Places shaded gray represent the same entity and holds the same concentration/flux.
Transitions were labelled as the reaction rate IDs in the original publication, and were
parametrised by their pre-place. The model consistency was rechecked in QSSPN, and
simulated identical results as COPASI (Appendix E.2 and E.3).
The kinetic insulin model was then coupled with HepatoNet1. The model in
its entirety is shown in Appendix G.1, including the layout and files that were used for
model simulations (Appendix G). Within the original kinetic insulin model, only one
gene product had a direct link to a metabolic reaction in HepatoNet1: G6Pase (r0396,
H2O(r) + Glucose-6P(r) → Glucose(r) + Pi(r)). To enhance the regulatory connection
between the insulin regulatory network and the metabolic network, phosphorylated
glycogen synthase kinase (pGSK)3b was designated as the active glycogen synthase
(GYS; r1388, 3 UDP-glucose(c) + Glycogenin-G8(c) → Glycogenin-G11(c) + 3
UDP(c)) [Peak et al., 1998, Mostafalou et al., 2015]. Comments in the original
publication also noted that another compound, phosphoenolpyruvate carboxykinase
(PEPCK), had a similar behaviour to G6Pase but it was not included in the original
kinetic model [Barthel and Schmoll, 2003, Mostafalou et al., 2015]. Therefore, the
activity of G6Pase was used to represent the activity of PEPCK and connected
with HepatoNet1 reactions r0123-4 for both cytosolic (c) and mitochondrial (m)
compartments of reaction; GTP + OAA → GDP + PEP + CO2.
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Figure 5.2 Kinetic insulin model in Petri net. The kinetic insulin model taken from
[Kubota et al., 2012] (top) was reconstructed using a PN formalism (bottom). Areas were
colour highlighted to represent the same modules, while the gray highlighted area was not
in the model but interpreted from the publication main text. Places were used to represent
signalling molecules (large), rate constraints (medium), degradation (small) and repeated
molecules (gray logic). Interactions as transitions, consumed reactions as standard edges
(point-ended arrows) and catalysed reactions as read edges (circle-ended arrows) were also
used to connect compounds as appropriate. Constraint nodes (G6Pase, PEPCK, and pGSK3b)
were implemented to connect the kinetic model to HepatoNet1.
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5.2.6 Model simulations
The QSSPN algorithm integrates QSSF set by the metabolic network with DT rep-
resented by the PN network. QSSF and DT interaction sets are connected by two
classes of PN places: constraint places set flux bounds in QSSF, translating place status
into flux bounds; objective places represent metabolic outputs of the QSSF network.
Specialised transitions are introduced as FLUX transitions so to extract flux values from
simulation solutions. The QSSF is the metabolic network (HepatoNet1) represented as
a stoichiometric matrix of which during simulation, the network is constrained by mass
balance and ultimately is at steady state at each time step during the simulation. The
reaction of interest was labelled as the objective function during these simulations. To
capture the range of the unique solution space, dFVA was performed with optimisation
set as minimisation and maximisation of the objective function.
In summary, the model presents a novel method of dFVA. The approach employs the
following steps:
1. Calculate the constraint and the objective nodes;
2. Update the metabolic model accordingly to (1);
3. Optimise the metabolic model using maximum optimisation dFBA;
4. Update the PN objective node according to the new objective.
5. Repeat (1-4) until simulation time has ended.
6. Repeat (1-5), except using minimum optimisation dFBA for step (3).
The majority of simulations were run using a maximal timestep of 0.01, a 1 % change
of place marking. However, this proved to be too computationally expensive when sim-
ulating the integrated model of insulin and HepatoNet1 optimising for TAG production.
Therefore, this setting was adjusted to 0.1. Under these conditions, simulations were
still of sufficiently high resolution to allow examination of network behaviour.
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5.2.7 Data analysis
Data were represented as mean ± SEM, unless otherwise specified. One-way ANOVA
with Dunnett’s test post hoc and two-way ANOVA with either Tukey’s or Sidak’s
multiple comparisons test post hoc were performed, as appropriate, to detect statistical
significance between groups. Statistical significance was set at P ≤ 0.05.
Area under the curve (AUC) was used to note differences in in silico predictions of TAG
accumulation. Statistical analysis of the computational predictions were not possible
as dFVA only provides one unique time course of maximal and minimal objective
function solution per perturbation. Therefore, dFVA predictions are only an n = 1 and
the objective flux is the only one of interest as these are the only unique solutions per
simulation. Other corresponding flux behaviours of the model are only an example of
many solutions that can be obtained for the unique minimum and maximum solution
of the objective function.
5.3 Results
The aim of this project was to build a dynamic, multi-scale computational model to
simulate the transport and metabolism of sugars and predict the effects this may have
on TAG metabolism. Alongside this, HepG2 cells were utilised as an in vitro model
to aid in silico model development and validate predictions. To represent the feeding
response, a regulatory kinetic model of insulin signalling was included. Altogether, this
study investigated whether there are differences between glucose and fructose substrate
utilisation on TAG metabolism.
5.3.1 Insulin sensitivity in vitro
HepG2 cells were treated with physiological and supra-physiological concentrations
of insulin to test insulin sensitivity (Figure 5.3). Cells responded with a nearly 2-fold
increase of pAKT/AKT expression after a postprandial-like dose of insulin (1 nM),
demostrating cells were responsive to insulin at physiological conditions. HepG2 cells
were also treated with a supra-physiological dose of 100 nM insulin, which elicited an
8-fold increase of pAKT/AKT expression in comparison to non-stimulated cells.
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Figure 5.3 HepG2 insulin sensitivity. HepG2 insulin sensitivity (n=3-4) was measured
by immunoblot detection of pAKTSer473. Cells were subcultured in low (4.8 mM) glucose
DMEM and treated with either 0, 1 or 100 nM of insulin in serum-free low glucose DMEM for
15 min. A representative blot with treatments as well as pAKT positive (+) and negative (-)
cell extract controls was included. Data were represented as a ratio of pAKT/AKT and shown
as mean ± SEM. One-way ANOVA with Dunnett’s test post hoc was performed to detect
statistical significant differences between insulin dose and vehicle denoted as * P < 0.05 and
**** P < 0.0001.
5.3.2 Sugar transport in vitro and in silico
As HepG2 cells were confirmed to be insulin responsive, cells were treated with a
supra-physiological dose of insulin (100 nM) to emphasise effects it may have on sugar
transport and metabolism, and subsequently TAG metabolism. Cells were treated with
serum-free medium containing either 25 mM of glucose or fructose with and without
insulin.
Cells consumed both glucose and fructose over time. Insulin stimulated cells consumed
glucose and fructose at a faster rate than non-insulin stimulated cells (Figure 5.4).
HepG2 cells also consumed glucose at a faster rate than fructose (P< 0.05). After the
first 24 h, medium glucose decreased by 9.3 ± 0.55 mM (equivalent to 0.97 mg/million
cells) and 11.6 ± 0.42 mM (1.14 mg/million cells) in non-insulin and insulin stimulated
cells, respectively. Meanwhile, medium fructose decreased by 7.7 ± 0.49 mM (equivalent
to 0.82 mg/million cells) and 9.6 ± 0.48 mM (1.0 mg/million cells) in non-insulin and
insulin treated cells, respectively. During the second 24 h period, the rate of uptake was
approximately halved (Figure 5.4C). However, the average uptake of glucose was still
more than the uptake of fructose with only a decrease in concentration by 5.2 ± 0.36
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mM (equivalent to 0.44 mg/million cells) and 5.9 ± 0.23 mM (0.47 mg/million cells) of
glucose and 3.9 ± 0.25 mM (0.39 mg/million cells) and 5.2 ± 0.34 mM (0.49 mg/million
cells) of fructose taken up in non-insulin and insulin treated cells, respectively. At
this time point, insulin still had a lasting effect on fructose uptake in comparison to
non-insulin treated cells (P< 0.05), whereas the effects of insulin in comparison to
non-insulin treated cells disappeared after 48 h in glucose-fed cells.
To evaluate whether the in silico model could capture the range of in vitro monosac-
charide uptake, the in silico model initial conditions were set as either 25 mM glucose
with 0 nM or 100 nM of insulin, or 25 mM fructose with 0 nM or 100 nM of insulin
(Figure 5.5). The objective function was set as either glucose transport (EX_Glucose)
or fructose transport (EX_Fructose) between the sinusoidal space (_s) and the exter-
nal space (_xt). dFVA minimisation was set towards production (positive flux) and
maximisation as consumption (negative flux) as shown below.
MIN → (+)
EX_Glucose: Glucose_s 
 Glucose_s_xt
(-) ← MAX
MIN → (+)
EX_Fructose: Fructose_s 
 Fructose_s_xt
(-) ← MAX
QSSPN dFVA maximum optimisation of glucose transport resulted in a rapid depletion
of glucose from medium (Figure 5.5A). The minimum optimisation of glucose transport
resulted in the accumulation of glucose in medium caused by gluconeogenesis. With an
acute stimulation of insulin, the production and export of glucose (seen as a positive
flux) was initially reduced but the rate of glucose production recovered to baseline
within six hours (Figure 5.5C). In contrast, the uptake of glucose (seen as a negative
flux) from the predicted dFVA maximum optimisation was unchanged with insulin
stimulation. Maximum optimisation of fructose transport resulted in a slower depletion
of medium fructose in comparison to glucose and no significant accumulation of fructose
in medium during minimum optimisation of transport (Figure 5.5B). Fructose transport
was unchanged with insulin stimulation.
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Figure 5.4 Insulin stimulated glucose and fructose uptake. Sugar concentrations in
media were measured at 0, 24 and 48 h. HepG2 cells (n=3-5) were subcultured in low (4.8
mM) glucose media, and treated with either 25 mM of glucose (A) or fructose (B) containing
serum-free DMEM with (+) and without (-) 100 nM insulin. The difference between 24 h
periods of monosaccharide concentration in media were also statistically analysed between
treatments (C). Media was not replenished during the period of measurements. Two-way
ANOVA with Sidak’s test (A and B) or Tukey’s (C) test post hoc was performed to detect
statistical differences between insulin and non-insulin treated cells, or between sugar and
insulin treated cells, respectively. Significance was denoted as * P < 0.05, ** P < 0.01, ***
P < 0.001 and **** P < 0.0001.
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The in vitro medium monosaccharide concentrations as seen in Figure 5.4A and Figure
5.4B were overlain, and found to be within the predicted dFVA ranges. The predicted
range of glucose concentrations in medium corresponded well with the in vitro data.
The simulation for glucose predicts a temporal response to insulin, which is consistent
with the observed effect in vitro. However, this effect was not seen with fructose. This
may be due to dFVA as the effect of insulin at the absolutes of the solution space may
be minimal as the system is already being driven to an extreme. This may explain why
effects were not seen in in silico, but in vitro data was in the middle of the response
range. Nonetheless in both instances, in vitro data were found to fit well within the
predicted dFVA solution space.
5.3.3 Intracellular lipid in silico and in vitro
The model was able to predict a physiologically feasible range of minimum and maximum
monosaccharide uptake (Figure 5.5). Additionally, the in vitro data fitted within this
predicted range. Therefore, investigations were carried out to detect the influence of
the type of monosaccharide utilisation on TAG metabolism. TAG production was set as
the objective function to maximise production seen as a positive flux (see below).
MAX → (+)
Acyl CoA + 1,2 DAG → TAG + CoA
Initial conditions were set with or without 100 nM of insulin with either a concentration
of 25 mM of glucose or fructose present in ‘medium’. With an initial concentration
of 25 mM glucose, the maximum optimisation of TAG production resulted in a rapid
accumulation of TAG over time (2.01 mM/g DW/h), while the minimum optimisation
resulted in no production. With insulin simulation, there was an acute reduction in
TAG production, at which the rate stabilised at 1.875 mM/g DW/h from timepoints 0.6
- 3.2 h. The rate of TAG production recovered to the initial rate after 6.4 h. However,
once medium glucose was depleted at approximately 40 h, TAG production reduced to
a slower rate (1.47 mM/g DW/h). In comparison to the non-insulin model simulation,
there was slightly more TAG accumulation in the insulin stimulated model with an
AUC of 4889 (mM/g DW)×h with no insulin and 4900 (mM/g DW)×h with insulin
stimulation. With fructose as a substrate, initial TAG production rates were no different
from glucose as a source of substrate (2.01 mM/g DW/h). The production of TAG with
insulin stimulation also reduced similarly as with glucose as the substrate. However,
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Figure 5.5 Predicted glucose and fructose transport. Monosaccharide transport was
simulated by dFVA in QSSPN with maximisation and minimisation of the objective functions:
glucose and fructose transport between the external space (medium) and sinusoidal space.
Maximisation was the uptake of monosaccharide, and minimisation was the production and
exportation back into the medium (external space). Representing the cell culture experiment,
the model initial state was set with either 25 mM of glucose (A) or fructose (B) with (+) and
without (-) the presence of 100 nM insulin in the medium. HepG2 glucose (A) and fructose
(B) medium concentration were also included from Figure 5.4. Glucose (C) and fructose (D)
transport rates were also observed. Data of results were shown as without (dotted lines) and
with (solid lines) 100 nM insulin stimulation with minimisation (light lines) and maximisation
(dark lines) fluxes.
TAG production was reduced at an early time point (approximately 24 h) as medium
fructose was depleted quicker. This led to the insulin stimulated model resulting in a
reduction in TAG production at a earlier time point than the non-insulin stimulated
model. Thus, insulin stimulation led to a lesser amount of TAG accumulation (4830
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(mM/g DW)×h AUC) in comparison to the non-insulin stimulated model (4967 (mM/g
DW)×h AUC).
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Figure 5.6 Predicted intracellular lipid. Intracellular lipid was simulated by dFVA in
QSSPN with maximisation and minimisation of the objective function: TAG production
within the cytosol. Maximisation was the maximum production of TAG and minimisation
was towards the null production of TAG. Representing the cell culture experiment, the model
initial state was set with either 25 mM of glucose (A) or fructose (B) with (+) and without
(-) the presence of 100 nM insulin in the medium. TAG production rates from an initial 25
mM glucose (C) or fructose (D) were also observed. Data of results were shown as without
(dotted lines) and with (solid lines) 100 nM insulin stimulation with minimisation (light lines)
and maximisation (dark lines) fluxes.
As no differences between glucose and fructose on TAG production were detected
from the multiscale model, HepG2 cells were used to detect the influence of insulin
and type of monosaccharide on hepatic intracellular lipid in vitro. HepG2 cells were
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A) B)
Figure 5.7 HepG2 intracellular lipid. Intracellular lipid was detected by Nile red staining
of HepG2 cells (n=5) at every 24 h for 72 h. Cells were subcultured in low (4.8 mM) glucose
DMEM and treated with either 25 mM of glucose (gold) or fructose (red) with (+) and
without (-) 100 nM insulin. Media was not replenished during the period of measurements.
Data shown as mean ± SEM were adjusted to background fluorescence from non-Nile red
stained cells and expressed relative to 25 mM glucose - (without insulin) treatment for each
time period (A) or at 0 h (B). Two-way ANOVA with Tukey’s test post hoc was performed.
Statistical significant differences between 24 h and each time point of respective treatments
were denoted as ** P < 0.01.
treated with or without 100 nM of insulin with either 25 mM of glucose or fructose.
Intracellular lipid was expressed as relative to 25 mM glucose treated cells without
insulin simulation at each time point and detected by Nile red (Figure 5.7A). Lipid
levels were found to be no different over time as measured every 24 h over 72 h between
glucose and fructose, or with and without insulin stimulation. However, if intracellular
lipid was adjusted to cells at 0 h, an increased amount of intracellular lipid was detected
by Nile red at 72 h across all treatments in comparison to 24 h levels (Figure 5.7B).
These results indicated that the cells produce TAG without monosaccharides; medium
monosaccharide concentrations would have been depleted at this point similarly as
shown in the QSSPN dFVA predictions. To confirm the model can produce TAG
without an initial amount of monosaccharide as a source of substrate, the model was
simulated without glucose or fructose. The TAG production rate in silico (1.47 mM/g
DW/h) was the same as seen in Figure 5.6 when sugars were depleted from medium.
TAG production in the absence of sugars was still influenced by insulin stimulation with
an acute reduction in rate, and thereafter increases to initial production rates.
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Figure 5.8 Predicted intracellular lipid in absence of monosacchardies. Intracellular
lipid was simulated by dFVA in QSSPN with maximisation and minimisation of the objective
function: TAG production within the cytosol. Maximisation was the maximum production of
TAG and minimisation was the null production of TAG. Representing a cell culture experiment,
the model initial state was set with no monosaccharide with (+) and without (-) the presence
of 100 nM insulin in the medium. Data were shown as with (solid lines) 100 nM insulin
stimulation and without (dotted lines) with minimisation (light lines) and maximisation (dark
lines) fluxes.
It was predicted by the in silico model and confirmed by the in vitro model that there
were no differences in TAG production between glucose and fructose, and no significant
long term effects seen after insulin stimulation. The data also demonstrated that
monosaccharides were not essential for TAG production but provide an extra source of
substrate, as TAG can be produced without glucose or fructose (Figure 5.8).
5.4 Discussion
Here, we propose and utilise a novel dynamic, multi-scale QSSPN approach that
combines a hepatocyte specific GSMN with a kinetic regulatory insulin model for the
study of NAFLD to investigate the differential effects of glucose and fructose on TAG
metabolism. Within this work, it is shown that the in silico model can predict in vitro
sugar transport and intracellular lipid accumulation.
114 Hepatic Glucose and Fructose Metabolism In Silico
Sugar transport
In vitro studies that have investigated the role of glucose and fructose in NAFLD
were discussed in Chapter 4. Our data confirms that HepG2 cells are able to import
glucose and fructose (Figure 5.4). Previous work has shown that fructose transport
is in competition with glucose [Okuno and Gliemann, 1986], and again in vitro data
within this chapter and Chapter 4 confirm this (Figure 4.7 and 5.4). If fructose is the
sole monosaccharide present in the medium, fructose is only then consumed.
To capture monosaccharide uptake and metabolism in silico, some essential modifi-
cations were necessary to ensure the metabolic network was representing the correct
hepatic specific metabolism (Table 5.1). The aim was to capture whole cell kinetics of
glucose and fructose rather than capturing isolated sugar transporter flux rates. In
general, individual glucose transporters have not been represented in human GSMNs
[Duarte et al., 2007, Thiele et al., 2013, Swainston et al., 2016], and likely do not need
to be as long as the net flux is represented by the inclusion of all transporter reactions
[Sahoo et al., 2014]. Additionally, the metabolic network was adapted to represent in
vitro conditions. Although there is no hepatocyte-derived cell line in the NCI-60, the
CORE dataset was used to capture general cancer-like cell properties.
It was also shown that HepG2 cells respond to insulin with an increase in expression
of the initial insulin signalling response of pAKT relative to AKT (Figure 5.3). Similar
levels of pAKT/AKT were seen as those reported in vivo with a 2-3 fold increase in
pAKT/AKT ratio [Agouni et al., 2010]. There was also an unexpected effect of insulin
on monosaccharide uptake as the main hepatic glucose and fructose transporter does
not respond to insulin, like how the main glucose transporter in muscle and adipose,
GLUT4, does [Bell et al., 1993]. As shown in Figure 5.4, insulin induced a small, but
significantly increase in the uptake of glucose and fructose. This could either be due
to an increase in transport activity, or as the transport rate is unlikely to be at Vmax,
an increase in monosaccharide metabolism. Fructose metabolism does not depend
on insulin but, glucose metabolism does respond to insulin by inducing glucokinase
gene expression and activating glycolytic enzymes [Tappy and Lê, 2010]. This could
explain the increase uptake of glucose in response to insulin, however the increase rate
of fructose uptake is left unexplained.
As shown in Figure 2.6, the liver possesses a specific hepatic enzyme that phosphorylates
fructose at a very fast rate, KHK, which converts it to fructose 1 phosphate (F-1P).
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F-1P is cleaved into dihydroxyacetone phosphate and glyceraldehyde by F-1P aldoase
(aldose B). Glyceraldehyde is then phosphorylated by triose kinase to glyceraldehyate
3-phosphate, which then can enter the glycolysis pathway. Depending on the metabolic
status, this could be converted into either glucose or glycogen, or provide substrates
for FA synthesis. Not only does fructose feed into the glycolysis and gluconeogenesis
pathway, but it also enhances glucose utilisation. Some insights have suggested that
GCK, a specialised enzyme for the first step of hepatic glucose metabolism, resides
in the hepatocyte nucleus during fasting and is bound to GKRP [De La Iglesia et al.,
1999]. The binding of GCK-GKRP is normally enforced by the presence of fructose 6-
phosphate. However, after fructose is metabolised, F-1P causes GCK to dissociate from
GCKR and relocate back into the cytosol [Massa et al., 2011]. Without fructose, high
concentrations of glucose, e.g. 15 mM, can stimulate the dissociation of GCK-GKRP.
However, F-1P is a much more potent stimulant that can activate this process at levels
as low as 0.2 mM. Insulin could also influence this process by regulatory mechanisms
(Figure 2.5). Insulin is known to positively stimulate GCK, PFK, PK, ACC, and FAS,
while inhibiting PEPCK, FBPase and G6Pase [Saltiel and Kahn, 2001]. Therefore,
insulin is much more likely to increase uptake by the influence of metabolic processes
that is independent from transport mechanisms and then, would have a direct effect
on glucose and fructose metabolism.
Intracellular lipid
Many immortalised cell lines lose their original functionality, and demonstrate pheno-
typic drift over time in culture. This has been assessed in detail in HepG2 cells to
ensure that lipid related studies are relevant. HepG2 cells have been shown to retain
the ability to synthesise in vivo-like TAG lipoproteins when exposed to extracellular FA
(e.g. OA) and to a lesser extent, glucose-sourced de novo lipogenesis [Gibbons et al.,
1994]. Insulin was found to slightly decrease TAG synthesis, but lost this effect with the
addition of OA in the medium [Gibbons et al., 1994]. Minimal effects of insulin were
observed in a HepG2-derived HepG2-C3A study [Iyer et al., 2010]. In silico predictions
of TAG production show that glucose and fructose produce the same maximal rate
of TAG production until levels of sugar concentrations fall below a threshold. This
threshold switches the limiting factor of TAG production from metabolism to the
transport of sugars. At this point, glucose in media is depleted quicker than fructose,
consistent with their affinities for GLUT transporters.
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Simulations of both glucose and fructose perturbations predicted an acute reduction in
TAG production (1.875 mM/g DW/h) after insulin stimulation between 0.6 - 3.2 h
timeponts, and did not returned to initial rates until after 6.4 h. This timeframe fits well
within the postprandial response as TAG production would have decreased 30 min after
feeding, and not returned to a pre-prandial state until after 6 h 30 min after feeding.
This counter-intuitive observation was also previously noted in a mathematical model
of hepatic lipid metabolism showing that liver TAG initially decreases when fed a high
fat diet, potentially explained by rising plasma insulin stimulated by carbohydrates
in the meal [Pratt et al., 2015]. However, the acute response of insulin had no long
lasting effects on TAG accumulation in silico, consistent with the experimental in
vitro data. Although insulin was still present in the extracellular space, the signalling
response returned back to baseline, as did TAG production rates until levels of sugar
were at a threshold where the transport of sugars was limiting for production. At
sugar concentrations where transport was the limiting factor, glucose-fed cells had an
increased level of TAG, while fructose-fed cells were predicted to have a lower level of
TAG after an equivalent of 72 h incubation. The in vitro model also confirmed this
outcome as there were no detected differences between glucose or fructose, with or
without insulin stimulation.
Assessing in silico approaches
A computational model has recently been published that investigated the role of glucose
and fructose in relation to NAFLD [Foguet et al., 2016]. This was a kinetic model
parametrised with 13C labelled glucose and fructose based experiments measured by
GC-MS of primary rat hepatocytes treated with 20 mM of glucose supplemented with
either 3 mM or 20 mM of fructose for 2 hours. However, caution is warranted on the
interpretation of acute effects and the extrapolation of animal to human metabolism.
It may also be missing components as it was representing a hepatocyte in isolation
and not a systemic disease that affects other tissues as well. Ideally, future work would
also be able to further distinguish the interplay of multiple cell types that reside in
the liver, such as HSCs and KCs. Nonetheless, the study by Foguet et al. was still
able to investigate crucial details of hepatic sugar metabolism. It was shown that the
additional 20 mM of fructose inhibited glycogen synthesis [Foguet et al., 2016]. This
was caused by KHK phosphorylating fructose and led to an accumulation of F-1P,
lowered the adenosine triphosphate (ATP) status, and lowered the activity of GCK
and PFK. However, the addition of 3 mM of fructose, a physiological relevant portal
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concentration (0.2 - 2 mM [Patel et al., 2015]), showed no adverse effects on intracellular
energy status. Interestingly, there was very little flux going through FA synthesis in
both experimental models [Foguet et al., 2016]. The authors attributed this outcome as
the result of isolating primary hepatocytes from fasted rats, plus the short experimental
incubation time. Similarly, the in vitro experiments performed within this chapter and
the previous one showed HepG2 cells fed glucose and fructose had no differential effects
in intracellular lipid over longer periods of exposure. The stoichiometric information
produced from [Foguet et al., 2016] could be implemented into this metabolic model in
order to incorporate specific rates of hepatic fructose and glucose metabolism, further
constraining simulations, for a more direct comparison.
NAFLD is now recognised as not only a disease of the liver, but one that involves
the dysregulation of normal whole-body metabolism. To study this, Bordbar and
colleagues created a human metabolic network with three cell type specific components
to be able to capture elements of a metabolic disorder as a systemic disease [Bordbar
et al., 2011]. Hepatocyte functional tests were carried out, including alternative sugar
metabolism. As a validation test, it was found that on a molar basis, glucose and
fructose produced the same amount of ATP (32.5 mol ATP/mol sugar). However, this
model only captures core hepatocyte metabolism as a purely stoichiometric network,
with non-dynamic behaviour, rather than trying to capture all the regulatory and
metabolic reactions within hepatocytes. Hence, the lack of ATP depletion with fructose
metabolism may be the result of missing network component, or that there is no
difference between the two monosaccharides on a equal molar basis. Future studies are
therefore needed to determine whether the predictions based on only core metabolism
will hold true when other metabolic subsystems are included in a dynamic, regulated
system.
Other computational models that have very recently been used to study NAFLD could
be used to differentiate the role of glucose and fructose. One application has used
a multi-tissue modelling approach with the use of mathematical equations with the
majority assumed to be at steady state, named SteatoNet [Naik et al., 2014]. This model
was used to identify critical metabolic and regulatory points that were involved in the
development of hepatic steatosis. It included six compartments representing the liver,
adipose tissue, macrophage, pancreas, peripheral tissue and blood. This model also had
multiple metabolic pathways including glucose, fatty acid, cholesterol and amino acid
metabolism represented by 194 reactions with 159 metabolites. Transcriptional and
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post-transcriptional regulation was included by the addition of 31 regulatory proteins
of transcription factors, hormones, cytokines, adipokines and other regulatory factors.
SteatoNet is comprised of differential algebraic equations based on classical Michaelis
Menten kinetics so as to attempt to capture large-scale metabolic comprehensiveness
without the need to parametrise the model fully. This method bypasses the requirement
of a highly detailed, comprehensive parameterisation with only 25 % of the published
model parameterised. A more recent study of NAFLD had used a GSMN with the
integration of human-derived transcriptomics data across patients with various levels of
fatty liver and human NAFLD metabolic flux data to test adaptability with increased
metabolic demands [Hyötyläinen et al., 2016]. The development of these integrated
models have been possible by more advanced experimental technology with enhanced
sensitivity and selectivity. This allows genome scale network to be contextualised
and clinical data to be integrated into a wider context of genome scale metabolism,
signalling, and regulation.
However, these approaches have only recently been published. During this time, QSSPN
was being developed to be able to fully capture multi-scale, dynamic behaviour under
regulation [Fisher et al., 2013] and is further being explored. The reason of utilising
HepatoNet1 instead of Recon is that HepatoNet1 is still arguably considered the
most comprehensive genome scale metabolic network of a human hepatocyte. Initially,
HepatoNet1 had lacked gene-protein-reaction associations making it difficult to carry out
integration of high quality -omics data. However, recent modifications to HepatoNet1
have been completed. These include the addition of Minimal Information Required
In the Annotation of Models (initiated by BioModels), increasing the annotation of
this GSMN. HepatoNet1 has also been integrated into the human whole cell GSMN,
Recon 2. As Recon undergoes development, the liver GSMN will inherently be further
developed. Future research could then utilise Recon 2.2 instead of HepatoNet1.
With better quality genome annotations and the increasing benefits of standardisation,
the applicability of genome scale models has vastly improved [Martins Conde et al.,
2016]. Although it is crucial to ensure the systems biology community is aiming
towards standardisation and unification [Pfau et al., 2015], it is also important to
further innovate novel approaches to allow a diverse range of application to target
specific research questions to capture the system as a whole and strengthen research
findings. Other possible avenues that could be explored is the utilisation of the
Human Metabolic Altas [Pornputtapong et al., 2015] such has been done to create
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GSMN Human Metabolic Reaction 2 and iHepatocytes2322 for the study of NAFLD
[Mardinoglu et al., 2014] and towards multi-tissue modelling [Naik et al., 2014] or the
Virtual Physiological Human [Viceconti et al., 2016]. Yet, QSSPN provides a unique
platform able to integrate a GSMN with gene and signal regulatory mechanisms in
a modular form that can be based on different tissues or levels of organisation. This
approach has the ability to capture the dynamics of a model by the integration of
qualitative and quantitative data, and further additions can be added once available as
shown by the integration of the insulin kinetic model with HepatoNet1 as done within
this chapter. One particular issue that may arise is the computational burden of these
models which grow ever more in their size and complexity. However, the exponential
increase in computational power means this increased complexity will not be a limiting
factor for future innovations.
5.5 Conclusion
It was found that in both the in vitro and in silico models utilised here, equal molar
concentrations of glucose and fructose did not have a differential effect on intracellular
lipid accumulation. It was confirmed that our in vitro model was able to utilise glucose
and fructose, while our in silico model also utilised glucose and fructose when TAG
production was maximised.
Within this work, we developed a novel predictive, multi-scale, computational model of
hepatic monosaccharide transport, signalling and metabolism validated experimentally
to an in vitro model of steatosis. Firstly, the integration of the regulatory insulin network
was to couple hormone regulation that would influence glucose and lipid metabolism,
which is essential when studying multifactorial systemic metabolic diseases. Additional
hormonal and signalling interactions as well as gene regulation [Fisher et al., 2013] can
be integrated in future work. This would be essential for a deeper level of understanding
in the development and progression of NAFLD. Secondly, this is the first basis of
integrating a GSMN with a published quantitative, kinetic signalling model to elucidate
dynamic behaviour. This was successfully implemented using QSSPN. This approach
has provided a feasible, physiological range of solutions that can be further refined and
interrogated in future work.

Chapter 6
Conclusion
6.1 Overview
Dietary fructose has been proposed to contribute to the pathogenesis of NAFLD.
However, current findings are conflicted as meta analyses of human intervention trials
have highlighted no differences in the extent of fat accumulation in the liver from
equimolar doses of fructose or glucose [Chiu et al., 2014]. In this context, the aim of
this work was to develop a computational model to predict the differential effects of
glucose and fructose on hepatic TAG production, and validate this to an in vitro model
of hepatic steatosis. The results from this work have shown that the in vitro hepatic
monosaccharide uptake and intracellular lipid were reproduced in our in silico model,
and similarly, detected no differential lipogenic effects of fructose.
6.1.1 Hepatic steatosis in vitro
Commonly used immortalised hepatocyte cell lines, HepG2 and HuH7, were evaluated
as an in vitro model of hepatic steatosis. These cells were treated for 24 h with a range
of physiological concentrations of FA, saturated PA and monosaturated OA, in cells that
were either acclimatised to low (5 mM) or high (25 mM) levels of glucose containing
culture media. In both cells lines, OA was shown to be more lipogenic than PA with a
higher magnitude of intracellular lipid after treatment with no apparent differences
between low and high glucose cultured cells. However, HepG2 cells were more sensitive
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to PA treatment with a significant reduction in viability at the lowest dose (100 µM)
according to the MTT assay. Meanwhile HuH7 cells required a higher concentration of
PA (400 µM) to induce a significant reduction in viability in comparison to OA treated
cells cultured in high glucose. Yet, HuH7 cells were affected by the vehicle, DMSO,
as it was shown to induce changes in viability in comparison to serum and serum-free
cultured cells. It was concluded that HepG2 cells were the most appropriate cell line
to use for future studies and HuH7 cells were no longer continued.
HepG2 cells were then utilised to investigate the impact of lipid loading on the
expression of GLO1 as it had been previously identified to be reduced in paediatric
NAFLD patients and in an animal model of NAFLD [Spanos et al., 2016]. HepG2 cells
were cultured in low glucose containing media and treated with either vehicle, 400 µM
PA or 500 µM OA for 24 h. OA induced a 4-fold increase in intracellular lipid relative
to vehicle and inversely, GLO1 protein expression was reduced by 40 % relative to
vehicle. PA also induced more intracellular lipid relative to vehicle, and a reduction of
GLO1 levels to a lesser extent; suggesting the altered expression of GLO1 is related
to the amount of lipid accumulated in the cells. The consequence of a lower GLO1
expression was found to be critical as an increased accumulation of GLO1’s substrate,
MG, was detected. As measured by LC-MS/MS, there was a significant 44 % increase
in the accumulation of intracellular MG induced by OA, while PA induced a 35 % rise
in intracellular MG levels in comparison to vehicle. MG accumulation was also detected
in the media with a similar 45 % and 46 % increase in medium concentrations induced
by OA and PA relative to vehicle, respectively. This data suggests lipid accumulation
increases MG formation and/or decreases its metabolism.
There are inherent limitations to using an immortalised cell line for investigating
a systemic metabolic disease. Examining isolated cells from a whole organ/body
simplifies to a model system for easier interpretations, but at the cost of studying a
system outside its natural environment. However, in vitro methods provide a way to
systematically investigate metabolic perturbations in a well controlled environment.
Other advantages are these cells can be grown for a prolonged period of time, and more
cost efficient, than primary cells that have a limited lifespan. However, a significant
amount of mutations must have occurred to immortalise these cells, hence the need for
characterisation to determine the appropriateness of the cell line for the investigation
under study [Guguen-guillouzo and Guillouzo, 2010, Green et al., 2015b].
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The response of the hepatocytes to FA treatment are consistent with the literature
[Gómez-Lechón et al., 2007, Ricchi et al., 2009, Chavez-Tapia et al., 2012]. Additionally,
this work has demonstrated and strengthen the evidence of a potential role of GLO1 in
NAFLD pathogenesis in vitro. Hepatic lipid loading was found to reduce GLO1 levels
as observed in an animal model of NAFLD and paediatric NAFLD patients [Spanos
et al., 2016]. Furthermore, the reduction of GLO1 expression was significant due the
accumulation of its substrate, MG, had significantly increased both intracellularly and
in medium as measured by the gold standard, stable isotopic dilution LC-MS/MS.
6.1.2 A mixed-nutrient model in vitro
HepG2 cells were also used to investigate if there were any differential effects of
the amount and type of monosaccharide on the rate of hepatic lipid and on lipid
species accumulation. Firstly, qualitative and quantitative Nile red quantification of
intracellular lipid were utilised to assess the amount of lipid in cells that were maintained
in either low or high glucose containing media. Cells that were maintained in high
glucose containing culture medium had a slight increase, but not statistically significant
amount of intracellular lipid than cells that were in low glucose containing medium.
However, after cells were treated with OA for 24 h, no differences between low and high
glucose culture cells were detected with either method of Nile red quantification.
Secondly, intracellular lipid in cells that were treated with glucose, or with an addition
of fructose, were quantified by Nile red and by the gold standard, GC-MS. HepG2 cells
were treated with either vehicle and 5 mM glucose, or 400 µM OA with either 5 mM
glucose, 25 mM glucose or 5 mM glucose + 20 mM fructose for 24 h. Intracellular lipid
was monitored over a 6 h period by Nile red and GC-MS quantification. The total
amount of lipid was measured by Nile red; and the individual lipid species (DAG and
TAG) were measured after TLC separation, and individual FA from within these lipid
fractions were quantified by GC-MS. The targeted FA were the treatment, OA, and
the ones that are most associated with DNL: PA, POA and VA.
OA was found to induce the majority of intracellular lipid with the incorporation
of itself into DAG and TAG fractions over 6 h. Additionally, OA-treated cells were
detected to have increased levels of PA, POA and VA in TAG fractions over 6 h.
Meanwhile, no detectable levels of PA, POA nor VA were found in DAG fractions. No
differences were detected between cells that were treated with OA and 5 mM glucose
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+ 20 mM fructose to cells treated with OA and 25 mM glucose. However, fructose
was not consumed during the first 6 h of treatment, which would explain the absence
of an effect on intracellular lipid. This confirms that glucose is the preferential sugar
substrate for HepG2 cells, as seen in the literature [Hirahatake et al., 2011]. Notably
after 6 h of fructose exposure and depleting glucose, fructose levels in medium were
increased compared to the initial timepoint. This observation was unexpected, but an
interesting result that suggests glycolysis flux was saturated and glucose may have then
been converted into fructose, possibly via the polyol pathway. However, this effect was
short-lived as fructose concentrations were lower in comparison to the initial timepoint
when measured after 24 h in an independent experiment.
Most recently, a study also investigated the effects of glucose and fructose alone, or in
various mixtures, in cotreatment with OA or a mixture of OA and PA after 24 h [Zhao
et al., 2016]. The most similar treatment in this study to that used in this thesis, 1
mM OA and 5 mM glucose + 20 mM fructose was also found not to induce an increase
of intracellular lipid in comparison to cells that were treated with 1 mM OA and 25
mM glucose. This may have been caused by OA treatment inducing intracellular lipid
levels to the saturation point, to which the amount of monosaccharide in co-treatment
could not have induced any more. Although not statistically significant, cells treated
with OA and 25 mM glucose had a slight increase of intracellular lipid across all
quantified lipids as measured by Nile red and GC-MS in comparison to the other OA
and sugar treatments. This may suggest the presence of DNL with the exposure of
greater amounts of glucose. The experimental media also did not include the use of
insulin, an essential regulator of carbohydrate metabolism, so to avoid an additional
factor that may cloud experimental interpretations. However, insulin was included
for the next set of in vitro experiments, with the exclusion of OA to investigate these
effects.
6.1.3 Glucose versus fructose in silico
The aim of this part of the work was to use an approach that would capture the dynamic
behaviour of monosaccharide transport and metabolism, and predict the subsequent
production of TAG on a genome scale level. QSSPN was utilised to integrate a
GSMN of human hepatocyte metabolism with glucose and fructose transport manually
constructed in PN and a kinetic model of hepatic insulin signalling reconstructed in
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PN. By integrating PN and CBM of GSMNs, QSSPN can predict the feasibility of
dynamic behaviours in a multi-scale model of gene regulation, signalling and whole-cell
metabolism. This was used to investigate the influence of glucose and fructose, with
and without insulin, on hepatic TAG production, and related this to hepatic steatosis.
Alongside this, HepG2 cells were used to provide in vitro data to experimentally
validate in silico predictions.
Firstly, HepG2 cells were confirmed to be responsive to insulin by the measurement
of pAKT/AKT. Insulin sensitive confirmed HepG2 cells were treated with either 25
mM glucose or 25 mM fructose, with and without insulin over 48 h. Sugar levels in
media were measured to monitor monosaccharide consumption. Insulin was found to
stimulate a faster rate of glucose and fructose uptake. This was somewhat unexpected
as the main hepatic glucose and fructose transporter does not respond to insulin,
like the main glucose transporter in muscle and adipose, GLUT4, does [Bell et al.,
1993]. Additionally, fructose metabolism does not depend on insulin although, glucose
metabolism does by inducing glucokinase gene expression and activating glycolytic
enzymes [Tappy and Lê, 2010]. This could explain the increase uptake of glucose in
response to insulin, however the increase rate of fructose uptake is left unexplained. The
in silico model together with our novel simulation method, dFVA, predicted minimum
and maximum flux rates. This allowed the calculation of extracellular glucose and
fructose, and triacylglycerol production over time, while also satisfying the demands of
a ‘healthy hepatocyte’. In vitro monosaccharide concentrations in medium over time
fitted well within the predicted ‘solution space’, confirming a good agreement between
our in vitro and in silico models.
Secondly, in silico simulations were set to replicate in vitro conditions in order to
predict the differential effects of glucose and fructose on TAG production with and
without insulin. Experimentally, intracellular lipid by Nile red was measured in HepG2
cells treated with glucose or fructose, with and without insulin. In silico predictions
suggested insulin induces a transient reduction on TAG production in a postprandial-
like manner, returning to initial production rates after 6 h in both glucose and fructose
fed models. However, no differential lipogenic effects of fructose compared to glucose
were predicted in silico, nor detected experimentally by our in vitro model over a 72
h incubation period. On the contrary, fructose has been previously shown to induce
intracellular lipid in HepG2 cells [Huang et al., 2011, Lanaspa et al., 2012]. Yet
conclusions are mixed, as it has also been shown that no differences were detected
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between glucose and fructose in the induction of lipogenic gene expression [Hirahatake
et al., 2011, Stamatikos et al., 2016].
As with all computational models, the limitations of this in silico model are the
assumptions and incompleteness. Although a kinetic model of insulin was added to
regulate carbohydrate metabolism, there are many other regulators of metabolism
that could be integrated, e.g. glucagon. Furthermore, the insulin model was based on
experimental data in primary rat hepatocytes, rather than in human hepatocytes. This
model is also restricted to parts of the metabolic network where the regulatory network
is understood as it is manually constructed based on prior knowledge. Yet, this approach
has shown a promising way to integrate regulatory networks with metabolism to be
able to simulate multi-scale, dynamic behaviour once data is available. Ultimately, all
models have their own set of advantages and disadvantages, and must be characterised
in order to determine its applicability. This model will be further developed in future
as this represents only one cycle of the systems biology approach of model construction,
validation and refinement [Kitano, 2002b].
6.2 Future work
This thesis presents a novel predictive, multi-scale, computational model of hepatic
monosaccharide transport, signalling and metabolism; which was developed and vali-
dated experimentally to an in vitro model of steatosis. Due to the phenotypic differences
detected between the cell lines used in this thesis, the importance of establishing a
well defined in vitro model was highlighted. This is the first instance of investigating
the influence of the type of monosaccharide on hepatocyte TAG with the aid of a
novel dynamic, multi-scale, computational model using QSSPN. At the current state
of the in silico model, no differential effects on TAG production were detected between
glucose and fructose. Importantly, this work was confirmed by an immortalised cell
line which is likely to have abnormal carbohydrate metabolism.
Future work could explore the use of Recon 2.2 as it has only just been published
[Swainston et al., 2016]. This model has updated FA metabolism and oxidative
phosphorylation, as well as full mass and charge balancing all reactions. Although
Recon is a global human GSMN, HepatoNet1 has been integrated into the previous
version, Recon2. Thus, Recon 2.2 may provide a higher quality, human hepatocyte
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specific GSMN. However, a critical assessment is required prior to utilising this model
to ensure hepatocyte-like functionality, e.g. bile acid synthesis, and for specifically
investigating hepatocyte sugar and lipid metabolism.
To represent more in vivo-like physiology, the in silico model could be constrained by
human in vivo flux data for the external metabolite set, instead of the NCI-60 CORE
dataset from cancer cell lines [Jain et al., 2012]. Validation experiments would then
need primary human hepatocytes to investigate if glucose and fructose have differential
effects on TAG production in a model of a ‘more normal’ carbohydrate metabolism
than immortalised cell lines. Glucose and fructose could also be labelled to monitor
its uptake as well as the first steps of metabolism in the cell. These experiments
can provide flux data that could be incorporated into the in silico model to capture
the first steps of hepatic sugar transport and metabolism representing more normal
physiological-like behaviour. The primary cells would need to be characterised to
determine the risk factors for steatosis, such as PNPLA3, and assess if mutations were
present in sugar and lipid metabolism that would influence results. It would also be
useful to determine the mode of glucose and fructose entry in these cells, as it is mostly
assumed to be GLUT2 as it is the most highly expressed GLUT and found to transport
both monosaccharides in oocyte studies.
Future in vitro studies will also need to use a medium that reflects physiological levels
of nutrients representing different types of meals that would be typically seen in the
portal vein after feeding. Although this would be highly complex, medium composition
could be simplified in the first instance by containing a baseline level of glucose, amino
acids, vitamin and minerals, but vary concentrations of fructose and lipid mixtures to
represent a healthy versus a westernised diet. With the use of advancing cell culture
equipment, the medium can be replaced accordingly to represent a typical feeding
schedule and excrete waste. Although insulin is the main hormone that influences
metabolism during the postprandial period, glucagon plays a major role of metabolism
during the fasting state. Therefore, the in silico model could also incorporate the
balance between these two major regulators of metabolism to capture the dynamic
response of the liver during feeding and fasting.
Ultimately, future work should aim towards having a higher impact on informing
whether fructose needs to be targeted specifically to prevent the development or
progression of NAFLD. It is clear that scientific evidence in this area is confusing as
NICE has not given specific recommendations due to the lack of relevant evidence, while
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EASL encourages the reduction of its consumption. However, it should be noted that
fructose is rarely ever consumed on its own and often as part of a hypercalorific diet.
Furthermore, there may be differences on how healthy versus fatty hepatocytes respond
to sugars. This is particularly relevant as 33 % of the UK population is estimated
to have hepatic steatosis already, and appropriate dietary advice could help prevent
progression, or encourage regression. Therefore, this work can be of use to investigate
underlying molecular and regulatory mechanisms of sugar and lipid metabolism in
response to mixed meals containing relevant, physiological levels of glucose and fructose,
without confounding excess energy, in both healthy and fatty livers.
6.3 Concluding remarks
Firstly, the work presented in this thesis has confirmed the response of hepatocyte
cell lines to saturated and mono-unsaturated fatty acid treatment with regards to
intracellular lipid and cell viability. An accumulation of methylglyoxal as a functional
consequence of reduced glyoxalase 1 levels in response to fatty acid induced lipid loading
in vitro was demonstrated in HepG2 cells, as quantified by the gold standard, stable
isotope dilution LC-MS/MS. This in vitro model of steatosis was utilised to demonstrate
a comparative response of intracellular lipid to low and high glucose acclimatisation.
HepG2 cells were also used to investigate the response to a mixed-nutrient treatment
composed of oleate and glucose or added fructose with no synergistic lipogenic effect
of added sugars detected as quantified by the gold standard, GC-MS.
Secondly, a novel method using QSSPN was demonstrated by integrating a human
hepatocyte GSMN constrained by in vitro data with a reconstructed network of
hepatic glucose and fructose transport, and a published kinetic model of hepatic insulin
signalling. This in silico model was used to perform predictive, dynamic simulations
of minimum and maximum flux rates by a novel simulation method, dFVA, with no
differential lipogenic effects detected between fructose and glucose. Furthermore, in
silico predictions were validated experimentally to an in vitro model of hepatic steatosis,
confirming no differential lipogenic effects of fructose in comparison to glucose. This
was the first instance of investigating the influence of the type of monosaccharide on
hepatocyte TAG production with the aid of a novel dynamic multi-scale, computational
model successfully implemented using QSSPN.
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Appendix A
Figure A.1 An example of an olive oil standard curve. An example of an olive oil
standard curve from which quantified intracellular lipid in relative fluorescent units (RFU) was
interpolated from standard concentrations of olive oil as described in Section 4.2.2. Standards
are n=1 of three technical replicates shown as standard deviation and plotted with a 95 %
confidence band.

Appendix B
Figure B.1 Thin layer chromatography lipid separation. Each internal standard;
heptadecanoic acid (FA), monoheptadecanoin (MAG), diheptadecanoin (DAG) and trihep-
tadecanoin (TAG), and lecithin as a phospholipid spot control, and combining mixture
(Internal Standard Mixture) were spotted onto a TLC plate (25 µg/standard) and underwent
separation as described in section 4.2.4.

Appendix C
Table C.1 Composition of RM-6
Chemical name % Composition Detected % Composition Accurancy (% error)
methyl oleate 41 44.81 ± 1.51 9.29
methyl palmitate 30 26.64 ± 0.45 11.19
methyl stearate 14 14.22 ± 0.24 1.57
methyl linoleate 7 7.16 ± 0.18 2.30
methyl palmitoleate 3 3.08 ± 0.02 2.51
methyl linolenate 3 3.09 ± 0.02 2.99
methyl myristate 2 1.79 ± 0.08 10.50
RM-6 was run under the same GC-MS settings as described in section 4.2.6. The %
composition was calculated based on four independent runs. RM-6 underwent some or
complete evaporation during each run and needed to be re-suspended in hexane before
each run. Data are shown as mean ± SD.
170 A certified lipid standard and fatty acid mass spectra
Figure C.1 Methyl-palmitoleate GC-MS mass spectra. A GC-MS result of the mass
spectra of methyl-palmitoleate in the mixture of authentic standards (RM-6). Palmitoleate
has a signature molecular ion at m/z = 268.
171
Figure C.2 Methyl-palmitate GC-MS mass spectra. A GC-MS result of the mass
spectra of methyl-palmitate in the mixture of authentic standards (RM-6). Palmitate has a
signature molecular ion at m/z = 270.
172 A certified lipid standard and fatty acid mass spectra
Figure C.3 Methyl-oleate GC-MS mass spectra. A GC-MS result of the mass spectra
of methyl-oleate in the mixture of authentic standards (RM-6). Oleate has a signature
molecular ion at m/z = 296.
Appendix D
Table D.1 DMEM medium nutrient composition
Components Molecular Weight Concentrationg/mol mg/L mM
Amino Acids
Glycine 75 30.0 0.400
L-Arginine hydrochloride 211 84.0 0.398
L-Cystine 2HCl 313 63.0 0.201
L-Histidine hydrochloride-H2O 210 42.0 0.200
L-Isoleucine 131 105.0 0.802
L-Leucine 131 105.0 0.802
L-Lysine hydrochloride 183 146.0 0.798
L-Methionine 149 30.0 0.201
L-Phenylalanine 165 66.0 0.400
L-Serine 105 42.0 0.400
L-Threonine 119 95.0 0.798
L-Tryptophan 204 16.0 0.078
L-Tyrosine disodium salt dihydrate 261 104.0 0.398
L-Valine 117 94.0 0.803
Vitamins
Choline chloride 140 4.0 0.029
D-Calcium pantothenate 477 4.0 0.008
Folic Acid 441 4.0 0.009
Niacinamide 122 4.0 0.033
Pyridoxine hydrochloride 204 4.0 0.020
Riboflavin 376 0.4 0.001
Thiamine hydrochloride 337 4.0 0.012
i-Inositol 180 7.2 0.040
Inorganic Salts
Calcium Chloride (CaCl2) (anhyd.) 111 200.0 1.802
Ferric Nitrate (Fe(NO3)3"9H2O) 404 0.1 2.5×10−4
Magnesium Sulfate (MgSO4) (anhyd.) 120 97.7 0.814
Potassium Chloride (KCl) 75 400.0 5.333
Sodium Bicarbonate (NaHCO3) 84 3700.0 44.05
Sodium Chloride (NaCl) 58 6400.0 110.3
Sodium Phosphate monobasic (NaH2PO4-H2O) 138 125.0 0.906
174 Cell culture medium composition
Table D.2 MEM Non-Essential Amino Acid Solution
Components Molecular Weight Concentrationg/mol mg/L mM
L-Alanine 89.093 890.0 9.990
L-Asparagine 132.118 1.32×103 9.998
L-Aspartic Acid 133.11 1.33×103 9.992
L-Glutamic Acid 147.13 1.47×103 9.993
Glycine 75.067 750.0 9.991
L-Proline 115.13 1.15×103 9.989
L-Serine 105.093 1.05×103 9.991
Appendix E
Figure E.1 Original kinetic insulin model. Simulation results of 0.01-1.0 nM insulin
perturbations on the protein expression of pAKT, pGSK3β and pS6K and transcript levels of
G6Pase [Kubota et al., 2012].
176 Comparisons of simulations
Figure E.2 Insulin model simulated in COPASI. COPASI simulations results of 0.01
(fasting, dotted line) and 1 nM (fed, solid line) insulin perturbations on the protein expression
of pAKT, pGSK3β and pS6K and transcript levels of G6Pase as seen in Figure E.1.
Figure E.3 Insulin model simulated in QSSPN. QSSPN simulations results of 0.01
(fasting, dotted line) and 1 nM (fed, solid line) insulin perturbations on the protein expression
of pAKT, pGSK3β and pS6K and transcript levels of G6Pase as seen in Figure E.2.
Appendix F
A) B)
Figure F.1 Glucose and fructose transport activity lists. Within Snoopy, glucose
(A) and fructose (B) transport are labelled as ENZYME to specify it as a constraint. The
compound is mapped to HepatoNet1 with the reaction ID and the transport rates based on
Michaelis-Menten activity is set within the activity look up table of 30 activity steps which
constrains the QSSF. The first column (left) is the concentration/amount, second column is
the lower flux bound, and the third column is the upper flux bound. As the transport system
is bidirectional and symmetrical, the bounds are open from a negative flux (consumption) to
a positive flux (release).
178 QSSPN constraint and objective lists in Petri net
A) B)
Figure F.2 TAG objective function. This example shows that within Snoopy, the
HepatoNet1 reaction ID for TAG production (r1223) is labelled as METABOLITE to specify
it as an objective function (A). This includes another type of activity table of 2 activity steps
with the first column as the real values from the linear programming optimisation and the
second column translates this to number of tokens. This example is set as 0 representing no
TAG production and 0 tokens; and the smallest number 0.00001 is set to indicate a threshold
of which TAG production flux can translate to 1 token which can then fire. Subsequently,
flux can go through the FLUX transitions (red transition, shown in Figure 5.1) where the
flux value through the reactions (r1223) can be extracted and monitored over time (B).
Appendix G
Figure G.1 The computational model. The full computational model including Hepa-
toNet1, the sugar transport model and the kinetic insulin model in a PN format as shown in
Snoopy software.
180 Computational model files and layout
Figure G.2 The QSSPN control file. The control file for setting the parameters, initial
state and Petri net monitors to run the QSSPN model.
181
A)
B)
Figure G.3 The HeptoNet1 model file. The day to day management of HepatoNet1 was
via a text file (A). However, MUFINS [Wu et al., 2016] has now been developed to manage,
integrate and simulate the models (B). Both are the same file, and the TAG production
reaction, r1223 is highlighted.
182 Computational model files and layout
Figure G.4 The files and scripts for running QSSPN. The set of files that were used
to run QSSPN simulations are as shown. A Petri net model in .spept Snoopy file, HepatoNet1
in .sfba file, and a control file. A bin folder holds the QSSPN scripts, and a RUN script file
was used to run the QSSPN simulations.
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Appendix I
Lactate	   dehydrogenase	   (LDH)	   and	   3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐
diphenyl	  tetrazolium	  bromide	  (MTT)	  assays	  were	  both	  performed	  to	  
assess	  cell	  viability	  in	  both	  HepG2	  and	  HuH7	  cells.	  	  
SYSTEMATIC	  CHARACTERISATION	  OF	  IN	  VITRO	  HEPATOCYTE	  
MODELS	  FOR	  STUDYING	  NON-­‐ALCOHOLIC	  FATTY	  LIVER	  DISEASE	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Non-­‐alcoholic	   faPy	   liver	  disease	   (NAFLD)	   is	  primarily	   linked	  with	   the	  metabolic	   syndrome,	  but	   the	  underlying	  molecular	  mechanisms	  and	  
impact	  on	  regulatory	  signalling	  pathways	  are	  poorly	  understood.	  As	  hepatocytes	  are	  the	  predominate	  cell	   type	   in	   the	   liver,	   immortalised	  
hepatocytes	  treated	  with	  faPy	  acids	  in	  vitro	  are	  models	  rouTnely	  used	  for	  studying	  NAFLD.	  However,	  the	  cell	  lines,	  culture	  media,	  treatment	  
condiTons	   and	  monitored	   endpoints	   vary	   in	   the	   published	   literature.	  Here,	  we	   systemaTcally	   characterised	   the	   response	   of	   two	  human	  
hepatocyte	  cell	  lines	  to	  treatment	  with	  saturated	  (palmiTc	  acid,	  PA)	  and	  mono-­‐unsaturated	  (oleic	  acid,	  OA)	  faPy	  acids	  under	  physiological	  or	  
high	  glucose	  condiTons.	  	  
INTRODUCTION	  
HepG2	  and	  HuH7	  cells	  were	  cultured	  in	  Dulbecco’s	  modiﬁed	  Eagle’s	  
media	  containing	  low	  [5mM]	  or	  high	  [25mM]	  glucose	  and	  10%	  foetal	  
bovine	   serum.	   Cells	   were	   then	   treated	   with	   physiological	   serum	  
levels	  of	  PA	  or	  OA	  [0-­‐500μM]	  in	  serum-­‐free	  media	  for	  24	  hours.	  	  
LipidTOX™	   staining	   and	   confocal	   microscopy	   was	   used	   to	   visualise	  
lipid	   accumulaTon	   in	   HepG2	   cells.	   Nile	   Red	   staining	   was	   used	   to	  
quanTfy	  intracellular	  lipid	  in	  both	  HepG2	  and	  HuH7	  cells.	  	  
EXPERIMENTAL	  DESIGN	  
INTRACELLULAR	  LIPID	  
CONCLUSION	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•  The	  magnitude	  of	  intracellular	  lipid	  accumulaTon	  varied	  between	  
cell	  lines	  in	  response	  to	  faPy	  acid	  treatment.	  
•  The	   faPy	   acid	   eﬀect	   on	   cell	   viability	   was	   dramaTcally	   diﬀerent	  
between	  cell	  lines,	  	  with	  results	  also	  inﬂuenced	  by	  assay.	  	  
•  Glucose	  had	  no	  eﬀect	  on	  the	  response	  to	  faPy	  acid	  treatment	  in	  
either	  cell	  line.	  	  
•  These	  models	  of	  hepatocyte	  lipid	  loading	  will	  be	  used	  to	  facilitate	  
an	   iteraTve	   systems	   biology	   approach	   of	   in	   silico	   model	  
reconstrucTon,	  hypothesis	  generaTon	  and	  experimentaTon.	  
Values	   are	   expressed	   as	  mean	   ±	   SEM;	  HepG2	   (n=3),	   PA-­‐treated	  HuH7	   (n=6),	   OA-­‐treated	  
HuH7	  (n=5).	  One-­‐way	  ANOVA	  with	  Tukey’s	  test	  post	  hoc.	  *	  P<0.05,	  **	  P<0.01,	  ***	  P<0.001,	  
****	  P<0.0001	  compared	  to	  vehicle.	  
Values	   are	   expressed	   relaTve	   to	   vehicle	   as	   mean	   ±	   SEM;	   HepG2	   (n=5),	   HuH7	   (n=4).	  	  	  	  	  	  	  	  
Two-­‐way	  ANOVA	  with	  Tukey’s	  test	  post	  hoc.	  *	  P<0.05,	  **	  P<0.01,	  ***	  P<0.001,	  ****	  P<0.0001	  
compared	  to	  vehicle;	  #	  P<0.05,	  ##	  P<0.01,	  ###	  P<0.001,	  ####	  P<0.0001	  between	  OA	  and	  PA	  in	  
blue	  (low	  glucose),	  yellow	  (high	  glucose)	  or	  black	  (both).	  
Vehicle	   500μM	  OA	  
Figure I.1 BASL 2013. Poster presented at BASL, London 2013
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Figure	   4.	   The	   publish	   insulin	   model	   (A)	   has	   been	   reconstructed	   in	   Petri	   net	  
format	   (B).	  Preliminary	  QSSPN	  simulaAons	  have	  been	   successful	   at	   replicaAng	  
the	  published	  model	  results.	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Very	   high	   doses	   of	   fructose	   alter	   human	   hepaAc	   insulin	   sensiAvity	   and	   increase	   lipogenesis.	   However,	   the	   relevance	   of	   these	   data	   to	  
populaAon	  consumpAon	  is	  unclear.	  The	  objecAve	  of	  this	  work	  is	  to	  develop	  a	  predicAve,	  mulA-­‐scale	  model	  of	  human	  hepaAc	  monosaccharide	  
transport,	  signalling	  and	  metabolism.	  	  
INTRODUCTION	  
•  We	  are	  able	  to	  reproduce	  hepaAc	  monosaccharide	  uptake	  in	  vitro	  
in	  our	  in	  silico	  model.	  	  
•  The	  current	  state	  of	  the	  model	  suggests	  that	  glucose	  and	  fructose	  
are	  not	  limiAng	  carbon	  sources	  of	  TAG	  producAon.	  
•  Next,	   the	   regulatory	   network	   will	   be	   connected	   with	   the	  
metabolic	  network	  to	  determine	  the	  eﬀects	  of	  insulin	  regulaAon	  
on	  sugar	  and	  lipid	  metabolism.	  
•  With	   integraAon	   of	   regulatory	   and	  metabolic	   networks,	   further	  
interrogaAon	   of	   the	   model	   will	   allow	   us	   to	   computaAonally	  
predict	   the	   outcomes	   in	   response	   to	   physiological	   levels	   of	  
glucose	  and	  fructose	  in	  healthy	  and	  faOy	  liver.	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Figure	   1.	   RepresenAng	   our	   model	   in	   Petri	   net	   formalism,	   HepatoNet1	   is	   the	  
hepaAc	  metabolic	  network	   (A)	  and	  glucose	  and	  fructose	  transport	  system	  (B).	  
In	   this	  model,	   triacylglycerol	   (TAG)	   producAon	   (C)	   was	  monitored	   during	   the	  
uptake	   and	   metabolism	   of	   glucose	   and	   fructose,	   while	   also	   saAsfying	   the	  
demand	  to	  maintain	  biomass	  (D).	  
UAlising	  quasi	  steady	  state	  Petri	  nets	  (QSSPN)1,	  the	  aim	  is	  to	  build	  a	  
mulA-­‐scale	   model	   composed	   of	   the	   HepatoNet12	   liver-­‐speciﬁc	  
genome	  scale	  metabolic	  network	   constrained	  by	   in	   vitro	   ﬂux	  data3	  
with	  the	  integraAon	  of	  a	  kineAc	  model	  of	  insulin	  signalling.	  	  
MONOSACCHARIDE	  TRANSPORT	  
TRIACYLGLYCEROL	  PRODUCTION	  
In	   these	   QSSPN	   simulaAons,	   we	   propose	   a	   novel	   computaAonal	  
analysis	   approached	   ‘dynamic	   ﬂux	   variability	   analysis’	   (dFVA).	  
Alongside	   this,	   in	   vitro	   monosaccharide	   uptake	   experiments	   were	  
performed	  in	  an	  immortalised	  hepatocyte	  cell	  line,	  HepG2	  cells.	  	  
Figure	   2.	   HepG2	   cells	   were	   subcultured	   in	   5	   mM	   glucose	   containing	   DMEM	  
supplemented	  with	  10	  %	  FBS.	  Ajer	   three	  days	  of	  growing	  to	  conﬂuency,	  cells	  
were	   treated	   with	   serum-­‐free	   25	   mM	   glucose	   (A)	   or	   25	   mM	   fructose	   (B)	  
containing	   DMEM.	   HepG2	   medium	   was	   sampled	   at	   0,	   24	   and	   48	   hours	   to	  
measure	  monosaccharide	  concentraAons	  (n=3-­‐5,	  mean	  ±	  SEM).	  
With	   this	   computaAonal	   method,	   maximum	   and	   minimum	   glucose	   (A)	   and	  
fructose	  (B)	  concentraAons	  have	  been	  predicted	  over	  Ame.	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Triacylglycerol	   (TAG)	   was	   also	   analysed	   by	   dFVA	   to	   elucidate	   the	  
eﬀects	  of	  glucose	  and	  fructose	  on	  TAG	  producAon.	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B	  
C	  
A	   B	  
A	   B	  
D	  
A	   B	  
Figure	  3.	  dFVA	  was	  performed	  with	  25	  mM	  glucose	  (A)	  or	  25	  mM	  fructose	  (B)	  to	  
determine	   the	  maximum	  (black)	  and	  minimum	  (grey)	  producAon	  of	  TAG	   from	  
each	  carbon	  source.	  Here,	  we	  were	  able	  to	  capture	  our	  in	  vitro	  consumpAon	  of	  
glucose	  (A),	  but	  not	  fructose	  (B).	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To	   date,	   we	   have	   replicated	   a	   published	   kineAc	   insulin	   signalling	  
network4.	  
Figure I.2 EASD NAFLD workshop 2016. Poster presented at EASD NAFLD workshop,
Copenhagen 2016
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Summer Meeting, 14–17 July 2014, Carbohydrates in health: friends or foes
Examination of methylglyoxal levels in an in vitro model of steatosis and
serum from patients with non-alcoholic fatty liver disease
E. M. Maldonado1, N. Rabbani2, P. J. Thornalley2, H. Wang3, M. Miller3, J. F. Dillon3
and J. B. Moore1
1Department of Nutritional Sciences, University of Surrey, Guildford, GU2 7XH, UK, 2Warwick Medical School,
Clinical Sciences Research Laboratories, Coventry, CV2 2DX, UK and 3Medical Research Institute, University of
Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
This abstract was presented as the Cellular and Molecular Nutrition Theme highlight.
Elevated levels of methylglyoxal (MG), a highly reactive glycating agent forming advanced glycation endproducts (AGEs), have been
associated with diabetes, obesity and vascular disease(1). However, its role in the hepatic manifestation of metabolic syndrome, non-
alcoholic fatty liver disease (NAFLD), is still a novel inquiry. The objective of these experiments was to assess MG levels in response
to lipid loading in the liver.
Immortalised human hepatocytes (HepG2 cells) cultured in physiological levels of glucose (5 mM) were treated with either satu-
rated (400 μM palmitic acid, PA) or mono-unsaturated (500 μM oleic acid, OA) fatty acids (n= 3). Fatty acid-induced lipid loading
was conﬁrmed by Nile red staining. MG content of cells and in culture medium was measured by stable isotopic dilution liquid
chromatography-mass spectrometry (LC-MS/MS)(2). The MG-derived major AGE, hydroimidazolone MG-H1, was assessed by com-
petitive ELISA in serum samples from a cohort of biopsy-conﬁrmed adult NAFLD patients (n= 62). Sample collection was under full
NHS ethical approval and conducted in accordance with the Declaration of Helsinki. One-way ANOVA with Dunnett’s test was used
to analyse the in vitro data. Pearson or Spearman correlations were used to examine MG-H1 relationship to histological features and
clinical biochemistries, followed by multiple linear regression analyses.
Fatty acid treatment resulted in a 4-fold increase of intracellular lipid in the OA-treated cells (Fig. 1; P< 0·01). MG increased by 44 %
in OA-treated cells compared to vehicle (Fig. 2; P< 0·05), while culture mediumMG increased by 46 % and 45 % in PA- and OA-treated
cells, respectively (Fig. 3; P< 0·05). SerumMG-H1 (n= 59) was inversely correlated with alanine aminotransferase levels, lobular inﬂam-
mation and hepatocyte ballooning (P< 0·001). MG-H1 was positively correlated with body mass index (BMI) (P< 0·0001) however,
there was no correlation between MG-H1 and steatosis or ﬁbrosis score and, surprisingly, in this cohort BMI was inversely correlated
to inﬂammation and ballooning. The multiple regression analyses resulted in no conclusive relationships between MG-H1 and variables
to predict NAFLD activity.
Accumulation of MG, as measured by LC-MS/MS, in fatty acid-treated cells and their associated medium suggests lipid accumu-
lation increases MG formation and/or decreases MG metabolism. In contrast, serum MG-H1 from patients with fatty liver measured
by ELISA did not correlate with extent of steatosis. If these ﬁndings can be corroborated by robust measurement of MG-H1 by
LC-MS/MS, increased MG and AGEs formation in hepatic steatosis in vivo may be localised to the liver where proteolysis likely
releases increased MG-H1 free adduct into plasma.
1. Rabbani N & Thornalley PJ (2011) Sem Cell Dev Biol 22, 309–317.
2. Thornalley PJ & Rabbani N (2014) Biochim Biophys Acta 1840, 818–819.
Fig. 1. Cellular Lipid Fig. 2. Cellular Methylglyoxal
Fig. 3. Medium Methylglyoxal
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Figure J.1 Nutrition Society Summer Meeting 2014. Published abstract from Nutri-
tion Society Summer Meeting, Glasgow 2014
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Summer Meeting, 6–9 July 2015, The future of animal products in the human diet: health and environmental concerns
Quantitative lipid proﬁling of the early response to either fructose or
glucose in an in vitro model of steatosis
E.M. Maldonado, B.A. Fielding, C.P. Fisher and J.B. Moore
School of Biosciences and Medicine, University of Surrey, Guildford, Surrey, GU2 7XH
Whether or not dietary sugars, including fructose, exacerbate hepatic lipogenesis and non-alcoholic fatty liver disease (NAFLD)
pathogenesis remains an unresolved question. Here, we quantitatively assess the early metabolic response to dietary sugars in oleic
acid (OA) treated HepG2 cells, a ‘mixed nutrient’ model of NAFLD.
HepG2 cells were sub-cultured in medium containing physiological levels of glucose (5 mM, 5G), then treated with vehicle (V + 5G),
400μMoleic acid (OA+ 5G) or OAwith an additional 20 mMofmonosaccharide as either glucose (OA+ 25G) or fructose (OA+ 5G+
20 F). Intracellular lipidwas quantiﬁed at 0, 2, 4, 6 and 24 h time points.Nile red, a neutral lipophilic ﬂuorescent dye,was used tomeasure
total intracellular lipid and quantiﬁed either relative to vehicle or from an olive oil standard curve. Gas chromatographymass spectrom-
etry (GC/MS) was used to measure intracellular lipid after Folch extraction with spiked internal standards. The extracted lipid was sepa-
rated into fractions (i.e. diacylglycerol,DAGand triacylglycerol, TAG)by thin-layer chromatographybefore quantiﬁcation of fatty acids
(e.g. palmitic acid, 16:0 and oleic acid, 18:1n9) in each fraction. Data in ﬁgure 1 were statistically analysed by two-way ANOVA with
Tukey’s test post hoc.
After a 24 h treatment with OA in 5 mM and 25 mM glucose, there was no difference in total intracellular lipid as detected by nile
red. This held true when an olive oil standard curve was used (n = 4, data not shown). However, at earlier time points, the rate of lipid
accumulation differed between treatments as detected by nile red (n = 4–5, statistical differences indicated as time point versus 0 h,
Fig. 1). When assessed by quantitative GC/MS, initial results show a higher accumulation of TAG in OA+ 25 G in comparison
to OA+ 5 G and OA+ 5G+ 20 F after 6 h of treatment; in particular, oleic acid in the TAG fraction (n = 1, Fig. 2). Interestingly,
a higher amount of DAG was detected in OA+ 5G+ 20 F treated cells in comparison to OA+ 25G; furthermore, higher amounts
of palmitic acid, oleic acid and the de novo lipogenesis associated fatty acids, 16:1n7 and 18:1n7, were also detected (n = 1, Fig. 3).
Data regarding a differential role for dietary sugars in liver fat accumulation and NAFLD pathogenesis is somewhat conﬂicted. A
recent meta-analysis of human intervention trials shows no difference in the extent of fat accumulation in the liver from equimolar
doses of fructose or glucose(1). However, our data shows an initial increase in DAG synthesis in response to co-treatment with
lipid and fructose; highlighting downstream signalling pathways fructose may modulate. Future studies will explore responses in
the presence of insulin and monitor early signalling responses to fatty acids and sugars using proteomic approaches.
1. Chiu S, Sievenpiper JL, de Souza RJ et al. (2014) Eur J Clin Nutr 86, 416–23.
Fig. 1. Relative intracellular lipid at 24 h. Fig. 2. TAG fraction at 6 h. Fig. 3. DAG fraction at 6 h.
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Figure J.2 Nutrition Society Summer Meeting 2015. Published abstract from Nutri-
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Summer Meeting, 11–14 July 2016, New technology in nutrition research and practice
Development of a dynamic multi-scale, computational model of human
hepatic glucose and fructose metabolism
E.M. Maldonado1, M.J. Tindall2, N.J. Plant1, A.M. Kierzek1 and J.B. Moore1,3
1Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK, 2Department of Mathematics
and Statistics and Institute for Cardiovascular and Metabolic Research, University of Reading, Reading RG6 6AX, UK
and 3School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK
Very high doses of fructose alter human hepatic insulin sensitivity and increase lipogenesis. However, the relevance of these data to
population consumption is unclear. The objective of this work is to develop a predictive, multi-scale model of human hepatic mono-
saccharide transport, signalling and metabolism. This computational model will be used to predict the regulatory and metabolic out-
comes to physiological levels of glucose and fructose in healthy and fatty liver.
Utilising quasi steady state Petri nets (QSSPN)(1), the aim of this work is to build a multi-scale model composed of: (i) the
HepatoNet1(2) liver-speciﬁc genome-scale metabolic network constrained by in vitro ﬂux measurements; (ii) a model of insulin signal-
ling created by integration of published kinetic models; and (iii) prediction of monosaccharide transport and metabolism, and
triacylglycerol production. Alongside this, an immortalised hepatocyte cell line, HepG2, was used to provide in vitro data to experi-
mentally validate in silico predictions. Both insulin sensitivity (n 3–4) and sugar in culture medium (−/ + 100 nM insulin; n 3–5) were
measured and analysed by one- and two-way ANOVA followed by Dunnett’s and Sidak’s test post hoc, respectively.
To date, we have reconstructed a dynamic regulatory network of hepatic glucose and fructose transport in Petri net formalism and
integrated this with HepatoNet1 constrained by in vitro data(3). Together with our newly proposed computational analysis approach,
‘dynamic ﬂux variability analysis’ (dFVA), simulations have predicted minimum and maximum transport rates allowing the calcula-
tion of extracellular glucose (Fig. 2) and fructose (Fig. 3) concentrations over time, while also satisfying the demands of a ‘healthy
hepatocyte’. Insulin sensitivity was conﬁrmed in HepG2 cells with a 1·7-fold increase (P= 0·037) of pAKT/AKT expression in re-
sponse to postprandial levels of insulin (Fig. 1). HepG2 medium glucose and fructose concentrations were found to be within the pre-
dicted dFVA range (Fig. 2–3). In addition, a signiﬁcant increase of sugar uptake was seen in insulin-treated versus untreated cells.
Preliminary QSSPN simulations have been successful at replicating the results of a published kinetic model of hepatic insulin
signalling(4).
In conclusion, we reproduced in vitro hepatic monosaccharide uptake in our in silico model. Future work will integrate the regu-
latory insulin signalling network to the metabolic network to predict the outcomes of insulin regulation on sugar and lipid metabolism
in response to physiological levels of glucose and fructose in healthy and fatty liver.
1. Fisher CP, Plant NJ, Moore JB, et al. (2013) Bioinformatics 29, 1–9.
2. Gille C, Bölling C, Hoppe A, et al. (2010) Mol Syst Biol 6, 1–12.
3. Jain M, Nilsson R, Sharma S, et al. (2012) Science 336, 1040–44.
4. Kubota H, Noguchi R, Toyoshima Y, et al. (2012) Mol Cell 46, 820–32.
Fig. 1. HepG2 pAKT/AKT. Fig. 2. Extracellular glucose. Fig. 3. Extracellular fructose.
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